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ABSTRACT 
 
Clostridium difficile, a Gram-positive spore-forming bacterium, is a source of considerable morbidity 
and mortality for patients treated in hospitals and other healthcare settings. Intestinal colonisation by C. 
difficile can cause infection (CDI) if the normal flora is disrupted, e.g. by the use of antimicrobials and 
some other drugs. Vaccines targeting C difficile main virulence factors, toxins A and B are currently 
undergoing clinical trials, however, their potential population impact is largely unknown. The work 
presented in this thesis aims to quantify the effectiveness of C. difficile vaccination in preventing hospital-
onset CDI, including both its direct effects (reduction in individual patient morbidity and mortality) and 
indirect effects (prevention of onward transmission of the bacteria) using a mathematical dynamic 
transmission model framework.  
Based on a systematic literature review, it was shown that mathematical dynamic-transmission models 
have become an increasingly popular tool to help understand the patient-to-patient spread of nosocomial 
pathogens and predict the impact of healthcare prevention and control strategies. Methods have generally 
improved, with an increased use of stochastic models, and more advanced methods for formal model 
fitting and sensitivity analyses. Nonetheless, in contrast to methicillin-resistant Staphylococcus aureus – 
another bacterium commonly found in the healthcare setting – the transmission of C. difficile has rarely 
been considered within a dynamic modelling framework. 
Using national English CDI hospital surveillance data to fit a generalised additive mixed-effects 
model, this thesis revealed that, in line with recent evidence based on highly discriminatory genetic typing-
methods, whilst transmission between symptomatic carriers was significant, this did not account for the 
majority of CDI cases in English hospitals. Asymptomatic carriers have been suggested as co-
contributors, but their role in transmission remains uncertain to date.  
Previous estimates of additional excess bed days attributable to healthcare-acquired-CDI have varied 
widely, partly due to methodological weaknesses, and no robust estimates from a European setting are 
available. Both form key determinants to help quantify the health and economic burden of CDI, and are 
also likely to have an impact on the transmission-dynamics of the infection. Therefore, this thesis 
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quantified the hospital burden of CDI, expressed in excess length of stay and mortality. A Cox 
proportional hazard model revealed that CDI was associated with a significantly decreased daily risk of 
discharge and increased risk of mortality, where the former was even further reduced for severe CDI 
patients.  Using a multi-state model more intuitive estimates, i.e. the excess length of stay associated with 
mild (5 days [1.1-9.5]) and severe CDI (11.6 days [95% CI = 3.6-19.6]) were obtained. 
Finally, the results of an individual-based “state-of-the-art” dynamic transmission model in an 
English ICU (with epidemiological parameters informed by the findings of the statistical models 
mentioned, and with data-driven patient movement between the community, LTCF and ICU) showed 
that in settings with in-hospital acquisition rates comparable to the national average in English ICUs, 
immunising three patient groups: LTCF residents, elective patients and patients with a history of CDI in 
the ICU, resulted in a 43%, reduction of ICU-onset CDI. This required a relatively high number of 
vaccine doses, and a targeted strategy involving patients at high risk of colonisation on admission, such as 
LTCF residents proved more efficient. As these results proved highly sensitive to the level of 
antimicrobial use and in-ward acquisition rates, it was concluded that vaccination might be most efficient 
when targeting patient risk groups or settings where implementation of antimicrobial stewardship proves 
challenging. 
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CHAPTER 1 
 
INTRODUCTION 
 
 
1.1 BACKGROUND 
 
1.1.1 C. DIFFICILE INFECTION 
 
Clostridium difficile is a Gram-positive, spore-forming bacterium, which can only multiply in 
anaerobic environments. The name derives from the spindle shape (kloster [Greek]) of this bacterium 
under the microscope, which proved difficult to grow in laboratory conditions (difficilis [Latin]). The 
pathogen was first discovered in 1935 by Hall and O’Toole and described as a coloniser of the normal 
intestinal flora of new-borns under the name Bacillus difficilis [1]. The association with human disease was 
not made before 1978[2, 3], when C. difficile was isolated from patients with antimicrobial-agent-associated 
pseudomembranous colitis (i.e. inflammation of the large intestine). As part of a healthy normal gut flora, 
the bacterium is rare, and in general, considered harmless to humans. However, disturbance of the normal 
gut flora can cause endogenous or ingested C. difficile spores to germinate and proliferate in the 
gastrointestinal tract.  In the event of these bacteria having the relevant functioning genes, they can 
release enterotoxin A and B, which are the bacterium’s main virulence factors [4, 5]. These toxins enter 
the colonic epithelial cells through endocytosis, where they damage the actin cytoskeleton, e.g. inactivate 
guanosine triphosphatases (GTPases) of the Rho family, hence inducing cell death[6]. Both toxins 
combined were thought necessary to cause C. difficile infection (CDI), however in more recent studies, 
TcdA+TcdB- as well as TcdA-TcdB+ mutants have been found able to cause disease in animals[7, 8].  
 The consequences of C. difficile in the human gut are diverse:  individuals can remain 
asymptomatic (C. difficile colonisation/carriage), which has been largely attributed to individuals’ immune 
response (see below) [9–11], or induce mild to severe clinical manifestations (CDI) varying from 
diarrhoea [12] to pseudomembranous colitis and even death[13, 14].  
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1.1.2 RISK FACTORS FOR ACQUIRING CDI 
 
Antimicrobial usage is one of the primary predisposing factors for CDI, in particular broad-
spectrum penicillins (e.g. amoxicillin), third-generation cephalosporins (e.g. ceftriaxone, cefotaxime), 
clindamycin and quinolones [15–17]. The increased susceptibility to acquiring CDI has been estimated to 
be highest during one month post antibiotic treatment [18]. Another well-recognised risk factor is old age 
(defined as ≥65 years) [16, 19]. The reasons for this are unclear, but are probably several-fold.  The 
elderly, for example, have a weakened immune system, increased presence of severe underlying diseases 
such as chronic renal disease and inflammatory bowel, conditions which have both been associated with 
the disease[19]. They also have increased risks from more prolonged/frequent hospitalisations and receipt 
of more of “at-risk” antimicrobials[19]. Another much debated, but now generally accepted CDI risk 
factor, is the use of gastro-acid suppressants (e.g. proton pump inhibitors and H2-receptor antagonists) 
[20].    
Continued exposure to factors disturbing the gut flora post identification of CDI, such as gastric 
acid suppressors and antibiotic usage, increase the patient’s risk of recurrence [21] (defined here by a 
second CDI episode within 60 days[22]), which is experienced by about 20 per cent of patients[22]; either 
due to re-infection or relapse [23]. Importantly, the host’s ability to mount an antibody response to one of 
C. difficile’s main virulence factors, toxin A, is proven to play an important role both in preventing 
recurrence [24, 25], as well as primary disease[9–11].  
The above listed risk factors are frequently present in patients receiving healthcare today.  When 
combined with an enhanced ability of C. difficile to spread from patient-to-patient (either directly or 
indirectly through healthcare workers or the environment, discussed later in section 1.1.4) this provides a 
“perfect storm” for CDI to be amplified. Indeed, hospitalisation in the previous three months is a 
recognised risk factor for developing the infection[16, 26]. ICU stay in particular has been recognised as a 
risk factor for CDI [15, 27, 28]. Although large epidemiological studies in this setting are rare, the severe 
nature of their underlying disease often causes a state of immunosuppression[29], and requires high levels 
of antibiotic prescribing[30]. Moreover, due to the high prevalence of stress-related mucosal damage 
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following severe conditions such as trauma, sepsis or burns[31], gastro-acid suppressants are frequently 
prescribed among the critical ill patients. The occurrence of nosocomial CDI is discussed in the next 
section (section 1.1.3.1).  
Similarly admission of patients from elderly nursing homes or long-term care facilities (LTCFs) 
where the prevalence of symptomatic and asymptomatic carriage can be high, has been recognised as a 
risk factor developing hospital-onset CDI [32]. This creates a potential amplifying “carousel effect” 
between these settings. This carousel is made all the more complex with the increase in CDI outside 
healthcare facilities (further discussed in section 1.1.3.3).  
1.1.3 THE BURDEN OF CDI 
 
 C. DIFFICILE IN THE HOSPITAL-SETTING 
 
C. difficile is the most common cause of healthcare-associated gastrointestinal infections in 
England[33], as well as in many countries across Europe [34]. In 2008, an European wide hospital-based 
survey funded by the European Centres of Disease Control (ECDC) revealed a weighted mean incidence 
of 4.1 (range: 0 – 36.3) CDI cases per 10,000 patient-days per hospital (i.e. 23 (0 – 276) per 10,000 
admissions) across Europe[35]. This was an increase compared to the first European-wide survey based 
incidence survey in 2005 (2.5 [0.1 – 7.1] per 10 000 patient-days) [36]. The emergence of a C. difficile strain 
with increased virulence dramatically changed the epidemiology of the disease. First introduced in the 
United States and Canada in 2003, Polymerase Chain Reaction (PCR) ribotype 027 (also referred to as 
restriction enzyme analysis (REA) type BI or pulsed-field gel electrophoresis (PFGE) type 1 (NAP1)) was 
associated with fluoroquinelone resistance[37] and large outbreaks of more severe CDI involving an 
increased risk of mortality and high relapse rates[38, 39]. In 2004, when BI/NAP1/027 reports were 
dominant among CDI cases in Canada, a prospective cross-hospital study in Quebec revealed an 
incidence of 225 cases per 10,000 admissions[37].  Similar trends were observed in Northern European 
countries, including England, as well as Belgium, France, and the Netherlands[40]. In 2014, ECDC 
supported another European wide survey, of which preliminary results have been presented at the 
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Healthcare Infection Society conference in 2014. A slight decrease in European wide estimates (3.7 per 
10, 000 patient-days) was reported; however more details are required to conclude on overall trends. 
In 2003/2004, England experienced its first outbreak of BI/NAP1/027 in Stoke Mandeville 
Hospital[41]. In the few years after that, England has seen sharp increases in the proportion of CDI 
events caused by this particular strain (i.e. from 25.9% in 2004/2005 to 41.3% in 2007/2008)[42], 
resulting in large outbreaks and a marked increase in death certificates mentioning C. difficile[43]. In 
response to these developments, all acute National Health Service (NHS) hospital Trusts have become 
subject to mandatory reporting of identified CDI cases in January 2004[44]. Initially, reporting comprised 
all CDI patients ≥65 years. Three years later, in 2007, this was extended to include cases >2 years old. 
Moreover, the C. difficile Ribotyping Network was introduced which provided culture and ribotyping 
services for all registered Trusts [45].  
With 55,635 annual cases reported (9.4 per 10,000 bed days), CDI incidence reached its peak in 
2006 in England (Figure 1). This was followed by a steep decline, which appears to have slowly levelled 
off, with 13,361 annual reports (3.7 cases per 10,000 bed days) in 2013/14, and a slight increase in the 
latest financial year (14,165 annual reports, and 3.9 per 10,000 bed days). 
Figure 1: Yearly CDI incidence as reported through the English mandatory surveillance system 
 
Total number of cases reported by all NHS acute Trusts eligible for reporting to the English mandatory surveillance 
scheme. The numbers reflect the proportion of CDI cases that were Trust apportioned, defined as onset at least 72h 
after admission to the hospital. Data: CDI mandatory surveillance database obtained from Public Health England. 
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A number of different factors may have contributed to the reduction in CDI rates. The 
introduction of government-led CDI reduction targets in 2007 (imposing, besides enhanced surveillance, 
improved hospital infection prevention and control and antimicrobial stewardship[33]) as well as a 
reduction in the prevalence of BI/NAP1/027, which coincided with the observed decline in CDI.  Figure 
2 illustrates CDI incidence per 10,000 bed days for all England’s NHS Trusts in 2014/15 against the 
national average, standardised by hospital size. To compare, other European countries that reached states 
of endemic CDI similar to England, such as the Netherlands and Finland, have reported stable incidence 
rates at 2.9 and 2.3 per 10,000 bed days respectively[46, 47]. 
Figure 2: Funnel plot of the reported CDI rates (non-Trust and Trust apportioned) in England across all Trusts for the 
financial year 2014/15 
 
Reported CDI rates per 10,000 bed days (y-axis) as a function of Trust size expressed in the number of yearly bed days 
(x-axis) in the financial year 2013/2014. Each black dot represents the CDI rates of one NHS acute Trust. The red line 
corresponds to the national average incidence; the black dashed and solid lines represent the 95th and 99th percentile, 
respectively. Trusts with reported CDI incidence outside the upper limits have significantly higher rates than the 
average among Trusts with similar annual bed days, whereas Trusts with reports outside the lower confidence limit 
have significantly lower rates.  
A wide variation in CDI incidence reports across Trusts is observed, with 25% (38) of the Trusts 
reporting higher incidences than the 95th percentile for Trusts of similar size (Figure 2). This relates in 
part to variability in hospital characteristics such as hospital demographics and case-mix (in Chapter 3 it is 
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shown that teaching hospitals have generally higher number of reports than general and specialised 
hospital). Nonetheless, also considering the recent increases in CDI incidence and lower stable incidence 
rates reported elsewhere, this suggests there remains scope for further efforts in the prevention and 
control of CDI in England.  
 
 C. DIFFICILE IN LONG-TERM CARE FACILITIES 
 
Routine data on CDI prevalence among the elderly residing in long-term care facilities (LTCF) is 
currently non-existent, and prevalence studies on symptomatic and/or asymptomatic carriage are sparse. 
Asymptomatic colonisation prevalence is thought to be generally high compared to other (community) 
settings. Carriage rates of 2-4 per cent[48–50] have been found among healthy elderly participants 
residing outside the hospital and long-term care facilities (LTCFs), whereas a recent systematic review 
found a weighted average of 14.8% (95% CI 7.6 – 24.0) in LTCFs[51].  The case-mix of these facilities 
(elderly, requiring frequent antibiotic use and hospitalisation, e.g.[52, 53]), have been suggested as 
contributing factors. Point-prevalence surveys of healthcare-associated infections (HCAI) and antibiotic 
use in European LTCFs commissioned by ECDC have provided some insights in CDI prevalence. The 
latest survey in 2013 revealed low CDI incidence in LTCFs across Europe. Overall, 3.4% (range: 0.4 – 
9.5) of the residents were found positive for a health-care associated infection[54]. Five per cent of these 
were gastrointestinal, and C. difficile caused 17.7% (range: 0 - 100) of these infections. However, it was 
acknowledged that over half of the countries involved provided data from LTCFs that were non-
representative for the nation.  
Admissions from LTCF have been associated with increased risk of hospital-onset CDI[32] and 
residing in an LTCF has been identified as an independent risk-factor for developing CDI[55]. The 
frequent interaction between hospital and LTCF populations, and the vulnerability of the latter patient 
group, highlight the need for accurate estimates of the health burden of CDI in these settings. 
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 C. DIFFICILE IN THE COMMUNITY 
 
In the United Kingdom (UK), between 1994 and 2004, at a time CDI incidence increased, a 
population-based study using the General Practice Research database[56] revealed that the number of 
patients with CDI reported in the community, with no hospitalisation in the previous year increased as 
well[57]. Similar patterns were observed in the US [58, 59] and elsewhere [60]. These community-
associated CDI (CA-CDI) cases, commonly defined as patients with onset of symptoms in the 
community and no hospitalisation in the preceding 12 weeks [61, 62] (Figure 3), have been correlated 
with younger age [63, 64] and less severe co-morbidity [63, 65]. The association with antibiotic use in 
these cases is less clear, i.e. numbers of cases associated with previous antibiotic usage have been found to 
be lower among CA-CDI cases e.g. [63]. Nonetheless, a recent meta-analysis involving nine studies 
concluded antibiotic exposure remained a major risk factor for CDI in the community [66].  
Figure 3: Time line for surveillance definitions of CDI  
 
Source: [61, 62] 
Heightened awareness of CDI (reflected in the introduction of voluntary and mandatory national 
surveillance systems globally [35, 67]), might have been partly responsible for the observed increases in 
CA-CDI incidence. Also, non-standardisation in definitions used for CA-CDI [64, 68], hampers 
comparison of reported incidence of CA-CDI over time and across countries and settings. The English 
mandatory surveillance definition for non-Trust apportioned CDI (i.e. onset of CDI within three days 
after admission) is problematic in that it ignores onset related to recent hospitalisation, as well as enabling 
potential misclassification due to reporting delays. Since its introduction in 2007, the reported fraction of 
non-Trust apportioned CDI has increased consistently over time (see Figure 1). This could suggest a 
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continuing increase in community-acquisitions, but is perhaps more likely to be a consequence of the 
successful prevention of healthcare-acquired CDI.   
Despite these recent developments, the majority of reported CDI continues to be healthcare-
associated in Europe and North America. In the US, which in 2009 introduced a population-based 
surveillance scheme for CDI comprising both hospital and GP reports, about one-third of the cases were 
identified as community-associated in the ensuing two years [69, 70]. Similarly, population-based studies 
in Sweden [65] and Canada[71] identified 28% and 27% respectively of all CDI cases as community-
associated. Also, in 2008, the aforementioned European-wide hospital survey reported that, although the 
percentage of the identified cases that were community-associated (i.e. onset of CDI in the community 
and no admission to a healthcare facility (hospital or nursing home) in the previous 12 weeks) varied; the 
majority (75/83) of the participating hospitals reported higher proportions of healthcare-associated 
CDI[35]. However, considering there is a lack of structural, population-based CDI studies involving the 
testing of patients with diarrhoea both in the community and the healthcare setting, showing either 
presence or absence of common risk factors [68], it remains difficult to establish the true burden of CDI 
outside healthcare facilities. 
 ECONOMIC BURDEN OF C. DIFFICILE 
 
The preceding sections have emphasised the significance of the health burden of CDI. As a 
result, CDI places a marked economic burden on healthcare systems. However, the majority of studies on 
the economic healthcare costs associated with CDI originate from the US, and have focused largely on 
the direct costs associated with hospitalised patients[72]. Estimates of incremental costs of the disease 
vary from $2,871 to $30,049 per (primary) hospital-onset CDI case [72, 73]. These estimated costs were 
mainly driven by the additional number of hospital-bed days required for infected individuals[72, 73]. 
Although general consensus is that CDIs are responsible for excess lengths of stay (LoS), e.g. [74, 75] as 
well as mortality, e.g. [76], estimates for this excess LoS have varied widely from 0 to 21 days[75, 77]. 
These studies have mostly suffered from inappropriate methods used, for example fail to account for 
time-dependent bias (i.e. the timing of onset of infection), and competing risk events (such as discharge 
and death)[77]. The former is likely to result in an overestimation of the excess number of bed-days, as 
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patients that stay in hospital longer, are at increased risk of acquiring the infection. This has been shown 
extensively for other healthcare-associated infections [78–81]. In contrast, ignoring competing risk events 
might underestimate additional stay, since patients that acquire the disease could be at increased risk of 
experiencing death [82, 83].  
Estimates of excess bed-days and mortality due to disease form the current basis for cost-
effectiveness analysis and policy-making[84]. Therefore, more robust studies, quantifying these individual 
patient outcomes are highly needed. In particular studies in European-settings are lacking, as is research 
investigating the impact of (heterogeneity in) individual patient characteristics. 
1.1.4 C. DIFFICILE TRANSMISSION DYNAMICS  
 
Transmission of C. difficile occurs via the faecal-oral route; i.e. humans can ingest the vegetative 
form of C. difficile or its spores. The vegetative form is unlikely to survive the acidity of the stomach. The 
spores however, can pass through to the intestine, where they can germinate into vegetative bacteria. The 
spores are released in the faeces and can persist in the environment for several weeks [85]. The shedding 
of C. difficile spores into the (hospital) environment by CDI patients with diarrhoea makes this group of C. 
difficile carriers a likely source of C. difficile transmission, either directly or indirectly (through contaminated 
surfaces or hands of healthcare workers). Indeed, C. difficile spores have been recovered from the skin and 
hospital rooms of symptomatic patients, as well as hands of healthcare workers treating symptomatic 
carriers [86–88], and to a lesser extent of asymptomatic carriers [52, 87, 89, 90].  
In more recent years, CDI acquisition from (inpatient) symptomatic carriers was found less 
prevalent then generally assumed [91–93]. Only 20 per cent of hospital-onset cases of CDI were found to 
share an epidemiological link or, indeed genomic link (as analysed by multi-locus-sequence typing 
(MLST)[91] and whole genome sequencing (WGS) analyses) with symptomatic CDI cases, from 2008 to 
2011 in Oxfordshire, UK [92, 93]. Interestingly, patients carrying BI/NAP1/027 were found to be linked 
more commonly to other in-hospital patients (~60 per cent), supporting the hypothesis that certain 
strains are associated with higher transmissibility than others[92]. Eyre et al (2013) discovered (also in 
Oxfordshire) high levels of genomic diversity in hospital and community isolates from symptomatic CDI 
cases [93]. This recent evidence suggests other routes of transmission, such as via asymptomatic carriers 
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or an environmental source might be of equal or some importance to acquisition; at least in endemic-
settings. Good-quality studies investigating the transmission potential of asymptomatic carriers have been 
limited. Using multi-locus variable number of tandem repeats analysis (MLVA), Curry and colleagues 
(2013) found that a similar percentage of cases was associated with symptomatic (~30 per cent) as with 
asymptomatic carriers (~29 per cent) [94] in a US university hospital. Asymptomatic carriers outnumber 
their symptomatic counterparts (with ratios of 4:1 being suggested, e.g.[13, 86]); this, in combination with 
their lower frequency of skin and environmental contamination, might suggest the former could act as a 
reservoir for acquisition, albeit with lower per capita infectivity. 
The transmission-dynamics of CDI and role of asymptomatic carriers in the transmission of C. 
difficile remains uncertain to date. The majority of these studies have been limited to one geographical area 
and further epidemiological studies using e.g. national datasets are needed to identify whether similar 
patterns are observed elsewhere.  
1.1.5 C. DIFFICILE PREVENTION AND CONTROL AND THE ROLE OF VACCINATION  
 
Infection prevention and control methods for CDI currently involve measures to reduce C. 
difficile spread (e.g. environmental cleaning, contact precautions such as isolation and improved hand 
hygiene withwith soap and water (alcohol does not kill C. difficile spores), and efforts to decrease patient 
susceptibility to CDI when exposed to C. difficile, primarily through improved antimicrobial 
stewardship[62, 95]. These measures of course have the potential to interact and so maximise reductions 
in the levels of C. difficile acquisition.  
The receptor-binding domains of C. difficile toxins A and B (TcdA and TcdB) have been the 
target for vaccine development [96]. By using such toxoid vaccines, an IgG antibody response is induced 
and hence damage to the colonic mucosa, i.e. infection, prevented at the time of C. difficile colonisation 
[97–101]. Hence, such a vaccine is not thought to protect patients from asymptomatic C. difficile 
colonisation[9, 102]. A C. difficile toxoid vaccine, with and without adjuvant, developed by Sanofi-Pasteur 
is currently undergoing phase III clinical trials. Other companies also have products in various phases of 
clinical development (Table 1 and Appendix A). 
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Table 1: C. difficile vaccination pipeline  
Vaccine  Antigen  Clinical phase  Trial number 
Sanofi Pasteur ACAM-CDIFF™ Formalin Inactivated 
toxins A and B from 
VPI 10463 
III   NCT01887912 
Valneva VLA84 (former Intercell IC84)  Recombinant fusion 
protein of toxin A and 
B binding regions 
II  NCT02316470 
Pfizer PF-06425090  Recombinant toxin A 
and B mutants, 
chemically inactivated  
II NCT02117570 
 
If vaccination does reduce the risk of developing diarrhoea and colitis, it has the potential to 
reduce healthcare costs not only by preventing primary onset, but also by reducing the spread of 
infectious spores into the environment, and subsequently to other individuals. Assessing this potential 
population-level effect will require careful population-based studies and/or mathematical models. 
1.1.6 MATHEMATICAL MODELS TO EVALUATE CDI VACCINATION POLICIES 
 
Mathematical models have proven useful in understanding the transmission of infectious 
pathogens, as well as the impact of single or combined intervention strategies [103, 104]. An important 
strength of such mechanistic models is that scenarios can be investigated, which would be considered 
unethical or unfeasible for studies using, for example, randomised-controlled trials. Also, indirect effects, 
such as herd-immunity (i.e. the reduction in the number of infectious individuals in the population leading 
to other patients being at decreased risk of acquiring an infection) can be captured using dynamic models, 
where the risk of infection changes over time, and is dictated by the number of infectious individuals in a 
population [105]. Mathematical modelling has therefore become a well-established tool for integrating 
information from epidemiological studies and vaccine trials in order to estimate the population-level 
impact of vaccination [106, 107].  
Models simulating C. difficile transmission are rare when compared to pathogens of comparable 
significance, such as methicillin-resistant Staphylococcus aureus (MRSA) (see Chapter 2 and Chapter 5). Lee et 
al (2010) remain the only group to estimate the cost-effectiveness of a hypothetical CDI vaccine. The 
authors used a static decision analytic approach, i.e. assumed a fixed (independent from the number of 
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infected individuals) risk of infection. They therefore did not incorporate the potential indirect effects of 
vaccination. The study compared outcomes of vaccinating patients at risk of primary CDI to a strategy 
involving the vaccination of patients at risk of recurrence. No details were provided on specific settings 
and on what target groups would involve these at risk populations[108]. Outcomes were found to be 
highly sensitive to the risk of acquiring CDI, emphasising that the added value of the vaccine may highly 
vary from setting-to-setting. Moreover, when a CDI vaccine reaches the market, modelling can provide 
useful insights into the appropriate target populations for vaccination.  
 
1.2  THESIS OUTLINE 
 
1.2.1 RATIONALE 
 
To summarise the above, CDI is a major cause of gastro-intestinal infections globally. CDI 
incidence in England has seen major reductions, but recent increases have been observed and there is still 
a significant disease burden. The patient populations in England and most of Europe are increasingly 
aged with greater risks of CDI.  This together with modern and complex healthcare delivery provides 
additional challenges to sustaining any CDI reductions.  In addition, other healthcare systems outside 
Europe have not been as successful in implementing CDI reduction measures, most notably antibiotic 
stewardship[109]. The current burden, and spectre of increasing CDI have resulted in the progression of 
Phase III clinical trials on a vaccine targeting C. difficile TcdA and TcdB. Mathematical models have 
proven useful for providing insights into the potential of vaccination and the (cost)-effectiveness of 
different vaccine and other prevention and control strategies. Mathematical models of CDI have been 
rare, but insights from other infections, commonly associated with healthcare-settings, could aid in 
deciding the most appropriate modelling framework.  
Any such model requires proper understanding of the epidemiology of the disease. In recent 
years, changes in our thinking regarding the epidemiology of CDI have occurred. Importantly: awareness 
of the occurrence of CDI in the community has increased; and sources other than symptomatic carriers 
are suggested to contribute to hospital-onset of CDI.  
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Despite these developments, the onset of CDI continues to be primarily hospital-acquired, where 
it has been responsible for major attributable costs. Therefore, if the vaccine is found to be efficacious on 
an individual level in the clinical trials, it is likely to have a marked impact when preventing cases in 
hospital-settings. Estimates of these costs have been primarily driven by excess bed-days, of which robust 
numbers from European-settings are lacking. Moreover, among the few studies that use appropriate 
methodology, estimates vary widely. Hence there remains considerable uncertainty in the literature on the 
impact of CDI on length of stay. 
Any examination of the overall impact of vaccination needs to account for (uncertainty in) the 
potential role of asymptomatic carriers to transmission as well as the potential influence of the 
community population, including LTCF where asymptomatic carriage is commonly found. Mathematical 
models aiming to simulate transmission and evaluate CDI vaccine effectiveness should therefore 
incorporate movements between hospital and community-populations, and, if evaluating cost-
effectiveness, should pay particular attention to the quantification of (the dominant cost-driver) excess 
hospital stay. 
 
1.2.2 AIMS AND OBJECTIVES OF THE THESIS 
 
The primary aim of this PhD thesis is to determine - through detailed analysis of the transmission 
dynamics and burden of C. difficile - the potential role of vaccination in the prevention of nosocomial 
spread of CDI. In order to reach the overall aim of the thesis, the following study objectives were 
defined: 
1) To develop a comprehensive overview of existing mathematical models of HCAI transmission-
dynamics and prevention and control. Hence, define what modelling methods are most 
appropriate for the investigation and evaluation of the spread of C. difficile and the potential 
effectiveness of C. difficile vaccination. 
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2) To improve our understanding of C. difficile epidemiology by investigating the level of patient-to-
patient transmission between symptomatic carriers in the hospital setting on a national level. 
 
3) To provide the first robust estimate of the burden of C. difficile expressed in excess length of 
hospital stay and hospital mortality in England. 
 
4) To use the evidence generated from objective one, two and three to develop a mathematical 
dynamic transmission model to investigate the spread of nosocomial C. difficile, and evaluate the 
effectiveness of infection prevention and control strategies involving vaccination in an English 
hospital setting. 
1.2.3 STRUCTURE OF THE THESIS 
 
This section describes in brief terms the outline of the thesis. The primary content of each 
chapter is described, and Figure 4 provides a schematic overview of the entire PhD thesis content.  
Figure 4: Schematic overview of the PhD thesis 
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Chapter 2: Presents the results of a systematic review, which was conducted to meet objective one. 
The status quo of the field of dynamic-transmission modelling of healthcare-acquired infections is 
discussed, i.e. the pathogens modelled, the research themes investigated, the methods employed and how 
these methods have developed over time.  
Chapter 3: Describes the role of symptomatic carriers in the transmission-dynamics of C. difficile in 
the hospital-setting, in order to gain better understanding of the hospital epidemiology of C. difficile, and 
therefore addresses objective two. By means of generalised-additive mixed-effects modelling techniques 
the study makes novel use of routinely collected weekly incidence English C. difficile mandatory 
surveillance data.  
Chapter 4: Demonstrates the impact of healthcare-acquired CDI (HA-CDI) on a patient’s expected length 
of stay in hospital and risk of in-hospital mortality, to improve our understanding of the health and 
economic burden that C. difficile creates in England, therefore addressing objective three. Multi-state 
modelling (MSM) and Cox-proportional hazard models are employed to account for time-dependent bias 
and competing risks and used to realise objective three. 
 
Chapter 5: Provides a detailed account of the development and parameterisation of the individual-based C. 
difficile model. Evidence was synthesised from multiple sources, and numerous analyses undertaken for 
model parameterisation. The developed model was then used to assess the effectiveness of vaccination in 
preventing the transmission of C. difficile in high-risk settings. Hence this meets objective four, as well as 
the overall objective of this thesis. 
 
Chapter 6: Discusses the implications of the findings of all studies in the context of existing evidence. 
Moreover, areas for future research are discussed. 
1.2.4 CONTRIBUTION OF THE CANDIDATE TO THE THESIS 
 
The work conducted on this thesis was linked to a major research grant funded by the Healthcare 
Infection Society (U.K. Registered Charity No. 286064). Three papers have been published based on the 
work undertaken in this thesis, which are presented in Chapters 2, 3 and 4. The research for these papers 
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was conducted during the time of PhD registration. The candidate was the lead and corresponding author 
for all papers, carried out the literature review and/or analysis and prepared all drafts of the paper. The 
co-authors’ contributions to the manuscripts were restricted to providing comments on the drafts 
prepared by the candidate. More detailed account of the contribution of the candidate and of the co-
authors to the work presented in this thesis is outlined at the start of each thesis chapter.  
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CHAPTER 2 
 
MODELLING THE TRANSMISSION OF HEALTHCARE 
ASSOCIATED INFECTIONS: A SYSTEMATIC REVIEW 
 
 
2.1 PREAMBLE TO RESEARCH PAPER 1 
 
Chapter 1 explained how mathematical models could be useful tools for quantifying the impact 
of new or existing intervention strategies. Also highlighted was the limited number of models that 
investigated C. difficile transmission dynamics at the time of initiation of this PhD thesis (three in total). As 
CDI is most commonly associated with healthcare-settings, it was thought that useful insights could be 
gained from modelling studies involving other healthcare-associated infections (HCAI). The last review 
on this subject was published in 2006 [10] and primarily aimed to provide a narrative on how models can 
improve our understanding of HCAI dynamics and hence aid in hospital infection control, rather than a 
systematic overview of what models have been published in the field.  
Research paper one, by systematically reviewing the literature, firstly, gives an overview of how 
mathematical models have informed the field of HCAI. Secondly, it presents what methods have been 
employed and how they have evolved over time, hence providing an overview of the technical 
developments in this field. Therefore overall, research paper one gives an understanding of the quality of 
HCAI transmission models, as well as directions for further modelling work to address existing and 
emerging HCAI related issues all relevant to the ultimate aims of this thesis. 
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Abstract 
 
Background: Dynamic transmission models are increasingly being used to improve our understanding of 
the epidemiology of healthcare-associated infections (HCAI). However, there has been no recent 
comprehensive review of this emerging field. This study aimed to summarise how mathematical models 
have informed the field of HCAI and how methods have developed over time. 
Methods: MEDLINE, EMBASE, Scopus, CINAHL plus and Global Health databases were systematically 
searched for dynamic mathematical models of HCAI transmission and/or the dynamics of antimicrobial 
resistance in healthcare settings. 
Findings: In total, 96 papers met the eligibility criteria. The main research themes considered were 
evaluation of infection control effectiveness (64%), variability in transmission routes (7%), the impact of 
movement patterns between healthcare institutes (5%), the development of antimicrobial resistance (3%), 
and strain competitiveness or co-colonisation with different strains (3%). Methicillin-resistant 
Staphylococcus aureus was the most commonly modelled HCAI (34%), followed by vancomycin resistant 
enterococci (16%). Other common HCAIs, e.g. Clostridum difficile, were rarely investigated (3%). Very few 
models have been published on HCAI from low or middle-income countries. The first HCAI model has 
looked at antimicrobial resistance in hospital settings using compartmental deterministic approaches. 
Stochastic models (which include the role of chance in the transmission process) are becoming 
increasingly common. Model calibration (inference of unknown parameters by fitting models to data) and 
sensitivity analysis are comparatively uncommon, occurring in 35% and 36% of studies respectively, but 
their application is increasing.  Only 5% of models compared their predictions to external data.  
Conclusions: Transmission models have been used to understand complex systems and to predict the 
impact of control policies. Methods have generally improved, with an increased use of stochastic models, 
and more advanced methods for formal model fitting and sensitivity analyses. Insights gained from these 
models could be broadened to a wider range of pathogens and settings. Improvements in the availability 
of data and statistical methods could enhance the predictive ability of models. 
Keywords: mathematical modelling, healthcare-associated infections, epidemiology 
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Introduction 
Health care-associated infections (HCAI) continue to cause a major burden on society, affecting 
more than 4 million patients annually in Europe alone, and causing an estimated 16 million additional 
bed-days responsible for €7 billion in direct medical costs [1]. In the United Kingdom, interventions such 
as improved hand hygiene, antibiotic stewardship and screening combined with decolonisation are 
believed to have set off a steep reduction in reported incidence of health care-associated methicillin-
resistant Staphylococcus aureus (MRSA) bacteraemia and Clostridium difficile infection with peak incidence in 
2003/04 and 2007/08 respectively [2]. Further progress in reducing the burden of HCAI is hindered by 
uncertainty surrounding the role of asymptomatic carriers [3, 4], environmental transmission [5–7] and 
the recent emergence of bacteria other than MRSA and C. difficile, such as enterobacteriaceae (e.g. 
Escherichia coli) [8]. Mathematical models are increasingly being used to obtain a deeper understanding of 
epidemiological patterns in hospital infections and to guide hospital infection control policy decisions, as 
is seen in other areas of infectious disease epidemiology [9].  
A previous review of the area provided insight into the type of models used for hospital 
epidemiology and highlighted their capacity to increase epidemiological understanding, and inform 
infection control policy [10]. This review, conducted in 2006, primarily aimed to explain the capacities of 
models and therefore was limited to a detailed description of a number of studies. Hence, the emerging 
trends in the area were not fully explored. Since 2006 the field has expanded considerably. We conducted 
a systematic review in order to establish how mathematical models have been applied in the field of 
HCAI, and how model methods have developed over time.  
 
Methods 
We searched Medline (1950 to present), EMBASE (1947 to present), Scopus (1823 to present), 
CINAHL (1937 to present) and Global health (1910 to present). Results were limited to peer-reviewed 
publications in English. Search terms and Medical Subject Headings (MeSH) for nosocomial organisms 
and antibiotic resistance were combined with search and MeSH terms for healthcare settings and 
mathematical models as follows: 
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 Nosocomial infections in general (e.g.”healthcare-associated infection$” or “hospital-acquired infection$”) 
OR 
 Nosocomial organisms (e.g. “C. difficile” or “Staphylococcus aureus”) OR Antimicrobial resistance 
AND Nosocomial (e.g. “hospital$” or “healthcare”) 
AND 
 Mathematical modelling or economic evaluation model (e.g. “stochastic” or “deterministic” AND 
“model”)  
We decided not to use search terms for nosocomial infection types (e.g. surgical site infections or 
urinary tract infections), since our review focuses on the transmission of infections from one individual to 
another, which cannot generally be accurately represented without knowing the causative organism.  
The complete search strategy is provided in the supporting material. All databases were searched 
identically, with exception of the MeSH terms, which were altered to the subject-heading dictionary used 
in each particular database. The final search was conducted on 11 December 2011.  Each title and 
abstract in the search result was independently screened by EvK and at least one of the other authors. 
Full text evaluation was conducted by EvK and in case of uncertainty, discussion took place with JR. 
Inclusion criteria 
Eligible studies had to fulfil the following criteria: 1) mathematical modelling of HCAI 
transmission and/or the dynamics of antimicrobial resistance; 2) dynamic transmission models only (i.e. a 
model which tracks the number of individuals (or proportion of a population) carrying or infected with a 
pathogen over time, while capturing the effect of contact between individuals on transmission [9]); 3) a 
primary focus on HCAI transmission in healthcare settings.  
Exclusion criteria 
Studies were excluded if they did not involve: 1) human to human transmission; or did involve 2) 
within host transmission only; 3) pharmacodynamics and pharmacokinetics of drugs (e.g. the impact of 
antibiotic exposure, exploring antibiotic tolerance and investigating fitness), 4) animal transmission of 
HCAI; 5) community transmission of pathogens spread in the healthcare environment as well, where 
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community spread was the focus of the paper (e.g. Severe Acute Respiratory Syndrome (SARS) 
epidemics); or 6) literature review without new primary studies.  Moreover, no editorials or letters to 
editors were included, except if a new mathematical model was introduced.  
 
Results 
The database search retrieved 2461 unique papers (Figure 5). After screening the titles and 
abstracts, 302 papers met the inclusion criteria and were thus eligible for full text evaluation. Review of 
the full text publications resulted in the inclusion of 94 relevant papers based on our selection criteria. An 
additional two papers were identified via reference screening [11, 12]. 
Figure 5 PRISMA flowchart 
 
  
 
 5171 records identified through 
database searching (357 from CINAHL 
plus, 1285 from EMBASE, 556 from 
Global Health, 1061 from Medline, 
1912 from Scopus) 
2 additional records 
identified by reference 
searching 
 2461 records after duplicates removed 
2461 records screened 
2159 records excluded after 
title-abstract selection based 
on eligibility criteria  
302 full-text articles assessed 
for eligibility 
96 of studies included in 
qualitative synthesis  
208 full-text articles 
excluded based on eligibility 
criteria  
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The distribution of these 96 papers over time demonstrates that HCAI transmission models have been 
increasingly employed since the introduction of the first model of nosocomial pathogens’ spread [13] 
(Figure 6). 
Figure 6: Number of HCAI modelling publications over time (1993 – 2011) 
  
Number of studies identified on modelling of HCAI and antimicrobial resistance spread in a nosocomial setting 
according to year of publication. 
 
Objectives of mathematical models of HCAIs 
 
Pathogens modelled 
Although HCAIs are often associated with antibiotic-resistant bacteria, HCAI models have 
involved antimicrobial susceptible pathogens as well. In this review, studies that did not specify a 
particular pathogen of concern, but that claimed to investigate antimicrobial resistant bacteria, were 
classified as antimicrobial resistant bacteria (ARB). Otherwise, the study was categorised as ‘HCAI in 
general’. Moreover, as the majority of patients can carry HCAI such as MRSA and C. difficile 
asymptomatically, many mathematical models simulate the epidemiology of colonisation, however for 
brevity we have referred to all models as concerning the epidemiology of HCAI in the text. 
Figure 7 shows that MRSA was the most common bacterial species studied (34%; 33 studies) 
[14–46], followed by Vancomycin-resistant Enterococcus (VRE) (or glycopeptide-resistant enterococci)  
(16%; 15 studies) [12, 18, 28, 31, 47–57] whereas C. difficile has rarely been the subject of a model (3%; 3 
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studies) [58–60].  As several studies investigated the dynamics of more than one pathogen, the total 
number of infection agents (N=102) listed in Figure 7 exceeds the total number of studies (N=96). 
Figure 7: Pathogens modelled in a nosocomial setting (1993 – 2011) 
 
Number of studies identified on nosocomial infection transmission according to pathogen type. MRSA= Methicillin 
resistant Staphylococcus aureus; ARB = Antimicrobial resistant bacteria; VRE = Vancomycin-resistant Enterococcus; 
HCAI = Healthcare associated infections; ILI = Influenza-like illness; SARS = Severe acute respiratory syndrome; 
TB= Tuberculosis; R-GNR= Third generation cephalosporin-resistant Gram-negative rods; HIV = Human 
immunodeficiency virus; ESBL = Extended-Spectrum Beta-Lactamases; CRE = cephalosporin-resistant 
Enterobacteriaceae 
 
Intervention effectiveness 
 
The first model of HCAI conceptualised the spread of antibiotic resistance in bacterial 
populations among hospital patients [13]. This was soon followed by models evaluating the effectiveness 
of interventions to reduce antibiotic resistance (e.g. antibiotic cycling or mixing). Since then, most HCAI 
models have aimed to quantify infection control effectiveness (64%; 62 studies). The infection control 
measures most frequently considered among these 62 papers have been: hand hygiene (37%; 23 studies), 
0 5 10 15 20 25 30 35
CRE
ESBL
HIV
Moraxella catarrhalis
Mycoplasma pneumoniae
R-GNR
Rotavirus
S. Aureus
TB
Norovirus
Pertussis
Pseudomonas aeruginosa
C. difficile
SARS
Influenza or ILI
HCAI in general
ARB
VRE
MRSA
Number of publications (N=96)
 
 
46 
patient isolation (24%; 15 studies), HCW cohorting (23%; 14 studies), antibiotic stewardship (21%; 13 
studies), and screening (18%, 11 studies). Figure 8 provides an overview of the main interventions 
modelled over time, emphasising that decolonisation and vaccination are more recent subjects of study. 
Moreover, a wider variability of interventions has been evaluated in the later years. Table 2 illustrates the 
type of interventions that have been evaluated for each HCAI pathogen. 
Figure 8:Main interventions evaluated over time (1993 – 2011) 
 
Illustration of the proportionate distribution of the seven most commonly investigated interventions by means of a 
modelling framework by the total number of publications in each time period. 
 
Table 2: Healthcare infection control interventions evaluated by a modelling framework (1997 – 2011) 
Pathogen  Interventions studied  First 
published  
 References  
MRSA  Hand hygiene  1997  [15–17, 28, 29, 33, 34, 37, 40, 44–46] 
  Antibiotic stewardship  1997  [16, 21] 
  Isolation  1997  [14, 16, 26, 32, 35, 41, 42, 45] 
  HCW cohorting  2002  [17, 29, 40, 44, 45] 
  Screening  2005  [14, 23, 25, 32, 34, 39, 44, 45] 
  Decolonisation  2009  [14, 25, 26, 33, 34, 40, 45, 46] 
  Patient cohorting  2007  [40] 
  Gown and glove use  2009  [32] 
  Other  2006  [43] 
VRE  Hand hygiene  1998  [12, 21, 28, 47, 49, 51, 54, 55] 
  Antibiotic stewardship  1999  [47, 51, 55] 
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  Isolation  2004  [12, 52] 
  HCW cohorting  1998  [12, 49, 51, 54, 55] 
  Screening  2004  [47, 52] 
  Decolonisation  2007  [50] 
  Patient cohorting  2008  [47] 
  Environmental cleaning  2008  [47] 
C. difficile  Other  2009  [59] 
ARB  Hand hygiene  1997  [92] 
  Antibiotic stewardship  1997  [65, 75, 79, 96, 98, 99, 101, 102] 
  Barrier precautions (i.e. not 
specified) 
 2000  [98] 
HCAI in general  Hand hygiene  1999  [86, 123] 
  Isolation  2005  [87, 88] 
  HCW cohorting  2006  [88, 123] 
  Screening  1999  [86] 
  Vaccination  2008  [88] 
  Barrier precautions (i.e. not 
specified) 
 2007  [76] 
  Patient cohorting  2005  [87, 124] 
  Environmental cleaning  2007  [124] 
  Antibiotic prophylaxis   2007  [76] 
  Antibiotic stewardship  2008  [103] 
  HCW cohorting  2005  [87] 
HIV  Sterilization of medical 
appliances 
 1999  [97] 
Influenza or ILI  Vaccination  2008  [80, 81, 95] 
  Prophylaxis  2009  [91] 
  Other  2008  [89, 125] 
Pertussis  Vaccination  2009  [70, 83] 
Rotavirus  Hand hygiene  2011  [78] 
  HCW cohorting  2011  [78] 
  Vaccination  2011  [78] 
SARS  Isolation  2007  [105] 
  Barrier precautions (i.e. not 
specified) 
 2005  [73] 
TB  Isolation  2007  [72] 
  HIV treatment  2007  [72] 
  Air ventilation  2007  [72] 
  Facial mask  2007  [72] 
 
Furthering epidemiological understanding 
Models are often used to increase epidemiological understanding. Hospital surveillance data, 
which is frequently used to inform HCAI models, can lack detail in what is needed for modelling 
purposes. For example, information on asymptomatic carriage and timing of events (e.g. infection) are 
often lacking. Several studies use new statistical methods to overcome such difficulties [31, 36, 48] and to 
allow for estimation of important epidemiological parameters (e.g. transmission rates) from different data 
sources, varying from routinely collected hospital data [56, 57] to strain typing [61] or genotype data [62]. 
Others use modelling techniques to determine the relative importance of potential transmission reservoirs 
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or acquisition routes  (of C. difficile [58, 60], VRE [50, 53], cephalosporin-resistant Enterobacteriaceae 
(CRE) [63] and SARS [64]. 
The ecological dynamics of pathogens have also been explored using models, including 
antimicrobial resistance [13, 65, 66]; co-colonisation with different pathogen strain types [27, 46] and 
competition between strains [24].  Another more recent subject of study is the potential impact of 
readmission of patients from settings such as long-term care facilities (LTCFs) or the community, as well 
as general movement patterns between healthcare institutes and/or the community on the transmission 
of MRSA [19, 25, 38, 67], antimicrobial resistance [68] and HCAI in general [69]. 
Economic outcomes were not considered in dynamic transmission models until 2011 [14, 23, 70]. 
Three recent papers applied dynamic modelling techniques to estimate the economic burden of disease 
(MRSA) [22] and norovirus [67], and to investigate economic incentives for infection control investments 
[71]. 
Country of study 
A number of studies (36%, 32 studies) did not specify a particular national setting. Of the 
publications that did; only three studies (3%) explored transmission of HCAI in lower and lower middle 
income countries [22, 72, 73] and another three looked at upper middle income China [15, 64, 74]. Studies 
have mainly concentrated on the United States (16%; 15 studies), the United Kingdom (13%; 12 studies) 
and the Netherlands (10%; 10 studies). 
Methods employed for mathematical modelling of HCAIs 
Stochastic vs. deterministic 
The first HCAI models captured transmission dynamics in single wards using deterministic 
approaches [13, 16]. As the population size in a single ward or hospital is likely to be small, a stochastic 
modelling approach may often be more appropriate as it can take account of the role of chance in 
determining transmission patterns. In Table 3, a definition of the modelling terms used for model 
classification is provided. Figure 9A shows that the proportion of stochastic models has increased steadily 
over time, and as Figure 10 illustrates, stochasticity was soon introduced (in 1997) [88] after publication of 
the first (deterministic) HCAI model. Several studies developed both a stochastic and a deterministic 
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version of a similar compartmental model to investigate whether projected intervention effects were 
partly a result of random fluctuation [18, 35, 40, 75–77]. Others use a deterministic model to interpret the 
findings of a stochastic model [78].  
Table 3: Definitions of modelling terms 
Term  Definition 
Deterministic 
model 
 A model in which there is no role of chance in the evolution of the states of the system, 
i.e. the model is ‘predetermined’ by the parameters and initial conditions [121]. 
Stochastic model  A model in which random (stochastic) processes can affect whether certain events or 
processes occur (e.g. the rate at which individuals are infected can vary by chance) 
[121].  
Compartmental 
model 
 A model in which the population is divided into subgroups (i.e. compartments), which 
represent the average values of individuals in a particular state (e.g. susceptible, 
infectious or recovered). Within each compartment, all individuals are homogenous [9].  
Individual-based 
model 
 A model in which single individuals are tracked rather than subgroups. Hence, each 
individual can be assigned different characteristics such as the probability of acquiring 
infection or causing transmission [9]. 
Model fitting/ 
model calibration 
 The inference of unknown parameters by choosing their values in order to approximate 
a set of data as well as possible. Examples of model fitting methods are least squares 
approximation maximum likelihood estimation and Markov Chain Monte Carlo 
Methods [122]. 
Model validation  Comparison of model predictions to external data, that is a model should be validated 
against observations from alternative data to the data used for model fitting [122].  
Univariate 
sensitivity analysis 
 Investigation of uncertainty in model parameters and its impact on model predictions 
by means of altering one parameter at a time whilst holding others at their base-case 
value.  
Bi/ multivariate 
sensitivity analysis 
 Investigation of uncertainty in model parameters by means of alteration of two (or 
more) parameters at a time whilst holding others at their base-case value. 
Probabilistic 
sensitivity analysis 
 A type of multivariate sensitivity analysis where multiple runs of the model are 
performed with random selection of input parameters.  
Dynamic 
transmission 
model 
 A model which tracks the number of individuals (or proportion of a population) 
carrying or infected with a pathogen over time, where the risk of transmission to 
susceptible at a given point in time is dependent on the number of infected (or 
colonised) individuals in the community [9].   
Static model  A model where the transmission risk is treated as a parameter exogenous to the model, 
i.e. it does not change with the number of infectious individuals in the population [9]. 
Force of infection  The rate at which infected individuals become infected per unit time [121] 
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Compartmental vs. individual-based 
Infectious disease models can have either an aggregate (or compartmental) structure (which 
tracks groups in the population) or an individual-based structure (which tracks individuals). The latter 
enables better incorporation of heterogeneity in patient characteristics such as patient demographics, 
contact patterns and disease history, but at the cost of increased computational burden. To date, most 
(73%; 70 studies) HCAI models have taken an aggregate approach, although the proportion of individual-
based models has increased over time (Figure 9A). In total, 26 publications (27%) took an individual-
based approach of which seven papers (8%) used both compartmental and individual-based modelling 
[25, 34, 60, 70, 79–81]. 
Figure 9: Development of HCAI model structure, and methods used over time 
A 
 
Model approach Proportion of models using a deterministic vs. stochastic and a compartmental vs individual-
based modelling approach by the total number of publications in each time period. Note that the categories are not 
exclusive, i.e. whereas all individual-based models identified are stochastic, compartmental models may be 
deterministic or stochastic. Moreover, a proportion of studies use a combination of the above listed modelling 
approaches (e.g. a deterministic compartmental model complemented by a stochastic individual-based model). 
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B 
 
Model methods Proportion of models that are fitted to data, have included uncertainty and are validated by 
consultation of two different datasets by total number of publications in each time period.  
 
C 
  
Methods used for characterising parameter uncertainty Proportion of models that have employed uni-variate, 
vs bi-variate vs probabilistic sensitivity analysis by total number of publications that incorporated parameter 
uncertainty in each time period. 
 
 
Model fitting to data 
Model parameter values can be based on existing studies, on assumptions, or estimated directly 
from data [82]. Unknown parameters, such as infection transmission rates, can be inferred by calibrating a 
model to empirical data. With the increasing availability of computational power, numerically-intensive 
statistical methods for parameter inference have become more accessible. As Figure 9B shows, although 
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only 35% (34 studies) of HCAIs models have incorporated some sort of calibration process to empirical 
data, this proportion has increased over time. Metrics used to quantify goodness of fit include the least 
square criterion  (minimisation of sums of squares between the observed data and the model predictions) 
[21, 56, 57, 72], maximum likelihood estimation (identification of the parameter value(s) that makes the 
observed data most likely) [18, 22, 24, 35, 53, 61, 63, 64] and since 2007, Bayesian methods; frequently 
using Markov Chain Monte Carlo (MCMC) approaches [19, 32, 40, 41, 50, 58, 62, 74] or a combination of 
MCMC and maximum likelihood estimation [36, 59]. A further seven studies reported fitting their models 
by comparing model predictions to observed epidemiological data but did not apply any formal 
quantitative approach [17, 29, 43, 60, 78, 83, 84]. 
 
Uncertainty in model predictions 
Infectious disease models are developed and informed using a combination of available evidence, 
for example on infection transmission, disease natural history and intervention effectiveness. As 
availability of such information is unlikely to be complete, mathematical models inherently include some 
degree of uncertainty. This uncertainty may relate to model parameter values, model structure (e.g. in 
terms of disease states incorporated and the relationship between them) or methodology used [9, 85].  
Parameter uncertainty was investigated by 36% of the studies (35 publications). As Figure 9B 
illustrates, similar trends as seen for the application of formal model calibration apply for the inclusion of 
parameter uncertainty. Also the methods used for parameter uncertainty have become more complex 
over time (Figure 9C). Of the 35 studies that have investigated parameter uncertainty, univariate 
sensitivity analysis (i.e. alteration of one parameter at a time whilst holding others at their base-case value) 
was conducted by 43% (15 studies) [18, 28, 29, 43, 44, 46, 60, 61, 67, 78, 79, 86–89]. The more 
computationally expensive probabilistic sensitivity analysis (formulation of uncertainty in the model 
inputs by a joint probability distribution, and propagating this uncertainty to the outputs [90]) is in general 
considered a rigorous method to account for uncertainty in the joint distribution of the parameters. This 
was employed by 51% (18 studies) [14, 32, 36, 40–42, 48, 50, 57–59, 62, 72, 74, 75, 80, 81, 91] among 
which Latin Hypercube Sampling (LHS) as a means of performing probabilistic sensitivity analysis was 
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conducted by four studies [72, 80, 81, 91]. Probabilistic sensitivity analysis utilizing LHS provides a 
rigorous method of incorporating and representing real uncertainty surrounding parameter estimates into 
model-based analysis where joint probability distributions for parameters are available. 
Model validation 
Model validation is rare in HCAI modelling. Ideally, a model should be validated by means of 
comparing the model predictions with observations from an alternative dataset than the one used for 
model fitting, although this is often difficult in practice. Four studies (5%) reported some kind of model 
validation based on at least two different data sets [50, 53, 72, 83]. However, only one study used a 
statistical approach [83], whereas the others included subjective comparison of the model predictions (on 
infection transmission) with genotype data [50, 53, 72] . 
Setting and interaction between settings 
Mathematical models of HCAIs have primarily been set in a single ward (49%, 47 studies), with 
the intensive care unit (ICU) being the most frequent setting modelled (26%, 25 studies) [14, 16, 22, 28, 
29, 31, 32, 36, 40–42, 45, 49, 52, 53, 55, 61, 63, 70, 76, 83, 87, 92–94] or a simplified hospital setting, 
lacking any further ward structure (31%, 30 studies) [12, 13, 24, 27, 33, 34, 38, 39, 45, 46, 51, 58, 60, 62, 
64, 66, 67, 73, 75, 79, 88, 95–103]. More recent studies however, have incorporated the interaction 
between general wards and the ICU [23, 43, 67]  or between different wards [11]. Although these ward or 
hospital-based models do not usually treat the hospital as a closed system (i.e. hospital admission and 
discharge rates from and to a 'general community' are frequently included), transfer patterns between 
healthcare institutes are rarely considered [19, 25, 68, 69, 71, 104], as are transmission dynamics within 
settings outside the healthcare facilities. The interaction between community and hospital transmission 
has been included for MRSA [30, 35], antimicrobial resistant bacteria as a whole [65], Severe Acute 
Respiratory Syndrome [74, 105] and tuberculosis [72]. Hence any possible long-term feedback between 
the hospital and other settings is not taken into account. Only two models concerned nosocomial 
transmission in a LTCF setting alone, i.e. of influenza [91] and norovirus [84] respectively. 
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Figure 10: Milestones of HCAI modelling 
 
Timeline listing new applications of mathematical models for HCAI and antimicrobial resistance over time as well as 
improvements of these models according to year of publication. 
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Discussion 
 
Models of MRSA transmission dominate the literature, followed by VRE, although to a 
considerably lesser extent. Both have been the subject of national surveillance and infection control 
policies in a variety of developed countries [106–108]. This may account for the relative abundance of 
modelling studies. Despite causing a high burden and being the subject of national control policies [109, 
110], C. difficile transmission has seldom been modelled. Similarly, bloodstream infections due to third-
generation cephalosporin-resistant E. coli, which have been estimated to cause  ~2,700 excess deaths and 
120,000 extra bed days in Europe in 2007 have been considered by only one study [63]. For comparison, 
MRSA was estimated to cause ~5,500 deaths and 256,000 additional bed days in Europe [111], yet has 
been the subject of over 30 studies. It seems then that the occurrence of models does not necessarily 
correlate to the burden of disease. This is also true in low and middle income countries, where a recently 
published systematic review [112, 113] demonstrated significantly higher prevalence of HCAIs than in 
high income countries; however, very few modelling studies have tackled the problems of HCAI in less 
developed settings.  
In terms of model methods, considerable changes can be identified over time. After the 
introduction of the first deterministic HCAI modelling study, inclusion of stochasticity has become 
common practice. The majority of the HCAI models evaluate infection control policies, for which sound 
model parameterisation and sensitivity analyses are required for reliable predictions. The use of more 
sophisticated methods for model parameterisation (e.g. MCMC) and uncertainty analysis has become 
increasingly common.  
HCAI models have also increased in complexity regarding the settings modelled. Although the 
majority of the models have considered a single ward (often ICUs), the apparent emergence of 
transmission of typical HCAIs in the community, in particular of MRSA [114], have resulted in models 
which consider the transmission of HCAI from a more holistic approach. As the long-term feedback loop 
related to hospital discharge and readmission of colonised patients and spread of HCAI pathogens in the 
community or settings as LTCFs can effect HCAI transmission dynamics [19, 68, 115], such approach 
can aid in providing a realistic estimate of existing and new infection control strategies’ effectiveness. 
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This review has some limitations. First of all we have exclusively considered peer-reviewed 
publications in English. This might have resulted in a slight inaccuracy in our results, e.g with regards to 
the modelling of particular pathogens in alternative national settings. We were exclusively interested in 
models exploring the patient-to-patient transmission of HCAI and antimicrobial resistance within 
healthcare settings (either directly, or mediated by healthcare workers and/or the healthcare 
environment). This has resulted in the exclusion of a higher number of models that elucidate the 
dynamics of antimicrobial resistance in its own right, which are summarised elsewhere [116, 117]. 
Moreover, this review intended to provide overall trends in the field of HCAI modelling, rather than a 
detailed account of the quality of individual models and of what these models have shown, which could 
be a valid future area of investigation.   
Compartmental models (which group individuals in classes) have predominated the field of 
HCAI modelling. The emergence of individual-based modelling allows for more realistic modelling of 
healthcare worker-patient contact (e.g. super spreading events) or incorporation of heterogeneity in 
transmission risk profiles of patients. However, these approaches are computationally far more intensive, 
are difficult to fit to data, and the inclusion of additional factors makes more demand on the data 
available. Detailed level data such as observed healthcare worker-patient contact collected for example via 
mote-based sensor networks, as has been done recently [118], could help parameterise such more 
complex models.  
Moreover, recent technological developments in microbiology have resulted in enhanced access 
to pathogen sequence data, which could help to further improve HCAI models. Such data are beginning 
to inform disease outbreaks e.g. of avian influenza A (H7N7) [119] and Foot-and-Mouth disease [120]. 
Importantly, the increasingly routine use of sequencing of genetic material for epidemiological purposes 
can provide valuable insight, such as aiding in the understanding of the role of asymptomatic carriers in 
transmission (e.g. of C. difficile) and evolution of antimicrobial resistance.   
Conclusions 
Transmission models concerning HCAI have showed a general enhancement in complexity, but 
have been almost completely limited to high-income settings, and have strongly focused on MRSA 
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transmission in hospital settings. Further improvements in the availability of data and statistical methods 
could enhance the insight gained from these models. 
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Supplementary material 
 
Search terms MEDLINE  
The search strategy was identical for EMBASE, Scopus, Global Health and CINHAL plus 
except for the MESH terms used, which were adjusted (or absent) for each database of concern. 
 
ti,ab  = Search for specified search term in title, abstract 
mp  = Search for specified search term in title, abstract, subject heading, heading word, drug  
    trade name, original title, device manufacturer, drug manufacturer, device trade name 
and    
    keyword 
/  = MESH/EMTREE term 
$  = Truncation 
adj(N)  = The maximum number of words allowed between the specified search terms 
 
 
 
 
1. clostridium.ti,ab. 
2. CDI.ti,ab. 
3. CDAD.ti,ab. 
4. VRSA.ti,ab. 
5. VISA.ti,ab. 
6. MSSA.ti,ab. 
7. MRSA.ti,ab. 
8. staphylococc$.ti,ab. 
9. Streptococc$.ti,ab. 
10. acinetobacter.ti,ab. 
11. klebsiella.ti,ab. 
12. Enterococc$.ti,ab. 
13. Escherichia.ti,ab. 
14. E Coli.ti,ab. 
15. Enterobacter$.ti,ab. 
16. citrobacter.ti,ab. 
17. serratia.ti,ab. 
18. Burkholderia.ti,ab. 
19. Pseudomonas.ti,ab. 
20. proteus.ti,ab. 
21. Chryseobacteri$.ti,ab. 
22. Flavobacteri$.ti,ab. 
23. Alcaligenes.ti,ab. 
24. Achromobacter.ti,ab. 
25. legionell$.ti,ab. 
26. Mycobacteri$.ti,ab. 
27. rotavirus.ti,ab. 
28. norovirus.ti,ab. 
29. Respiratory Syncytial Viruses.ti,ab. 
30. Hepatitis.ti,ab. 
31. ebola.ti,ab. 
32. Varicella-zoster.ti,ab. 
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33. Cytomegalovirus.ti,ab. 
34. Adenovirus.ti,ab. 
35. Giardia lamblia.ti,ab. 
36. Candida albicans.ti,ab. 
37. Aspergillus.ti,ab. 
38. Cryptococc$.ti,ab. 
39. Cryptosporidi$.ti,ab. 
40. herpes$.ti,ab. 
41. SARS.ti,ab. 
42. Severe Acute Respiratory Syndrome.ti,ab. 
43. Influenza.ti,ab. 
44. Microbial-drug-resistan$.ti,ab. 
45. Antibiotic-resistan$.ti,ab. 
46. Antimicrobial-resistan$.ti,ab. 
47. Multidrug resistan$.ti,ab. 
48. or/1-47 
49. hospital$.ti,ab. 
50. nosocomial.ti,ab. 
51. healthcare.ti,ab. 
52. health care.ti,ab. 
53. exp hospital/ 
54. exp hospital units/ 
55. or/49-54 
56. 48 and 55 
57. exp Clostridium/ 
58. Clostridium difficile/ 
59. exp Clostridium Infections/ 
60. exp Staphylococcus aureus/ 
61. exp Staphylococcal Infections/ 
62. exp Escherichia coli/ 
63. exp Escherichia coli Infections/ 
64. exp Streptococcus/ 
65. exp Streptococcal Infections/ 
66. exp Klebsiella/ 
67. exp Klebsiella Infections/ 
68. exp Acinetobacter/ 
69. exp Acinetobacter Infections/ 
70. exp Enterobacter/ 
71. exp Citrobacter/ 
72. exp Serratia/ 
73. exp Serratia Infections/ 
74. exp Enterococcus/ 
75. exp Burkholderia/ 
76. exp Pseudomonas/ 
77. exp Burkholderia Infections/ 
78. exp Pseudomonas Infections/ 
79. exp Proteus/ 
80. exp Proteus Infections/ 
81. exp Flavobacteriaceae/ 
82. exp Alcaligenes/ 
83. exp Achromobacter/ 
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84. exp Legionella/ 
85. exp Mycobacterium/ 
86. exp Rotavirus/ 
87. Rotavirus Infections/ 
88. exp Norovirus/ 
89. exp Respiratory Syncytial Viruses/ 
90. Influenza, Human/ 
91. exp Hepatitis, Viral, Human/ 
92. exp Enterovirus B, Human/ 
93. exp Enterovirus/ 
94. Enterovirus Infections/ 
95. exp Herpesviridae/ 
96. Ebolavirus/ 
97. exp Adenoviridae/ 
98. exp Giardia/ 
99. SARS Virus/ 
100. Severe Acute Respiratory Syndrome/ 
101. Candida albicans/ 
102. exp Aspergillus/ 
103. exp Cryptococcus/ 
104. exp Sarcoptes scabiei/ 
105. exp Drug Resistance, Microbial/ 
106. or/57-105 
107. 48 or 106 
108. 55 and 107 
109. exp Cross Infection/ 
110. Infectious Disease Transmission, Professional-to-Patient/ 
111. Infectious Disease Transmission, Patient-to-Professional/ 
112. Cross infection.mp. 
113. (professional-to-patient adj2 tranmission).mp. 
114. (patient-to-professional adj2 transmission).mp. 
115. (patient-to-patient adj2 transmission).mp. 
116. (Healthcare-associated adj2 infect$).mp. 
117. (Healthcare-associated adj2 disease$).mp. 
118. (Hospital-acquired adj2 infect$).mp. 
119. (Hospital-acquired adj2 disease$).mp. 
120. (Hospital-onset adj2 infect$).mp. 
121. (Hospital-onset adj2 disease$).mp. 
122. (Nosocomial adj2 infect$).mp. 
123. (Nosocomial adj2 disease$).mp. 
124. (Hospital adj2 transmiss$).mp. 
125. (Hospital adj2 infect$).mp. 
126. HCAI.mp. 
127. HAI.mp. 
128. or/109-127 
129. Mathematic$.ti,ab. 
130. Compartment$.ti,ab. 
131. Stochastic.ti,ab. 
132. Deterministic.ti,ab. 
133. transmiss$.ti,ab. 
134. Epidemi$.ti,ab. 
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135. Individual-based.ti,ab. 
136. Population-based.ti,ab. 
137. dynamic.ti,ab. 
138. or/129-137 
139. Model$.ti,ab. 
140. Model?ing.ti,ab. 
141. Framework$.ti,ab. 
142. or/139-141 
143. 138 and 142 
144. Models, Theoretical/ 
145. mathematical computing/ 
146. Basic Reproduction Number/ 
147. Basic reproduction number.mp. 
148. Effective reproduction number.mp. 
149. Computer Simulation/ 
150. Markov chains/ 
151. Monte Carlo Method/ 
152. Bayes Theorem/ 
153. exp Stochastic Processes/ 
154. or/144-153 
155. ((Mathematic$ or Compartment$ or Stochastic or Deterministic or Transmission or 
Epidemi$ or Individual-based or population-based or Markov or Bayesian or equation or 
theoretic$ or cost-effective$ or cost-benefit or cost-consequence$ or $economic$ or discrete-
event or micro or agent-based or decision or decision-analytic or decision-tree) adj5 (Model$ or 
Model?ing or Framework$ or simulation$)).ti,ab. 
156. 108 or 128 
157. 154 or 155 
158. 156 and 157 
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CHAPTER 3 
 
NOSOCOMIAL TRANSMISSION OF C. DIFFICILE IN 
ENGLISH HOSPITALS FROM PATIENTS WITH SYMPTOMATIC 
INFECTION 
 
 
3.1 PREAMBLE TO RESEARCH PAPER 2 
 
Research paper one presented in the previous chapter, showed that dynamic transmission models 
have been used extensively to evaluate a wide range of hospital infection prevention and control 
policies[1]. In the discussion of the paper, the value of increased routine availability of genetic sequence 
data to help understand the epidemiology of HCAI was touched upon. Indeed, in more recent years, 
molecular typing data have been increasingly used in epidemiological studies to investigate the phylogeny 
and spread of pathogens[2–6]. Around the time of submission, i.e. 2012, similar data was published in a 
series of research papers relating to C. difficile. These studies found a high level of genomic diversity 
between symptomatic CDI patients, and identified only among a minority of the symptomatic patients in 
hospitals a genetic and epidemiological link to other hospitalised patients in an endemic setting [7–9].  
The overall aim of this thesis is to investigate, in a modelling framework, the effectiveness of 
vaccination in a hospital-setting representative for England. The level of cross-transmission and the 
sources of transmission of an infection are important for choosing a model structure. For example, if 
person-to-person transmission is low, the population-effect of any intervention (i.e. reducing the risk of 
infection for the (hospital) population by reducing the number of transmission sources) including 
vaccination will be minimal or non-existent, and therefore a static model would suffice[10].  
While the aforementioned whole genome sequencing work [7–9] shed some light on the 
transmission dynamics of C. difficile, the work was restricted to a limited number of hospitals and there 
remained a need to examine whether such trends were evidenced at a national level. Therefore, using the 
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English mandatory CDI surveillance data, research paper two examines the transmission dynamics of 
CDI at a national level as well as by hospital type (general, specialist and teaching hospitals). A statistical 
model is developed to investigate the presence of clustering in symptomatic CDI patients in hospitals in 
England between 2008 and 2012, indicative of CDI transmission in the hospital setting. This was the first 
time the importance of CDI in-hospital transmission was quantified at a national level. 
This statistical model demonstrates a novel use of routinely collected mandatory data, providing 
clinically relevant insights into CDI epidemiology. The approach can be easily implemented in settings 
outside England, as well as for alternative infectious agents, as has recently been done for E. coli 
bloodstream infections[11]. 
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Abstract 
Background: Recent evidence suggests that less than one-quarter of patients with symptomatic nosocomial 
Clostridium difficile infections (CDI) are linked to other in-patients. However, this evidence was limited to 
one geographic area. We aimed to investigate the level of symptomatic CDI transmission in hospitals 
located across England from 2008 to 2012.  
Methods: A generalized additive mixed-effects Poisson model was fitted to English hospital-surveillance 
data. After adjusting for seasonal fluctuations and between-hospital variation in reported CDI over time, 
possible clustering (transmission between symptomatic in-patients) of CDI cases was identified. We 
hypothesised that a temporal proximity would be reflected in the degree of correlation between in-
hospital CDI cases per week. This correlation was modelled through a latent autoregressive structure of 
order 1 (AR(1)).  
Findings: Forty-six hospitals (33 general, seven specialist, and six teaching hospitals) located in all English 
regions met our criteria. In total, 12,717 CDI cases were identified; seventy-five per cent of these 
occurred >48 hours after admission.  There were slight increases in reports during winter months. We 
found a low, but statistically significant, correlation between successive weekly CDI case incidences 
(phi=0.029, 95%CI: 0.009-0.049). This correlation was five times stronger in a subgroup analysis 
restricted to teaching hospitals (phi=0.104, 95%CI: 0.048-0.159).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
Conclusions: The results suggest that symptomatic patient-to-patient transmission has been a source of 
CDI-acquisition in English hospitals in recent years, and that this might be a more important 
transmission route in teaching hospitals. Nonetheless, the weak correlation indicates that, in line with 
recent evidence, symptomatic cases might not be the primary source of nosocomial CDI in England.  
 
Keywords: Clostridium difficile, mixed-effects model, hospital-acquired infections  
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Introduction 
Clostridium difficile infection (CDI) is a source of considerable morbidity and mortality for hospitalised 
patients, and its prevention, control and treatment place a substantial burden on healthcare systems[12, 
13]. Since 2007, in addition to improved antimicrobial stewardship and mandatory surveillance, enhanced 
infection control measures to prevent C. difficile transmission have been implemented in England. These 
measures have focused on isolating symptomatic patients and improving hospital-cleaning regimens, with 
the goal of meeting government-led CDI reduction targets. Reported cases of CDI have dropped from 
55,498 in 2007/08 to 18,005 in 2011/12[14], at a time when the prevalence of the hyper-virulent C. difficile 
BI/NAP1/027 also decreased[15]. Apart from improved antimicrobial stewardship, guidelines for CDI 
prevention and control assume that symptomatic patients in hospitals account for most C. difficile 
transmission and consequent infection (CDI). However, in 2012 and 2013, research using whole genome 
sequencing of hospital and community isolates from Oxfordshire, United Kingdom, has challenged this 
assumption. Eyre et al found a high level of genomic diversity in samples from symptomatic CDI patients. 
Moreover, only a minority of hospital-onset cases of CDI were found to share an epidemiological link as 
well as genomic link with a symptomatic CDI case[7–9].  
This recent evidence was limited to a small sample of hospitals that were all located in one English 
county. To explore whether these new developments in our understanding of the epidemiology of CDI 
are more generally applicable, we investigated the presence of clustering in symptomatic CDI patients, 
indicative of patient-to-patient C. difficile transmission, in a wide range of hospitals in England between 
2008 and 2012.  
Methods 
Data  
The dataset consisted of mandatory reported details of each identified CDI case >2 years of age 
collected from all 167 National Health Service (NHS) Trusts via a web-enabled surveillance system, held 
by Public Health England (PHE)[16]. Details included the dates of admission and faecal sampling, patient 
category (e.g. inpatient, outpatient etc.) and age. Data covering the period between April 2008 and March 
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2012 were extracted from this surveillance scheme. To ensure consistency in the reported observations, 
we restricted our analyses to NHS acute trusts that followed the Department of Health’s CDI testing 
guidance according to a survey held in 2010[17]. In England, a two test screening algorithm has been 
advocated and hospital trusts are recommended to test patients with diarrhoea (Bristol Stool Chart types 
5-7)[18] using either a GDH Enzyme Immunoassay (GDH EIA), a nucleic acid amplification test 
(NAAT) or the Polymerase Chain Reaction (PCR), followed by a toxin sensitive EIA (or a cell cytotoxin 
neutralisation assay). If both the first test and the second test are positive, the case is eligible for reporting 
to PHE[19]. This resulted in the selection of data from 46 hospitals, belonging to 28 individual NHS 
acute Trusts, and excluded any of the Oxfordshire hospitals (see Table 4). Only CDI positive in-patients 
were included for analysis (i.e. excluding regular attendees, outpatients and patients having visited only 
accident and emergency departments). In order to evaluate healthcare facility associated infections, 
patients with onset of symptoms <48 hours after admission were excluded[20]. We aggregated the 
reported data per hospital by week, using the date of faecal sampling as the time of onset of CDI related 
symptoms.  
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Table 4: Description of CDI data from 46 selected hospitals 
  N  Median/ 
Mean for 4 
year period 
 IQR 
Q1-Q3  
 Median/ 
Mean p.w. 
 IQR 
Q1-Q3 
 Cases per 10,000 
bed-days 
available 
(mean/median) 
Number 
of weeks 
 209   -   -  -  -  - 
Beds 
available 
per 
hospital 
 -  422/423  243-515  -  -  - 
General  
(n=33) 
 -  444/416  346-500  -  -  - 
Teaching 
(n=6) 
 -  837/754  799-941  -  -  - 
Specialist 
(n=7) 
 -  134/169  95-243  -  -  - 
CDI 
cases 
reported 
 12,717  244/276  138-377  1/1.3  0-2  4.1/4.6 
General    8,974 
(70.6%) 
 253/272  194-352  1/1.3  0-2  4.1/4.5 
Teaching   3,348 
(26.3%) 
 551/ 558  331-690  2/2.7  1-4  5.6/6.4 
    
Specialist 
  395  
(3.1%) 
 37/56  30-77  0/0.27  0-0  1.8/3.1 
CDI 
cases 
reported 
with 
onset 
>48h 
  9,574   184/208  104-270  1/1.0  0-1  3.1/3.5 
General    6,779 
(70.8%) 
 200/205  140-247  1/1.0  0-2  3.2/3.5 
Teaching   2,504 
(26.2%) 
 370/417  252-534  1/2.0  0-3  4.1/5.3 
Specialist      291  
(3.0%) 
 31/42  28-53  0/0.2  0-0  1.2/2.2 
Summary statistics of CDI cases reported to the English mandatory surveillance system by a selection of 46 
hospitals from the period of April 2008 to March 2012. IQR = Interquartile range; p.w. = per week
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Statistical methods 
 
A generalized additive mixed-effects Poisson model, allowing for overdispersion, with a log link[21, 
22], was used for the weekly observations of CDI counts. Three effects were identified that required 
inclusion in the linear predictor of this model. Firstly, hospital was introduced as a categorical variable to 
allow for potentially strong clustering due to differences in size, case-mix, and region (see Table 4) 
Secondly, a fixed polynomial-by-hospital interaction term was included to accommodate varying rates of 
change (primarily decline) over the four-year period in observed CDI per hospital; Figure 11 shows the 
time series of symptomatic CDI per hospital. Thirdly, a cyclic effect was included using a periodic 
penalised cubic regression spline to accommodate seasonal patterns of CDI, as have been observed 
previously in settings outside England, and which have been attributed to increased levels of “at risk" 
antibiotic use (e.g. ciprofloxacin) during the winter months (January to March), and influenza (which can 
lead to secondary bacterial infections requiring antibiotic treatment)[23–25]. The intention was that these 
three terms would account for the longitudinal behaviour of weekly CDI counts. Finally, a random error 
term was added to the linear predictor with an autoregressive correlation structure of order 1 (AR(1)) that 
would accommodate local (in time) departures from this base model. The autoregressive component of 
this error would be an indicator of local statistical dependence, and its presence would serve as a 
proposed marker for transmission between symptomatic cases (either directly, or indirectly via the hands 
of healthcare works or hospital surfaces contaminated by symptomatic cases). Full details of the model 
are provided in the supplementary material. 
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Figure 11: Observed weekly number of CDI per hospital over the four-year study period 
 
Grey dots represent the weekly-observed CDI cases within all hospitals from April 2008 to March 2012. X-axis: Week 0 corresponds to the first week of April 2008 and week 209 
to the last week of March 2012.   Red line: the incidence trend over time illustrated by cubic smoothing spline fit (for illustration). 
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All analyses were performed with R 3.0.1 (Team R Development Core, website: http://cran.r-
project.org/) using the R package mgcv[26] and splines. To account more accurately for the decline in 
observed CDI since 2007, the comparative fit of three polynomials, linear, quadratic and cubic was 
assessed using Akaike Information Criterion (AIC). We added a cyclic (periodic) penalised cubic 
regression spline over the variable week of the year and compared model fit with and without this 
smoothing term representing seasonal variations, again based on AIC (see supplementary material). The 
standardized residuals were examined for significant departures from normality[27]. In addition, the Box-
Pierce portmanteau statistic was used to indicate serial dependence. 
Results 
Descriptive statistics 
The 46 hospitals reported 12,717 CDI cases in the four-year study period, of which 9,574 (75.3%) 
had an onset >48 hours after admission.  Between 2008/09 and 2009/10 there was a 30.6% decline in 
CDI reported from these healthcare facilities, in comparison to 20.9% (2009/10 to 2010/11) and 15.7% 
(2010/11 to 2011/12) in the years thereafter. This is in line with national figures (29.1%, 18.0% and 
17.1% respectively). Teaching hospitals reported the highest number of cases, which did not change once 
adjusted for their larger hospital size (expressed in the median number of cases per 10,000 bed-days 
available, where available bed-days is a crude estimate of the number of hospital beds in 2013[28] 
multiplied by the number of days covered by the study,  see Table 4).  
Base-model assuming no transmission patterns 
For all three representations of the base-model, a model including seasonal patterns provided a 
moderately better fit, and a combination of seasonality and a cubic time trend proved the best model fit 
(see Supplementary table 1). By examining the correlogram of the final base-model’s normalized residuals, 
we could identify whether there was evidence of serial dependence (Figure 12A). Such dependence could 
be explained by transmission between symptomatic CDI carriers. Figure 12A illustrates a low but 
significant correlation between cases in a given week and symptomatic carriers present in the hospital one 
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and two weeks earlier (p<0.05), with a slightly stronger correlation at two weeks. Taking a total of a 20-
week interval (as transmission events between hospital cases with an onset further than 20 weeks apart is 
assumed to be unlikely), the model revealed a highly significant Box-Pierce Q-statistic (X2 = 54.59, 
degrees of freedom (df) = 20, p = 0.00005), indicating non-independence. Therefore, the AR(1)-model 
was fitted, with the best fitting cubic polynomial to represent the decline in CDI over time, as well as 
seasonality.  
Figure 12: Dependence between observed weekly number of CDI – base-model 
 
A and B: autocorrelation function (ACF) of normalized residuals of the base-model fitted to data of all hospitals 
(A) and of teaching hospitals only (B) including a fitted cubic representation of the CDI trend over time and 
seasonality. The blue lines correspond to the threshold for significance of correlation (dependence) (p<0.05) 
between lagged weekly observations up to week 20. E.g. crossing of this threshold by the base-model residuals at lag 
1 and lag 2 for the model fitted to all hospitals suggests that a correlation exists between the observed CDI in a 
given week and the number of CDI cases present in the hospital one and two weeks earlier. 
 
AR(1)-model assuming transmission patterns  
Supplementary figure 1 presents the seasonal variation of CDI in hospitals within our sample fitted 
by the AR(1)-model, and shows a slight increase during the months January to March. Assuming that 
symptomatic cases primarily caused acquisition among patients admitted to hospital up to one week later 
and, to a lesser extent, to cases admitted beyond this time (i.e. the AR(1) structure), the estimated 
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magnitude of dependence was low, but statistically significant (ɸ = 0.029 (95% CI = 0.009-0.049). This 
suggested that transmission between symptomatic CDI cases was affecting the weekly-observed CDI, but 
that its role in acquisition might be limited.  This transmission pattern between observed weekly CDI was 
not fully explained by the AR(1) structure, as is indicated by the significant correlation at lag(week) 2 still 
being present after having fitted the AR(1) covariance structure (Box-Pierce Q-statistic (X2  = 44.4, df = 
20, p-value = 0.001)) (see Figure 13A). 
AR(1)-model by hospital type 
The negative correlation presented in the AR(1) cubic model after week 20 (Figure 13A) implied that 
the model might be over-fitting our data. Also, diagnostic plots suggested deviation from normality in the 
model’s standardized residuals (see Supplementary figure 2A).  This can be explained by the large 
variability in the number of reported cases per hospital, with a much greater number of reports and 
related rate of change in reports over time from teaching hospitals compared to just a few cases from 
specialist and some general hospitals. As a consequence, a hospital-specific term in the model 
representing the change in CDI reports over time might not be suitable for hospitals with only a few 
cases reported, whereas such specification is required to represent the CDI trend in teaching hospitals. 
Fitting the model to the more homogeneous group of teaching hospitals only, revealed a stronger, but still 
relatively low statistically significant correlation between CDI cases and patients present in the hospital 
one week later (ɸ = 0.104 (95% CI = 0.048-0.159) (see Figure 13A), which was captured by the AR(1)-
structure (Box-Pierce Q-statistic X2 =23.2, df=20, p=0.281) (see Figure 13B).  
Figure 14 illustrates the cubic AR(1) model predictions in comparison to the observed teaching 
hospital data and Supplementary figure 2, the model diagnostics.  
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Figure 13: Dependence between observed weekly number of CDI – AR(1)-model 
 
A and B: autocorrelation function (ACF) of normalized residuals of the AR1-model fitted to data of all hospitals 
(A) and of teaching hospitals only (B) including a fitted cubic representation of the CDI trend over time and 
seasonality. As in figure 2, the blue lines correspond to the threshold for significance of correlation (dependence) 
(p<0.05) between lagged weekly observations up to week 20. Crossing of this threshold by the AR(1)-model 
residuals at lag 2 suggests the AR(1) structure (symptomatic cases primarily cause acquisition of C. difficile among 
patients admitted to hospital up to one week later and, to a lesser extent, to cases admitted beyond this time), does 
not fully explain the dependence structure between weekly observations. 
 
Figure 14: AR(1) model fit teaching hospitals 
 
Grey dots represent the weekly-observed CDI cases within the teaching hospitals from April 2008 to March 2012. 
X-axis: Week 0 corresponds to the first week of April 2008 and week 209 to the last week of March 2012.   Blue 
line: fit of the AR(1) model with a cubic representation of the rate of change of CDI over time and seasonality.  
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Discussion 
In this study we explored the significance of symptomatic patient-to-patient CDI transmission in 
English hospitals as a source of hospital onset CDI. We found a statistical significant signal of 
dependence between symptomatic CDI patients spending time in hospital close in time, which suggested 
symptomatic patient-to-patient transmission of CDI was present. Nonetheless, the low magnitude of 
correlation between weekly cases in the AR(1) model, implies that the role of symptomatic carriers in 
CDI-acquisition was not as important as previously supposed. The highest number of CDI cases was 
reported in teaching hospitals, which corresponded to their overall prevalence of HCAI being among the 
highest according to the English National Point Prevalence Survey on Hospital-acquired infections 
(HCAI)[16]. This could be attributed to the more vulnerable case-mix of such hospitals, whom might be 
more prone to acquiring CDI[29].   Taking CDI reports from the teaching hospitals only, the association 
between symptomatic carriers was somewhat stronger, but still relatively low. Our findings are in line with 
recent evidence from whole genome sequencing of 1223 isolates from healthcare (among others from 
two large acute teaching hospitals, one specialist and one general district hospital) and community onset 
CDI cases in Oxfordshire, England isolated from 2008 to 2011[7]. Less than 20% of the genetically linked 
CDI positive cases had documented hospital contact with a symptomatic patient7. In addition, 45% of the 
included CDI cases could not be related to any other symptomatic case (community or healthcare setting) 
as they were too genetically diverse[7]. Even considering the reported low sensitivity of the toxin EIA 
test[20] used for CDI identification in the referenced study, the diversity argues for alternative sources of 
many CDI cases. 
Improved infection control, with a primary focus on preventing transmission, such as hand hygiene, 
isolation of symptomatic cases, and environmental cleaning, might result in lower rates of successful 
transmission between symptomatic cases following contact[30]. In addition, once a patient comes in 
contact with C. difficile or its spores, the development of CDI is dependent on the disruption of the 
normal gut flora, primarily due to antibiotic use such as broad-spectrum cephalosporins and 
quinolones[31, 32]. Nonetheless, this would not explain the origin of symptomatic patients lacking a 
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shared spatial-temporal and/or genetic link. C. difficile has been recovered from hospital rooms occupied 
by both symptomatic and asymptomatic carriers[33–35] and its spores can persist in the environment for 
as long as 20 weeks[36]. Therefore, transmission from contaminated hospital surfaces could suggest 
symptomatic hospital cases are unrelated, whereas actually indirect-cross infection could have occurred. 
However, a genetic link would still be found if cases had acquired their infection from the same 
contaminated hospital surface. If no restrictions were applied to the infectious period, incubation period 
or length of ward contamination, 27% of the sequenced samples in the earlier mentioned study shared 
both a genetic and an epidemiological hospital contact [7]. Alternatively, asymptomatic carriers could 
contaminate hospital surfaces with lower intensity than symptomatic carriers, hence cause acquisition at 
low frequency, which could potentially explain the wide genomic diversity among cases [37]. 
Importation of symptomatic and asymptomatic carriers from community-settings such as long-term 
care facilities (LTCF) has also been suggested as a source for hospital-onset CDI[38, 39]. A population-
based study conducted in the United States showed that out of a total of 416 identified CDI cases, 41% 
had onset of symptoms in the community or within 48 hours after admission and no hospitalisation in the 
12 weeks prior to onset[40].  We excluded patients with an onset of CDI <48 hours into admission. This 
is a frequently used, but arbitrary, cut-off to define community-acquired HCAI. Hence it is possible that 
our data included asymptomatic patients who acquired the bacteria elsewhere, and developed symptoms 
in the hospital >48 hours after admission. Moreover, in addition to onset within 48 hours into admission, 
no hospitalisation in the past 12 weeks is an often-used additional requirement for community-acquired 
CDI [11].  As we did not have information on previous hospitalisation, the possibility exists that cases 
defined as community-acquired in our data, and were therefore excluded, actually were hospital-acquired 
cases, i.e. patients who acquired C. difficile in their previous stay, but started to develop symptoms after 
discharge and were re-admitted with symptomatic CDI. Furthermore, approximately 20% of cases with a 
first occurrence of CDI experience recurrence after discontinuation of treatment[41, 42]. Re-admitted 
CDI carriers, who resolved their symptoms but remained colonised resulting in a recurrent episode once 
e.g. put on at risk antibiotics, could be partly responsible for the low correlation between symptomatic 
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carriers. However, considering the known chances of relapse, we do not expect these can be primarily 
responsible for the results of this study.  
Finally, and although not our primary focus, we found evidence of seasonal variations in CDI 
incidence in our selection of English hospitals, with slightly elevated reports of hospital-associated 
symptomatic CDI in the winter months. Seasonality has been suggested in relation to increased levels of 
CDI related antibiotics during the winter months in settings outside of England[23–25]. Comparison of 
variability in antibiotic prescribing patterns within English hospitals with fluctuations in hospital reported 
CDI incidence would be an interesting area of investigation. Nonetheless, the seasonal component in our 
model only explained a small proportion of the behaviour of the weekly reported CDI (reflected by a 
moderate decrease of AIC), and we would like to urge for more research on the presence of seasonal 
patterns of CDI in England.  
This study had several limitations. Firstly, we selected weekly intervals for our analysis. Both the 
incubation time and infectious period of C. difficile have not been quantified with certainty.  Studies have 
suggested that person-to-person transmission occurs primarily within a week (ranging from a median of 1, 
4 or 8 days after CDI diagnosis)[8], whereas a median incubation time of 2-3 days[20] to 18-33 days has 
been proposed[8]. Hence, onset of symptoms following symptomatic patient-to-patient transmission 
might occur after the one-week time interval, which could have affected the strength of correlation 
between weekly incidences. Secondly, strains may vary in their pathogenicity[43] and transmissibility[9].  
The routinely collected surveillance data did not contain ribotype specific information, so we could not 
establish to what extent our results are strain-specific as well as whether the hospitals in our sample are 
representative with regards to strain prevalence. Moreover, the AR(1) structure was unable to fully explain 
the correlation between weekly cases close in time using data from all hospital types, whereas it could for 
the teaching hospitals only. This might be a consequence of the stochastic nature of the few CDI cases 
reported by the smaller hospitals included in the overall dataset. Alternatively, teaching hospitals might 
have better environmental cleaning practices in place and/or are more likely to change antibiotic 
prescribing practices following an outbreak, resulting in more rapid containment. Further research is 
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needed to clarify the observed heterogeneity in reported hospital-acquired infection rates and 
transmission between teaching and non-teaching hospitals. Finally, alternative causes of dependence of 
the weekly CDI observations cannot be ruled out, e.g. a Scottish study[44] identified a temporal 
correlation between antibiotic use and HA-CDI [44]. However, as the results of the referenced study[44] 
suggest, it is unlikely that antibiotic hospital consumption will fluctuate between weekly time intervals.  
After investigation of the association between monthly variations in antibiotic use and monthly variations 
in observed CDI, Vernaz and colleagues (2009) identified that, for almost all of the antibiotics 
investigated, the association with observed CDI was significant with a lag of several months (among 
others ciprofloxacin, fluoroquinolones and cefuroxime) [44]. In addition, cases arising from asymptomatic 
carriers or environmental sources might correlate in space and time as well. However, the level of onward 
transmission from asymptomatically colonised individuals is highly uncertain, nor has foodborne 
transmission of C. difficile to humans been established with certainty [45, 46]. Given the infectious nature 
of symptomatic C. difficile cases, especially in settings with high antibiotic use, we expect symptomatic 
patient-to-patient transmission to be the most conservative explanation.  
Despite the limited information present in routinely collected hospital infection data, this study has 
provided further insight in the hospital transmission dynamics of C. difficile.  Our results indicate that 
patient-to-patient transmission when only those patients with symptomatic CDI are considered, may 
account for a small number of transmission events. To improve our understanding of the epidemiology 
of CDI, the role of other patient groups should be considered, such as those in the community and 
asymptomatic carriers, as well as the importance of indirect transmission from contaminated surfaces in 
the hospital environment and the role of antibiotic use. Individual-level patient data, which can inform 
dynamic transmission models would certainly aid the investigating and quantification of the potential 
sources of CDI transmission[47–49] and will be another area of our further investigations. 
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Supplementary material 
A1. Model description 
The following generalized additive mixed effects Poisson model allowing for overdispersion, with 
a log link[1, 2] was used for fitting to the data of all hospitals as well as of the teaching hospitals alone: 
 
𝑌𝑗𝑡|𝑅𝑗𝑡  ~ 𝑃𝑜𝑖𝑠𝑠𝑜𝑛(𝜆𝑗𝑡) 
log(𝜆𝑗𝑡) = 𝛼𝑗 + 𝑓1𝑗(𝑡) + 𝑓2(𝑡𝑤.𝑜.𝑦.) + 𝑅𝑗𝑡 
 
Where, 𝜆𝑗𝑡 indicates the observed number of CDI cases 𝜆 at week t in individual hospital j, given the 
random error term 𝑅𝑗𝑡 (see later), 𝛼𝑗 and 𝑓1(𝑡) are the individual hospital intercept and representation of 
the cross-sectional trend respectively, and  𝑓2(𝑡𝑤.𝑜.𝑦.)  the seasonal variation in CDI incidence. The 
alternative representations of the longitudinal CDI trend were specified as a linear, quadratic and cubic 
polynomial respectively. We added a cyclic (periodic) penalised cubic regression spline over the variable 
week of the year, i.e. 𝑓2(𝑡𝑤.𝑜.𝑦.) =  ∑ 𝑏?̃?
𝑘−1
𝑖=1 (𝑡𝑤.𝑜.𝑦.)𝑆𝑖; we provided the end points of the smoother (i.e. 
the first and last week of the year, week 1 and week 53) and allowed automatic generation of the 
remainder knots (knots specify adjacent intervals, where each interval represents an individual 
polynomial)[3]. Finally, 𝑅𝑗𝑡  denotes the residual term in hospital j at week t, which were of primary 
interest.  We assumed a temporal proximity pattern and allowed for additional Poisson variation Zt~iid 
N(0, σ2). This temporal proximity assumed that incidences of weeks close in time are strongly correlated, 
and that this correlation faded rapidly over time according to  𝑅𝑗𝑡 = ϕ
𝑘𝑅𝑗 (𝑡−𝑘) + 𝑍𝑡 , 𝑘 = 1, 2, ….[4], k 
represents the weekly distance between the incidence observations and ϕ corresponds to the strength of 
the correlation, i.e. the correlation coefficient. If ϕ𝑘= 0, this corresponds to no (auto)correlation, and 
thus no weekly CDI dependence, indicating no symptomatic transmission. If ϕ𝑘= 0 and σ2 = 0, the data 
follows a simple Poisson distribution.  
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A2. Model Fitting 
 
The base-model (assuming no transmission, i.e. excluding AR(1)) was fitted by a penalised 
likelihood using the command gam() (library mgcv).  The different polynomials, denoting alternative 
representations of the CDI  incidence trend, were fitted by generating a B-spline basis matrix without 
interior knots using the command bs()(library splines) and seasonality was represented by a cyclic cubic 
smooth function using the command s(.., bs = “cc”) (library mgcv)[3]. The models were fitted both with a 
Poisson and quasi-Poisson distribution, the latter to allow for overdispersion (represented by a scale 
parameter >1 (Supplementary table 1) which is common in hospital count data. For all three 
representations of the base-model, a model including seasonal patterns provided a moderately better fit 
(with a reduction in AIC of 15.3, 14.3, 16.3, for the linear, quadratic and cubic null-models including 
seasonality, respectively).  For the seasonal trend, the distributional assumption under the null-hypothesis 
(chi-square) does not have a firm theoretical basis and is conditional on the smoothing parameter (i.e. the 
degrees of freedom estimated for the smooth term). Hence, the p-value provided by the gam model for 
the seasonal trend is an approximation and should be considered with care[3]. However, considering the 
reduction in AIC, seasonality was kept in the model. Supplementary table 1 summarizes model fit of the 
different representations of the declining incidence trend over time and adjusting for seasonality. A linear 
representation provided the worst model fit. Both the quadratic and the cubic time trend showed a 
considerable improvement in model fit in comparison to the linear trend, while the cubic time trend 
showed a moderately better fit in comparison to the quadratic time trend. As a next step, we added an 
AR(1) temporal covariance structure using the Penalised Quasi-likelihood based (PQL) based command 
gamm()(library mgcv). In contrast to gam(), this command allows the addition of patterned covariance 
structures. This method can work poorly (i.e. underestimate the standard error of the fitted parameters) 
for Poisson data with a mean number of counts of less than five[1, 5].  Comparison of model fit by a 
penalised likelihood and PQL resulted in similar model estimates for our base-model, which provided 
confidence in the PQL method used for our data. Another caveat of the PQL method is the lack of a real 
likelihood. Hence, it was not possible to formally test whether the inclusion of the AR(1) residual 
correlation structure indeed did improve model fit. For this reason, we evaluated the estimated value of 
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ϕ𝑘 (i.e. whether departure from 0), and the autocorrelation function (ACF) coefficients of the best fitting 
null-model and AR(1) model normalized residuals to test departure from independence (p <0.05). 
 
Supplementary table 1: Comparison of model fit for the base-model including alternative representations of the CDI 
incidence trend 
All 
hospitals 
 Poisson      Quasi-
Poisson 
      
Model  AIC  X2  p-value 
seasonality 
 AIC  F  p-value 
seasonality 
 Scale 
parameter 
Linear  + 
seasonality 
 22544  25.91  0.0002  NA  25.91  .0006  1.095 
Quadratic + 
seasonality 
 22454  24.99  0.0003  NA  2.837  .0008  1.081 
Cubic + 
seasonality 
 22426  27.31  0.0001  NA  3.131  .0003  1.074 
Cubic no 
seasonality 
 22442  -  -  NA  -  -  1.076 
Teaching 
hospitals 
 Poisson      Quasi-
Poisson 
      
Model  AIC  X2  p-value 
seasonality 
 AIC  F  p-value 
seasonality 
 Scale 
parameter 
Linear + 
seasonality  
 4054   6.54  0.142  NA   .003  .374  1.304 
Quadratic + 
seasonality  
 4032   6.33  0.108  NA   .156  .222  1.282 
Cubic + 
seasonality  
 4018  18.18  0.005  NA  .854  .016  1.266 
Cubic no 
seasonality 
 4025  -  -  NA  -  -  1.273 
AIC = Akaike Information Criterion, the lower the value, the better the fit. Upper half of table: model fit to 
data of all hospitals. Lower half: model fit to data from teaching hospitals. Left half of table: model fit assuming a 
Poisson distribution. Right half: model fit assuming an overdispersed Poisson (quasi-Poisson) distribution) 
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Supplementary figure 1: Seasonal variations of symptomatic C. difficile infection with onset >48 hours after admission 
 
 
Fitted cyclic penalised cubic regression spline (representing season variations) for the cubic AR(1) model fitted to 
data of all hospitals (A) and data of the teaching hospitals only (B). 
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Supplementary figure 2: Diagnostics of cubic AR(1)-models 
 
Residual diagnostics of AR(1)-model fitted to data of all hospitals, including a fitted cubic representation of CDI 
behaviour over time and seasonality. A: Quantile-Quantile (Q-Q) plot, deviation from a straight line denotes 
deviation from normal distribution. B: Residuals plotted against the linear predictor. C: frequency distribution of the 
model residuals. D: data against fitted values. E-H: Residual diagnostics of AR(1)-model fitted to data of teaching 
hospital only. 
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CHAPTER 4 
 
EXCESS LENGTH OF STAY AND MORTALITY DUE TO 
CLOSTRIDIUM DIFFICILE INFECTION: A MULTI-STATE 
MODELLING APPROACH 
 
 
4.1  PREAMBLE TO RESEARCH PAPER 3 
 
As laid out in Chapter one, estimates of LoS and mortality are key determinants to help quantify 
the health and economic burden of hospital-acquired infections, including CDI[1]. Previous estimates of 
additional excess bed days attributable to healthcare-acquired (HA)-CDI have varied widely, partly due to 
methodological weaknesses[2]. Patients that stay in hospital longer are at increased risk of acquiring a 
nosocomial infection. Therefore, a ‘naïve’ approach of retrospectively comparing the mean LoS of CDI-
negative patients to the mean LoS of CDI-positive patients would result in biased estimates, i.e. inflate the 
effect of hospital stay attributable to CDI[3]. Retrospectively matching cases to controls based on the time 
to exposure, that is, matching exposed patients (e.g. CDI cases) to unexposed patients that were in hospital 
at least as long as the time (t) of CDI-onset in the exposed person, accounts for this so-called time 
dependent bias to some extent[4]. However, as this approach conditions on events that occur after the time 
of exposure, i.e. matches exposed patients to unexposed patients that are still in hospital at time t and 
remain negative until discharge, selection bias is introduced[5].  
 
Both of these methods have predominated in CDI literature[2, 6]. At the time of publication of 
research paper three, the only two previous studies that did employ appropriate methods, that is Cox 
proportional hazard modelling including CDI as a time-dependent exposure and/or multi-state modelling 
(both are further explained in research paper three), reported very different results, i.e. no CDI attributable 
stay[7] compared to an additional stay of six days[8]. Hence there remains considerable uncertainty in the 
literature on the impact of CDI on length of stay. Moreover, no robust estimates of the excess LoS due to 
CDI are available from an English, nor European-setting. 
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From the perspective of modelling the effectiveness of CDI vaccination, the excess time that 
CDI patients spend in hospital and/or the in-hospital risk of mortality are important. Both give insight into 
the incremental cost of the infection, and additionally are likely to have an impact on the transmission-
dynamics of the infection. Research paper three is the first to investigate excess LoS and mortality due to 
CDI in a large English hospital using robust and currently preferred methods. Moreover, the paper 
investigates the impact of the severity of CDI on these outcomes. As research paper three reports on the 
severity of CDI of patients in our sample, the infection causing ribotypes, as well as patient co-morbidities, 
the work allows for interpretation of the generalisibility of the findings to other hospitals or regions.  
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Abstract 
Background: The burden of healthcare associated infections (HCAI), including healthcare-acquired 
Clostridium difficile (HA-CDI) can be expressed in terms of additional length of stay (LoS) and mortality. 
However, previous estimates have varied widely and, although some considered time of infection onset 
(time-dependent bias), none considered the impact of severity of HA-CDI; this was the primary aim of 
this study. 
Methods: The daily risk of in-hospital death or discharge was modelled using a Cox proportional hazards 
model, fitted to data on patients discharged in 2012 from a large English teaching hospital. We treated 
HA-CDI status as a time-dependent variable and adjusted for confounders. In addition, a multi-state 
model was developed to provide a clinically intuitive metric of delayed discharge associated with non-
severe and severe HA-CDI respectively.   
Findings: Data comprised 157 (including 48 severe) HA-CDI cases amongst 42,618 patients. HA-CDI 
reduced the daily discharge rate by nearly one-quarter (HR: 0.72 (95% CI: 0.61-0.84) and increased the in-
hospital death-rate by 75% compared with non-HA-CDI patients (HR: 1.75 (95% CI: 1.16-2.62). 
Whereas, overall HA-CDI resulted in a mean excess LoS of ~7 days (95%CI = 3.5 – 10.9), severe cases 
had an average excess LoS which was twice (~11.6 days [95% CI = 3.6-19.6] that of the non-severe cases 
(~5 days [1.1-9.5]).  
Conclusions: HA-CDI contributes to patients’ expected LoS and risk of mortality. However, when 
quantifying the health and economic burden of hospital-onset of HA-CDI, the heterogeneity in the 
impact of HA-CDI should be accounted for.  
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Introduction 
Clostridium difficile, is a considerable cause of healthcare acquired infections (HCAI) in Europe and 
the United States[9, 10]. In common with other HCAI, patients with healthcare-acquired Clostridium 
difficile infection (HA-CDI) place a serious health and economic burden on the hospital system. Previous 
economic analyses of HA-CDI have shown that direct healthcare, and opportunity, costs due to excess 
length of hospital stay (LoS) were the main HA-CDI cost drivers[11–14]. However, a recent review of 
publications on HA-CDI associated additional hospital stay, showed wide variation in excess LoS, ranging 
from 2.8 to 16.1 days[2]. These studies primarily used simple regression models, which did not account 
for the timing of onset of infection (“time-dependent bias”)[15]. Hence, they may overestimate the 
duration of excess hospitalisation, as a longer stay in hospital may increase the risk of infection. This has 
been demonstrated rigorously for other HCAI[1, 15, 16] but  has rarely been explicitly explored for HA-
CDI[2].  
Two recent publications, which implicitly adjust for “time dependent bias”, reported very 
different results[7,8]. Forster et al, using a Cox proportional hazards model, concluded that HA-CDI 
patients had a median excess LoS of six days,[8], while Mitchell et al found no significant impact of HA-
CDI on hospital stay[7]. Mitchell et al utilised multi-state model (MSM), that in addition to appropriately 
adjusting for both time to event bias and the competing end-points related to nosocomial infections, 
namely discharge and death[7], also provided more easily interpretable results than the proportional 
hazards model. In their conclusion, Mitchell et al posit that their results, and the difference to earlier 
estimates, could potentially be explained by milder HA-CDI due to a lack of circulating hypervirulent 
PCR ribotype 027 in their locality (Tasmania, Australia).   
As the clinical presentation of HA-CDI can range from mild diarrhoea to pseudomembranous 
colitis and even death, and the prevalence of severe HA-CDI can vary regionally, due to differences in 
ribotype prevalence[17–19] and case-mix[20], it is important for any estimation of attributable LoS and 
mortality to consider these heterogeneities. In this study, we demonstrate the impact of severe infection 
on the expected delayed discharge and mortality associated with HA-CDI based on a Cox proportional 
hazard model as well as MSM techniques. Hence, we provide, for the first time, a robust estimate of 
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excess LoS due to HA-CDI in an English teaching hospital and quantify the additional impact of severe 
HA-CDI on LoS and mortality.     
Methods 
Data 
Data were collected from Guy’s and St Thomas’ National Health Service (NHS) Foundation 
Trust, a teaching hospital including two sites with ~1200 beds. Details of all inpatients discharged in 2012 
(namely: age, primary diagnosis code, dates of admission and discharge, and discharge status [i.e. 
discharge alive or death]) were extracted from the Trust’s electronic patient record database.  These data 
were linked to the Trust’s voluntarily collected HA-CDI surveillance database containing information on 
date of onset of symptoms, markers of HA-CDI severity, antibiotic treatment and, where known the 
ribotype that caused the infection. In order to evaluate only those infections that were hospital-acquired, 
patients with symptom-onset ≤48 hours after admission and all patients with a LoS ≤48 hours were 
excluded from analyses. 
Severe HA-CDI 
Severe HA-CDI was defined by the clinical presence of one or more of four indicators: i) 
peripheral white blood cell count >15x109/L; ii) acutely rising serum creatinine (>50% increase above 
baseline); iii) temperature >38.5˚C; or iv) radiographic evidence of colitis or endoscopic appearance of 
pseudomembranous colitis[21].  
Procedure 
Proportions and medians were compared using the X2 test and Mann-Whitney-Wilcoxon test 
respectively. We used a Cox proportional hazards model to estimate the impact of HA-CDI on the risk of 
hospital discharge alive or death. This method can adjust for time-dependent bias and take into account 
the impact of important non-HCAI variables such as age and co-morbidity score on LoS. Hence, the 
method can identify and adjust for important confounders.    Nonetheless, it does not produce an easily 
interpretable metric (namely hazard ratios) for economic analysis. Therefore we constructed a suitable 
MSM, to quantify the average excess LoS caused by the event of interest, i.e. HA-CDI.  However, using 
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established methodology, MSM do not account for the potential confounding effect of other variables. As 
an alternative, we stratified our data by each of the relevant confounders, and performed the MSM on 
these subsamples. 
Statistical analysis 
Cox Regression Model 
The risk of in-hospital death or discharge was modelled with a Cox proportional hazards model, 
with HA-CDI treated as a time-dependent risk factor. We added the covariates age and co-morbidity to 
assess their confounding effects on the risk of in-hospital death or discharge. Co-morbidity was expressed 
in a Charlson co-morbidity index score[22] based on the patients’ primary diagnosis code. These primary 
diagnoses were classified using International Statistical Classification of Diseases and Related Health 
Problems 10th Revision (ICD-10) codes[22].  
Multi-state Model 
We developed a MSM with four states; admission with no HA-CDI (state 0), HA-CDI (state 1), 
discharge alive (state 2) and death in hospital (state 3)[23].  Since we were solely concerned with HA-CDI, 
we assumed all patients were admitted to the hospital without infection. Uninfected patients remained in 
state 0 from admission until discharge (state 2) or in-hospital death (state 3).  Infected patients entered 
state 1 and then remained in that state until discharge or death. This competing end-points approach 
allowed for assessment of the impact of mortality due to HA-CDI on a patients’ expected excess stay, e.g. 
whether HA-CDI-related mortality may in fact shorten expected LoS. Secondly, prolonged LoS 
associated with HA-CDI was estimated by constructing a MSM where the two competing end-points 
were combined as a single state[24]. Transitions between states were determined by time-varying hazards, 
which were estimated using the Aalen-Johansen estimator[25]. For each point in time t (in days), the 
expected LoS for HA-CDI and non-infected patients was compared. The unadjusted expected change in 
LoS was then calculated as the average difference in LoS of HA-CDI and non-HA-CDI cases across all 
days, weighted relative to the frequency of the possible events (i.e. HA-CDI, discharge alive and in-
hospital death) on each day[5]. Bootstrapping[26] was used to obtain robust standard error-based 
confidence intervals. 
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To assess the effect of specific confounders identified by the Cox regression model, we 
performed the MSM comparing patients within their risk group by stratification, for each potential 
confounding variable separately. Also, to evaluate the effect of severe HA-CDI on excess LoS, a stratified 
analysis was conducted, comparing mean differences in LoS of non-severe HA-CDI and severe HA-CDI 
cases respectively to non-infected patients.  
All analyses were performed with R 3.0.1 (Team R Development Core, website: http://cran.r-
project.org/). The R-packages mvna and etm were used to estimate the excess LoS and standard errors[25, 
27] and the R-package survival was used for the Cox model. 
Results 
Descriptive statistics 
The data comprised a total sample of 42,618 patients, 157 (0.4%) of whom had an episode of 
HA-CDI, of which  48 (30.6%) were severe (Table 5). The median age was 72 years [Inter-quartile range 
(IQR) = 57-82] for the infected, which was significantly higher than the median age of non-infected 
patients (47 [IQR = 26-68], p < 0.0001). The vast majority of all patients had no reported co-morbidities 
(91.6%, 39,146 patients). This percentage was slightly lower in the HA-CDI infected patient group 
(84.7%, 133 patients), than in the non-infected group (91.9%, 39,013 patients, p = 0.002)).  On average, 
patients with severe HA-CDI had spent a shorter time in hospital until identification of the infection than 
non-severe cases (Table 5). Moreover, after detection, the median LoS was longer for severely infected 
patients (Table 5).  Finally, the causative PCR ribotypes were known for 113 (72.0%) of the HA-CDI 
patients. None of these patients had an infection caused by hypervirulent PCR ribotype 027 
(Supplementary table 2). 
111 
 
Table 5: Demographic characteristics of the Guy’s & St Thomas hospital patients discharged in 2012 
Variable  Non-infected 
N = 42,461 
 Infected 
N=157 
 Non-severe HA-CDI 
N = 109  
 Severe HA-CDI 
N=48 
 Total 
N=42,618 
Age (N (%))           
>65 years old  13,446 (31.7)  102 (65.0)  73 (67.0)  29 (60.4)  13,548 (31.8) 
Co-morbidity (N (%))           
Charlson index score = 0  39,013 (91.9)  133 (84.7)  96 (88.1)  37 (77.1)  39,146 (91.9) 
Charlson index score ≥ 1  3,448 (8.1)  24 (15.3)  13 (11.9)  11 (22.9)  3472   (8.1) 
Death (N (%))           
Yes 
 
 801   (1.9)  24 (15.3)  15 (13.8)  9 (18.7)  825   (1.9) 
Length of stay  
(Median/Mean [IQR]) 
 
 
 4.0/7.6 [2.0-8.0]  25.0/36.6 [15.0-50.0]  29.0/36.6 [15.0-50.0]  22.5/36.8 [14.8-44.8]  4.0/7.7 [2.0-8.0] 
Length of stay pre-
infection  
(Median/Mean [IQR]) 
 
 NA  9.0/15.8   [4.0-18.0]  10.0/17.1 [4.0-22.0]  7.0/12.1 [3.8-12.3]  NA 
Length of stay post-
infection  
(Median/Mean [IQR]) 
 
 NA  12.0/21.1 [6.0-25.0]  11.0/19.5 [6.0-24.0]  13.5/24.6 [7.8-27.8]  NA 
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Cox regression model results 
HA-CDI-positive patients had a lower daily chance of being discharged (alive or dead) than non-
infected patients (Table 6). Both age of the patient (i.e. older or younger than 65 years old), and the 
patient’s co-morbidity were significant confounders, and the adjusted daily hazard of discharge (AHR) for 
HA-CDI patients was 0.72 [95% Confidence Interval (CI): 0.61-0.84] (Table 6). Moreover, HA-CDI 
patients were at higher risk of experiencing in-hospital death than HA-CDI-negative patients (AHR = 
1.75 [95% CI: 1.16-2.62]. Accounting for severity of the infection revealed that, compared to non-infected 
patients, severe cases had a daily likelihood of discharge which was two times more reduced than the 
probability of discharge of non-severe cases (Table 6). However, severe infection did not result in a 
further elevated chance of dying in hospital (Table 6). 
Multi-State Model results 
The four state multi-state model, which allowed for competing end-points, and the three state 
combined end-point model provided similar estimates for the excess LoS. Thus mortality due to HA-CDI 
did not seem to have an impact on the estimated additional days of hospitalisation associated with HA-
CDI. For this reason, the outcomes of the combined end-point model are presented only. The average 
extra number of days (unadjusted for confounders) spent in hospital due to HA-CDI was ~7 days [95% 
CI = 4 – 11] (Table 6). Patients with severe HA-CDI had, on average, twice the additional LoS of non-
severe cases, but with overlapping confidence intervals (Table 6). Stratification of our sample by age and 
co-morbidity score still showed an impact of HA-CDI on the patients’ stay. Among HA-CDI patients 
<65 years of age (55 patients in total), we found an average excess LoS of ~7 days [95% CI = 1-14 days 
[associated with HA-CDI; for the >65 population (133 patients) this was ~6 days [95% CI = 2-11].  A 
sample restricted to patients with a co-morbidity score <1 only (133 patients) showed an excess LoS of 
~7 days [95% CI = 3-11] whereas an average excess LoS of ~10 days [95% CI = -1-21] associated with 
HA-CDI was found for patients with a score of >1 (24 patients).   
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Table 6: Hazard ratios for in-hospital death or discharge alive and excess length of stay estimated from the Cox Regression Model and Multi-State Model 
 
 Hazard ratio for discharge alive  
(95% CI)a 
 Hazard ratio for in-hospital  
death (95% CI)a 
 Hazard ratio for discharge alive or 
death (95% CI)a 
 Excess 
LOS (95% 
CI)d 
 
Exposure 
 
Time adjustedb 
 
Fully 
adjustedc 
 
Time 
adjustedb 
 
Fully 
adjustedc 
 
Time 
adjustedb 
 
Fully adjustedc 
  
All CDI 
 
 0.66 (0.56-0.77)  0.72 (0.61-0.84)  1.98 (1.33-2.96)  1.75 (1.16-2.62)  0.73 (0.64-0.84)  0.79 (0.69-0.92)     7.2 (3.5-10.9) 
Severe CDIe 
 
 0.53 (0.39-0.71)  0.59 (0.44-0.79)  2.11 (1.17-3.79)  1.76 (0.95-3.25)  0.62 (0.49-0.76)  0.69 (0.54-0.85)  11.6 (3.6-19.6) 
Non-Severe CDI 
 
 0.73 (0.60-0.88)  0.79 (0.66-0.96)  1.91 (1.13-3.22)  1.74 (1.03-2.93)  0.80 (0.67-0.95)  0.86 (0.71-1.03)  5.3 (1.1-9.5) 
CI, confidence interval; LOS, length of hospital stay; CDI, Clostridium difficile infection. To estimate the hazard ratios for discharge alive and in-hospital death respectively, the observations 
on patients who experienced a competing risk event were censored, i.e. removed from the risk set used for the hazard calculation at time of occurrence of the event, based on the 
principles of the cause-specific hazard function.  
a. Cox regression model.  
b. Cox regression model with time to infection included as a time-dependent variable. 
c. Cox regression model with time to infection included as a time-dependent variable, and age (<65 and >65 years) and comorbidity (Charlson Comorbidity Index score <1 and ≥1) 
included as covariates.  
d. Multi-state model 
e. The estimates for non-severe and severe CDI were fitted by including CDI type as a three level time-dependent categorical variable (0. No infection; 1. Non-severe CDI and 2. Severe 
CDI) 
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Discussion 
 The findings of this study showed that HA-CDI resulted in a prolonged LoS of ~ 7 days. 
Moreover, the daily mortality rate of HA-CDI patients was almost twice that of non-HA-CDI infected 
patients, as has been suggested elsewhere[28]. In addition, we found that severe infection increased the 
average expected excess LoS associated with HA-CDI. Our LoS estimates are comparable to the median 
additional six days estimated by a Canadian study, which also adjusted for the time dependency of the 
impact of HA-CDI[8],   but contradict the findings of a recent study by Mitchell and co-workers (2013) 
using a comparable MSM conducted in an Australian hospital who suggested that HA-CDI did not result 
in excess LoS7.  As the MSM of Mitchell et al did not implicitly adjust for such potential confounders, 
difference in case-mix among the different hospital settings (UK and Australia) could have been 
responsible for the differences in measured excess LoS[29]. However, stratified MSM results (by age, and 
co-morbidity index score respectively) revealed that both younger and older HA-CDI patients had an 
increased average LoS of about 6-7 days, and patients of both co-morbidity groups had an increased 
expected LoS related to CDI, so this is not likely to be the reason. Moreover, the non-severe HA-CDI 
patients in our sample still had a significantly increased LoS of ~5 days, thus even the potential lack of 
severely infected patients in the Australian sample would have most likely resulted in an effect on LoS.  
However, with only three published studies using appropriate methods, little can be concluded with 
regards the heterogeneity in the findings. More appropriate analyses of existing datasets (e.g. those 
reviewed by Mitchell et al (2012)[2]) might be a sensible way forward.   
Our dataset was collected as part of routine record keeping in a large teaching hospital, which led to 
a number of limitations in our study. Firstly, the number of patients with HA-CDI was small, which 
resulted in relatively large standard errors for the risk group stratified MSM analysis. A larger dataset 
would have allowed sufficient power to sub-stratify the analysis further. Secondly, the co-morbidity index 
was calculated using only the primary diagnosis code of each patient, as more detailed information was 
not available to the researchers. Therefore, our analysis might not have fully adjusted for the effect of 
concomitant conditions. Finally, patients that spend a longer time in hospital are at increased risk of 
acquiring an HCAI other than HA-CDI, which could have extended their LoS rather than HA-CDI. 
However, considering the construction of the MSM, we expect this is accounted for: HA-CDI positive 
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patients which were in hospital at a given number of days post-onset were compared to admitted HA-
CDI negative patients still in hospital after this number of days. Thus, both these populations were 
arguably equally at risk of acquiring a HCAI other than HA-CDI.  
In conclusion, we present work confirming the heterogeneity among patients of the health and 
economic burden of CDI. To our knowledge, the results of our research have provided the first severity 
specific estimate of the additional LoS and excess mortality due to CDI. We believe that the techniques 
presented here could be applied, locally, nationally and regionally to provide policy makers with an 
estimate of the burden of CDI for their patient population and severity of CDI. 
Funding 
This work was supported by the Healthcare Infection Society. 
  
116 
 
References 
1. Graves N, Harbarth S, Beyersmann J, Barnett A, Halton K, Cooper B: Estimating the cost of health 
care-assodated infections: Mind your p’s and q's. Clin Infect Dis 2010, 50:1017–1021. 
2. Mitchell BG, Gardner A: Prolongation of length of stay and Clostridium difficile infection: a 
review of the methods used to examine length of stay due to healthcare associated infections. 
Antimicrob Resist Infect Control 2012, 1:14. 
3. Beyersmann J, Gastmeier P, Wolkewitz M, Schumacher M: An easy mathematical proof showed 
that time-dependent bias inevitably leads to biased effect estimation. J Clin Epidemiol 2008, 
61:1216–1221. 
4. Wolkewitz M, Beyersmann J, Gastmeier P, Schumacher M: Efficient risk set sampling when a time-
dependent exposure is present: matching for time to exposure versus exposure density sampling. 
Methods Inf Med 2009, 48:438–43. 
5. Schulgen G, Schumacher M: Estimation of prolongation of hospital stay attributable to 
nosocomial infections: New approaches based on multistate models. Lifetime Data Anal 1996, 
2:219–240. 
6. Gabriel L, Beriot-Mathiot a: Hospitalization stay and costs attributable to Clostridium difficile 
infection: a critical review. J Hosp Infect 2014, 88:12–21. 
7. Mitchell BG, Gardner A, Barnett AG, Hiller JE, Graves N: The prolongation of length of stay 
because of Clostridium difficile infection. Am J Infect Control 2013:1–4. 
8. Forster AJ, Taljaard M, Oake N, Wilson KW, Roth V, van Walraven C: The effect of hospital-
acquired infection with Clostridium difficile on length of stay in hospital. CMAJ 2012, 184:17–8. 
9. Bauer MP, Notermans DW, van Benthem BHB, Brazier JS, Wilcox MH, Rupnik M, Monnet DL, van 
Dissel JT, Kuijper EJ: Clostridium difficile infection in Europe: a hospital-based survey. Lancet 
2011, 377:63–73. 
10. Kuijper EJ, Coignard B, Tüll P: Emergence of Clostridium difficile-associated disease in North 
America and Europe. Clin Microbiol Infect 2006, 12 Suppl 6(October):2–18. 
11. Dubberke ER, Olsen MA: Burden of Clostridium difficile on the healthcare system. Clin Infect 
Dis 2012, 55 Suppl 2(Suppl 2):S88–92. 
12. Dubberke ER, Reske K a, Olsen M a, McDonald LC, Fraser VJ: Short- and long-term attributable 
costs of Clostridium difficile-associated disease in nonsurgical inpatients. Clin Infect Dis 2008, 
46:497–504. 
13. McGlone SM, Bailey RR, Zimmer SM, Popovich MJ, Tian Y, Ufberg P, Muder RR, Lee BY: The 
economic burden of Clostridium difficile. Clin Microbiol Infect 2012, 18:282–9. 
14. Ghantoji SS, Sail K, Lairson DR, DuPont HL, Garey KW: Economic healthcare costs of 
Clostridium difficile infection: a systematic review. J Hosp Infect 2010, 74:309–318. 
15. Van Walraven C, Davis D, Forster AJ, Wells G a: Time-dependent bias was common in survival 
analyses published in leading clinical journals. J Clin Epidemiol 2004, 57:672–82. 
117 
 
16. Barnett AG, Beyersmann J, Allignol A, Rosenthal VD, Graves N, Wolkewitz M: The time-
dependent bias and its effect on extra length of stay due to nosocomial infection. Value Heal 2011, 
14:381–386. 
17. Wilcox MH, Shetty N, Fawley WN, Shemko M, Coen P, Birtles A, Cairns M, Curran MD, Dodgson 
KJ, Green SM, Hardy KJ, Hawkey PM, Magee JG, Sails a D, Wren MWD: Changing Epidemiology of 
Clostridium difficile Infection Following the Introduction of a National Ribotyping-Based 
Surveillance Scheme in England. Clin Infect Dis 2012, 55. 
18. Walker a S, Eyre DW, Wyllie DH, Dingle KE, Griffiths D, Shine B, Oakley S, O’Connor L, Finney J, 
Vaughan A, Crook DW, Wilcox MH, Peto TE a: Relationship Between Bacterial Strain Type, Host 
Biomarkers, and Mortality in Clostridium difficile Infection. Clin Infect Dis 2013, 56:1589–600. 
19. Goorhuis A, Bakker D, Corver J, Debast SB, Harmanus C, Notermans DW, Bergwerff A a, Dekker 
FW, Kuijper EJ: Emergence of Clostridium difficile infection due to a new hypervirulent strain, 
polymerase chain reaction ribotype 078. Clin Infect Dis 2008, 47:1162–70. 
20. Henrich TJ, Krakower D, Bitton A, Yokoe DS: Clinical risk factors for severe Clostridium 
difficile-associated disease. Emerg Infect Dis 2009, 15:415–22. 
21. Debast SB, Bauer MP, Kuijper EJ: European Society of Clinical Microbiology and Infectious 
Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin 
Microbiol Infect 2014, 20 Suppl 2(March):1–26. 
22. Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali W a: New ICD-10 version of 
the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol 2004, 57:1288–94. 
23. Beyersmann J, Wolkewitz M, Allignol A, Grambauer N, Schumacher M: Application of multistate 
models in hospital epidemiology: advances and challenges. Biometrical J 2011, 53:332–350. 
24. Angelis G de, Allignol A, Murthy A, Wolkewitz M, Beyersmann J, Safran E, Schrenzel J, Pittet D, 
Harbarth S: Multistate modelling to estimate the excess length of stay associated with meticillin-
resistant Staphylococcus aureus colonisation and infection in surgical patients. J Hosp Infect 2011, 
78:86–91. 
25. Allignol A, Schumacher M, Beyersmann J: Empirical Transition Matrix of Multi-State Models : 
The etm Package. J Stat Softw 2011, 38:1–15. 
26. Davison AC, Hinkley DV: Bootstrap Methods and Their Application. New York: Cambridge University 
Press; 1997. 
27. Jackson CH: Multistate models for panel data. J Stat Softw 2011, 38. 
28. Hensgens MPM, Goorhuis A, Dekkers OM, van Benthem BHB, Kuijper EJ: All-Cause and 
Disease-Specific Mortality in Hospitalized Patients With Clostridium difficile Infection: A 
Multicenter Cohort Study. Clin Infect Dis 2013, 56:1108–16. 
29. Louie TJ, Miller M a, Crook DW, Lentnek A, Bernard L, High KP, Shue Y-K, Gorbach SL: Effect of 
age on treatment outcomes in Clostridium difficile infection. J Am Geriatr Soc 2013, 61:222–30.  
 
118 
 
Supplementary material 
Supplementary table 2: Average length of stay post-infection and number of deaths stratified by ribotype 
PCR ribotype  Patients 
N (%) 
 Deaths 
N (%) 
 Severe infection 
N (%) 
 Mean LoS  
post-infection 
 IQR (Q1-Q3) 
001     6   (3.8)  0 (0.0)    2  (0.3)    9.8    4.8 - 36.0  
002    21 (13.4)  6 (28.6)    9  (42.9)  22.0    8.0 - 27.0 
005    14  (8.9)  2 (14.3)    3  (0.2)  19.6    3.5 - 30.8 
014/020    23 (14.6)  2 (8.7)    6  (0.1)  30.0  11.5 - 36.0 
015    17 (10.8)  2 (11.8)    6  (35.3)  24.4  10.0 - 30.0 
017     2   (1.3)  0 (0.0)    0  (0.0)    9.0    6.5 - 11.5 
018     4   (2.5)  0 (0.0)    1  (0.3)    8.8    4.8 - 10.5 
023     4   (2.5)  1 (0.3)    0  (0.0)  30.5    5.8 - 49.3 
038     3   (1.9)  1 (0.3)    0  (0.0)  47.0  10.0 - 65.5 
064     2   (1.3)  0 (0.0)    0  (0.0)    2.5    2.3 -   2.8 
078    10  (6.4)  3 (30.0)    4  (0.3)    9.2    1.5 - 16.0 
106     7   (4.5)  1 (14.3)    0  (0.0)  16.1    9.0 - 22.0 
Unknown/UT    44 (28.0)  6 (13.6)  15 (34.1)  20.0    6.8 - 23.3 
UT = PCR ribotyping not possible  
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Supplementary figure 3: Length of Stay HA-CDI cases stratified by HA-CDI PCR ribotype 
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Supplementary figure 4: MSM weights 
 
MSM  weights, i.e. the average difference in LoS of patients of HA-CDI infected and non-infected patients across all days are 
weighted relative to the frequency of the possible events (i.e. HA-CDI, discharge alive and in-hopistal death) on each day.  
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CHAPTER 5 
 
MATHEMATICAL MODEL OF THE POPULATION-LEVEL 
EFFECT OF CLOSTRIDIUM DIFFICILE VACCINATION AS 
PART OF AN INTEGRATED INFECTION CONTROL 
STRATEGY  
 
 
5.1 PREAMBLE TO RESEARCH PAPER 4 
 
The previous chapters have provided considerable insight for choosing and parameterising an 
appropriate modelling framework with which to address our final research objective: to evaluate the 
effectiveness of infection prevention and control strategies involving vaccination in an English setting. In 
research paper three (Chapter 4), CDI was shown to place a significant hospital burden through 
increasing patients’ hospitals stay and mortality[1]. Therefore, if a CDI vaccine were able to prevent 
hospital-onset CDIs, it could have a marked impact. Within the hospital, although ICUs can vary 
markedly in their case mix, the critically ill, and often immunosuppressed status of ICU patients 
necessitates high levels of antimicrobial usage. Hence, this population has been described as at increased 
risk of CDI acquisition[2–4], and could therefore act as a marker for whether vaccination is likely to be a 
valuable hospital infection and prevention tool. We therefore chose to have the focus of the model 
centred on the ICU.  
In research paper two (Chapter 3) it was shown that transmission from symptomatic carriers was 
present in English hospitals [5]. This justifies the use of a dynamic modelling framework to investigate the 
effectiveness of CDI vaccination in a hospital setting. Since the time of publication of research paper one, 
six additional dynamic transmission models have been published, in addition to the previous three 
mentioned. All nine models concerned hospital-spread of C. difficile, pre-dominantly using 
compartmentalised models[6-15], splitting the population into subgroups sharing particular characteristics 
of relevance for disease. A majority of the models assumed the hospital or ward population was resistant 
to colonisation and subsequent infection unless exposed to antibiotics [8, 9, 12, 13, 15]. As antimicrobial 
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usage remains the primary risk factor for CDI [16–18], and for the sake of model parsimony, 
incorporating such an assumption could be justified.  A more recent model allowed individuals to become 
colonised and develop CDI without the traditional pre-disposing factors[10, 11]. However limited data 
were provided, hindering the verification of the model’s biological plausibility. Though such occurrences 
have been observed (see Chapter 1), the frequency of CDI among non-traditional risk groups is 
unknown.  
Whilst admission and discharge from a homogenous source of individuals outside the hospital 
has been assumed in previous model frameworks[6, 8, 10–14], no model has incorporated readmission 
dynamics. As a consequence, all models, except one [6], have ignored relapse of CDI, for the primary 
reason that the probability of this occurring during the patient’s initial stay is low. This could be of 
relevance considering patients can remain colonised for an average period of one month or longer [19, 
20]. One possible area where vaccination could be effective is in preventing recurrent disease (defined as 
relapse), as suggested by Lee et al.[21]. Vaccination may also aid in preventing re-infection among 
frequently hospitalised patients. Moreover, the high prevalence of C. difficile carriage observed in LTCFs 
[22], suggests distinguishing between admissions from general community populations and LTCF 
populations should perhaps be considered in the evaluation of the impact the effectiveness of 
vaccination. In an individual-based model, patients can be tracked separately over time. Therefore this 
approach allows for the incorporation of readmission dynamics, as well as the incorporation of 
heterogeneity in risk factors associated with infection, such as observed higher levels of antibiotic usage in 
LTCF populations as compared to community populations[23–26]. Unfortunately, the lack of data on 
CDI incidence in settings outside the hospital (Chapter 1) limit the possibilities for incorporating a long-
term feedback loop between these settings, as was suggested in research paper one[27]. 
In this chapter, evidence generated from research paper one, two and three are combined to 
develop a mathematical dynamic transmission model to investigate the spread of nosocomial C. difficile, 
and evaluate the effectiveness of infection prevention and control strategies involving vaccination in an 
English setting. Extensive analysis of English national datasets and local level data from individual 
hospitals was conducted to inform key parameters and simulate the English ICU-setting as closely as 
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possible. Vaccine performance is evaluated under different strategies using the developed transmission 
dynamic model. Moreover, as shown in research paper two (Chapter 3), cross-transmission from 
symptomatic patients explained just a fraction of the variation in weekly CDI incidence observed. Hence, 
there remains considerable uncertainty around the alternative routes of CDI acquisition. To account for 
this, we performed scenario analysis, exploring the potential role of transmission from asymptomatic 
carriers. Similarly, to account for variation among ICUs with regards to levels of CDI risk, vaccine 
effectiveness is modelled under different scenarios of antibiotic usage and levels of cross-transmission. 
Hence, Chapter 5 meets objective four, as well as the overall objective of this thesis.  
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Abstract 
Background: Early clinical trials of a C. difficile toxoid vaccine show efficacy in preventing individual 
infection (CDI). However, the population-level impact of vaccination remains unknown. This study 
performed a model-based evaluation of the effectiveness of CDI infection control strategies involving 
vaccination, including potential indirect effects (prevention of onward transmission of the bacteria). 
Methods: A state-of-the-art dynamic model of CDI, simulating transmission and control on an individual-
patient level, with a focus on the Intensive Care Unit (ICU), was developed. The model incorporated data 
on patient movements between the hospital, community and long-term care facility (LTCF), using 
English national datasets and local level data from individual hospitals for model-parameterisation. We 
evaluated vaccination of: 1) patients with a previous CDI-occurrence in the ICU; 2) LTCF-residents; 3) 
Planned surgical admissions and 4) All three strategies combined. 
Findings: In our baseline scenario, 10.8 patients per 1000 admissions developed CDI in the ICU, of which 
31% was ICU-acquired. Immunising all three patient groups resulted in a 43% [interquartile range (IQR) 
42 – 44], reduction of ICU-onset CDI on average. Among the strategies restricting vaccination to one 
target group, vaccinating elective patients proved most effective (35% [34–36] reduction), but required 
146 [133 – 162] doses to prevent one case of CDI. Immunising LTCF residents was most efficient, 
requiring 14 [11 – 17] doses to prevent one case, but only reduced ICU-onset CDI by 9% [7 – 11]. Ward-
based transmission rates, antimicrobial consumption and the transmission potential of asymptomatic 
carriers had significant effects on CDI incidence in the population, and therefore effectiveness and 
efficiency of the vaccination strategies. 
Conclusions: Vaccination can aid markedly in CDI prevention. Strategy success depends on the interaction 
between hospital and catchment populations, and importantly, consideration of importations from 
elsewhere which we find to substantially impact hospital dynamics. The contribution of asymptomatic 
carriers to C. difficile acquisition should be an area of future investigation, as well as careful examination of 
groups at high risk for colonisation on admission and subsequent healthcare-onset CDI. Vaccination may 
be most effective in settings or patient groups where antimicrobial stewardship has not been (or can not 
be) implemented successfully.  
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Introduction 
Clostridium difficile is a Gram-positive, spore forming bacterium that is an important cause of 
gastrointestinal infection in Europe[28]. Since 2007, C. difficile infections (CDIs) have dropped 
dramatically in England, from 55,489 cases reported across the National Health Service (NHS) and 9.4 
cases per 10,000 bed days to 13,361 cases and 3.9 per 10,000 bed days in 2014/15[29]. Similar trends and 
rates are seen in other European countries[30], whereas in the US, despite observed reductions, incidence 
rates remain generally high, with nine hospital-onset cases reported per 10,000 bed days in 2014[31]. 
Prevention and control of CDI aims to reduce the organism’s acquisition and spread. Measures 
include environmental cleaning, isolation and hand hygiene, as well as efforts to decrease patients’ 
susceptibility to CDI, primarily through improved antimicrobial stewardship[32, 33].  Recently, vaccines 
targeting two C. difficile toxins  (TcdA and TcdB) have been developed[34–37] and, following promising 
results in  phase I and II clinical trials[34, 38],  Phase III trials are now underway[39].   These vaccines 
induce an IgG antibody response and therefore aim to prevent infection in colonised individuals[34, 40–
43]. A successful vaccine that prevented the primary, or recurrent, onset of CDI would directly reduce 
morbidity and mortality in the vaccinated individual but should also have a population-level effect, by 
reducing the spread of infectious spores from infected individuals into the environment, and thus 
preventing onward transmission of the bacteria. However, current evidence, based on highly 
discriminatory genetic typing-methods[44–46] as well as statistical modelling[5], suggests patients with 
symptomatic CDI are not the only contributors to hospital-onset CDI[47–49]. Such research makes it 
unclear which patient groups would be optimal to target with a C. difficile vaccine to prevent onward 
transmission and the development of CDI. Therefore, any examination of the overall impact of 
vaccination needs to account for C. difficile transmission, including the potential role of asymptomatic 
carriers [47–49].  
CDI places a substantial burden on healthcare systems, and previous economic burden studies of 
CDI have shown that direct healthcare costs due to excess length of hospital stay (LOS) were the main 
cost drivers of the infection[50–52]. Within the hospital, patients in the intensive care unit (ICU) are likely 
to benefit from additional CDI prevention measures, considering their increased risk for CDI[16, 53, 54]. 
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Although ICUs can vary markedly in their case mix, their critically ill status often causes a state of 
immunosuppression[55], and requires high levels of antibiotic prescribing[56]. Other risk factors 
associated with CDI, such as gastro-acid suppressants are frequently prescribed among ICU patients[57]. 
The elderly in long term care facilities (LTCF) are another high-risk population. Although there is 
no routine systematic surveillance of CDI in LTCF, nor is CDI testing performed routinely in this setting, 
evidence from individual LTCFs[22] have shown that carriage rates are high among these elderly 
residents. Admissions from LTCF have been associated with increased risk of hospital-onset CDI[58] and 
residing in a LTCF has been identified as an independent risk-factor for developing CDI[59]. Therefore, 
this group of individuals has been suggested as a potential target population for vaccination, as have 
elderly patients with planned elective surgery who share many of the underlying risk factors  (frailty, 
hospital admission and antimicrobial usage) in common with the LTCF cohort [39]. Moreover, 
considering about 20% of CDI patients experience recurrent CDI[60], either due to re-infection or 
relapse[61], and primarily as a result of continued exposure to factors disturbing the gut flora post 
identification of CDI[62], patients with a history of CDI are a potential third target group for vaccination.   
Transmission dynamic mathematical modelling is a well-established tool that can be used to 
extrapolate vaccination trial results to the population-level[63, 64]. In the case of C. difficile these methods 
would allow the exploration of vaccination while taking into account the different modes of 
acquisition[65]. To date, only a few attempts have been made to investigate the spread of C. difficile in the 
hospital setting by the application of dynamic-transmission models[6, 8–13, 15, 27]. One modelling study 
suggested that CDI vaccination could be cost-effective in preventing initial CDI in situations of relatively 
high CDI acquisition risk and/or low vaccine costs, but primarily in terms of recurrent CDI[21]. 
However, this study did not account for the indirect (i.e. population-) effects, nor investigated specific 
target groups for vaccination (other than (unspecified) patients at risk and patients with an earlier episode 
of CDI).  
The prevention of CDI through vaccination is likely to have the greatest impact on the health 
and economic burden of CDI when hospital-onset is prevented, in the ICU in particular. We thus 
investigated the effectiveness of the four strategies described below, in terms of preventing CDI in the 
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ICU. A dynamic transmission model was developed, that accounted for potential population-effects, as 
well as uncertainties related to the epidemiology of CDI. 
Methods 
Model framework 
A discrete-time, individual-based, stochastic, dynamic transmission model[66] was developed, 
simulating the transmission and control of CDI in a hypothetical 30-bed ICU in England serving a 
community of 100,000 individuals. Individual patient movements between the ICU, the hospital, 
surrounding community and long-term care facilities (LTCF) were modelled (see Figure 15 for model 
schematic).  
Figure 15: Model framework 
 
P = Patients protected from colonisation, hence infection; S = Patients susceptible to colonisation, hence infection; Cimm = Patients colonised 
with C. difficile that mount an immune response; Cn_imm= Patients colonised with C. difficile that fail to mount an immune response; I = Patients 
with CDI; LTCF = Long-term care facility  
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Transmission process 
Patients with a normal gut flora were assumed protected against C. difficile colonisation 
(represented by compartment P in Figure 15). Consumption of ‘high risk’ antimicrobials (defined as 
broad-spectrum penicillins, third generation cephalosporins, clindamycin, and quinolones) was assumed 
to result in susceptibility to colonisation (compartment S) because of their deleterious effect on the 
microbiota[67–69]. Each day, susceptible patients (S) could become colonised with C. difficile through 
transmission, with the daily risk of colonisation (λt) increasing linearly with the number of transmitting 
CDI patients in the ICU ward (Table 7). The per day probability of colonisation, given at least one CDI 
or colonised patient on the ICU described the likelihood of transmission through direct contact between 
susceptible and infectious patients, and indirect contact between susceptible patients, contaminated staff 
and the environment. It was assumed that contacts (with patients, staff or the environment) occurred 
randomly and were homogenously distributed among patients.  
Table 7: Model parameters and assumptions 
Parameter Description Base value Source  
 
  
Transmission parameters 
   
β1 Probability of transmission from infected patients, per day 0.0074 Fitted# 
β2 Probability of transmission from colonised patients, per day 0.0037 Fitted# 
λt Probability of a susceptible patient becoming colonised, per day 1-(1-β1)It(1-β2)Ct   
 
  
Patient parameters 
   
θ Incubation time (days) 18 (Gamma) [44, 48] 
s Duration of symptoms (days) 4 (Poisson) [20, 44, 70] 
c Duration of colonisation (days) 30 (Exponential) [19, 71] 
Licu Average length of ICU stay 6 [72] 
αgm 
Fraction of patients admitted from GM on antimicrobials on 
admission to the ICU 
0.081 PPS[73]*# 
αicu Fraction of patients on antimicrobials in the ICU on a given day 0.219 PPS[73]*# 
picu Probability of initiating high risk antimicrobials in ICU ward per 
day 
picu = 1-(1-αicu)1/Licu  
αltcf 
Fraction of patients directly admitted from LTCF on antimicrobials 
on admission to the ICU 
0.040 PPS[25, 26]* 
αcom 
Fraction of patients directly admitted from the community on 
antimicrobials on admission to the ICU 
0.012 PPS[23, 24]* 
fltcf = fcom 
Fraction of patients admitted to ICU from the LTCF/ community 
that develop a natural immune response against disease 
0.240 [74]* 
ai_ltcf Fraction of patients from LTCF that were infected on admission to 
the ICU 
0.050 H* 
ac_ltcf Fraction of patients from LTCF that were colonised on admission 
to the ICU 
0.010 H* 
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as_ltcf  Fraction of patients from LTCF that were susceptible on admission 
to the ICU 
altcf -( ai_ltcf + ac_ltcf) - 
ai_com Fraction of patients from the community that were infected on 
admission to the ICU 
0.003 H 
ac_com Fraction of patients from the community that was colonised on 
admission the ICU 
0.028 H 
as_com Fraction of patients coming from the community that was 
susceptible on admission to the ICU 
(1- altcf)-( ai_com + 
ac_com) 
- 
 
  
Movement parameters 
   
altcf Fraction of patients admitted from LTCF 0.040 PPS[75] 
adirect_icu Fraction of patients admitted directly into ICU from any 
community setting 
0.510 HES 
aelect_icu_ltcf Fraction of patients in the ICU that were admitted for elective 
surgery from LTCF 
0.110 HES  
aelect_icu_com Fraction of patients in the ICU that were admitted for elective 
surgery from community 
0.300 HES  
dn Daily probabilities of discharge from the ICU for protected, 
susceptible and asymptomatic patients  
Supplementary 
table 5 
[72, 76]  
di 
Daily probabilities of discharge from the ICU for infected patients  
Supplementary 
table 5 
[72, 76, 77] 
µn Daily probabilities of death in the ICU for protected, susceptible 
and asymptomatic patients  
Supplementary 
table 5 
[72, 76] 
μi= µn Daily probabilities of death in the ICU for infected patients 
Supplementary 
table 5 
[72, 76, 77] 
rltcf Probability of readmission for LTCF residents within three months 0.220 HES  
rcom Probability of readmission for community residents within three 
months 
0.120 HES  
τ Mean time between discharge and readmission (days) 29 (Exponential) HES  
 
 
 Vaccination parameters 
   
e 
The probability of vaccination resulting in successful acquired 
immunity (vaccine efficacy) 
1 A# 
ε Duration of vaccine-acquired immunity (years) 2 A 
aelect_hospital Fraction of hospital admission that are elective  0.504 HES[78] 
aicu Fraction of hospital admissions that involve an ICU stay 0.018 HES[79] 
Bltcf Median number of beds per LTCF 37 CQC 
Nltcf Total number of LTCFs in England with a size of ≥20 beds 8,639 CQC 
Ntrust Total number of acute Trusts reporting ICU records in England 143 HES[79] 
t Simulation time (years) 5 - 
* Included in probabilistic sensitivity analysis; # Included in scenario analysis. PPS = Point prevalence survey data 
(reference provided refers to which point prevalence data); H= Individual hospital data; HES = Hospital Episode 
Statistics; A = Assumption, CQC = Care Quality Commission data 
 
 
A proportion of patients can mount a natural immune response against C. difficile toxins, and are 
protected from infection[80, 81]. Therefore, a distinction was made between patients that remained 
asymptomatic (compartment C) and those that suffered from infection (compartment I) following an 
incubation period.  After successful treatment, patients lost their infection status but remained colonised 
with C. difficile. Colonisation status was lost after an average period of four weeks[19, 71]. About 20% of 
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patients experience recurrence[60, 61]; either due to re-infection or relapse[61], primarily as a result of 
continued exposure to factors disturbing the gut flora post identification of CDI[62].  To simulate relapse 
whilst still colonised, the model allowed recovered patients to have another episode of CDI following 
successive antimicrobial use but without transmission from another patient. Finally, post vaccination, 
patients are assumed protected from disease, however not from colonisation[81, 82]. 
Model assumptions 
1) 100% bed occupancy was assumed, i.e. discharge or death of a patient resulted directly in the 
admission of a new patient. 
2) Daily time-steps were used with patient discharges from the ward occurring at the beginning 
of each day. 
3) Patients could be admitted from the community or from a LTCF. Patients either resided in a 
LTCF or the community for the full simulation period (five years).  
4) At time of admission, a data-informed probability (Table 7) determined whether the ICU 
admission was directly from outside the hospital (i.e. from LTCF or community) or an 
internal hospital transfer.  The source of the admission determined the probability of having 
been prescribed antimicrobials outside the ICU. 
5) Transmission-events were simulated in the ICU, whereas a fixed importation rate of 
colonised and infected individuals from the community and LTCF was assumed. The time 
spent elsewhere in hospital (and thus the transmission elsewhere in hospital) prior to ICU 
admission is not captured in the model. However the importation rates were informed by 
ICU admission data (see model parameterisation), therefore implicitly incorporated 
acquisition during the time spent elsewhere in hospital. 
6) Patients could be discharged whilst still colonised with C. difficile. Once discharged, colonised 
patients recovered from C. difficile colonisation at a constant rate (Table 7) irrespective of 
whether they were immunised. 
7) The vaccine did not protect patients from colonisation. Vaccine derived immunity was 
assumed to last for a period of two years (internal communication with Sanofi Pasteur). 
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Intervention strategies  
We considered the following four strategies, comparing each to no vaccination (strategy 0):  
1) Vaccination of patients who have experienced an episode of CDI in the ICU, at the time of 
discharge from the hospital, as they are at risk of experiencing recurrent infection; 
2) Vaccination of LTCF residents in the catchment area of the hospital irrespective of whether 
they are to have planned elective surgery[39];  
3) Vaccination of patients with planned elective surgery in the hospital catchment area [39].  
4) Vaccination of all the above listed patient groups. 
Model output  
The absolute reduction in number of cases per 1000 admissions for each strategy compared to a 
strategy without vaccination (strategy effectiveness) was evaluated, as well as the number of doses 
required to avert one case in the ICU (strategy efficiency). Patients who acquired C. difficile colonisation in 
the ICU, and did not mount a natural or acquired immune response, but were discharged from the ICU 
pre-symptom-onset, were defined as new infections without ICU-onset. C. difficile imported in the ward 
comprised either community-acquired cases or cases readmitted to the ward after a colonisation/infection 
acquired in a previous ICU stay.  
Scenario analysis 
There exists considerable uncertainty in the transmission rates of C. difficile. Considering the 
current uncertain role of asymptomatic carriers in the transmission of C. difficile[46, 83], three assumptions 
were simulated, covering the transmission potential from these carriers as follows:  
1) Asymptomatic carriers transmitted at half the rate of symptomatic carriers (2:1); the “base 
case”;  
2) Asymptomatic carriers did not spread C. difficile (1:0);    
3) Asymptomatic carriers transmitted as efficiently as symptomatic carriers (1:1)    
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In addition, ICU-based acquisition rates of CDI vary across the country (median 0.8 [interquartile 
range: 0 – 2.1] per 1000 patient days) in 2013/14[84]. This could relate to heterogeneity in levels of 
successful infection prevention and control, or regional differences in prevalence of more transmissible 
strains such as BI/NAP1/027[85, 86]. To represent different hospital settings (see Model 
Parameterisation for analysis), intervention effectiveness was evaluated assuming:  
1) Average levels of transmission according to these estimates (AT); the “base case”  
2) High levels of transmission (HT). 
 On analysis of national data[73], hospitals and ICUs across the country vary in their 
antimicrobial prescribing practices (see Model Parameterisation for analysis). To consider this between-
ICU heterogeneity in antimicrobial consumption, the following scenarios were simulated and the 
effectiveness of vaccination evaluated in both settings: 
1) Average antimicrobial use (AA), the “base case”;  
2) Low antimicrobial use (LA). 
Given that currently any CDI vaccine is currently still facing clinical trials; the efficacy of a CDI 
vaccine is unknown. To account for this, vaccine performance was evaluated under: 
1) High vaccine-efficacy (100%), the “base case”; 
2) Medium vaccine-efficacy (70%); 
3) Low vaccine-efficacy (50%). 
Combinations of the above listed possibilities were simulated under the base case assumption for 
asymptomatic carriers (Symptomatic/ Asymptomatic transmissions (2:1)), representing the following ICU 
scenarios: 
- Scenario 1: Average transmission (AT) + Average antimicrobial use (AA) + High vaccine-
efficacy (100%); the “base-case” scenario 
- Scenario 2: High transmission (HT) + Average antimicrobial use (AA) + High vaccine-efficacy 
(100%); 
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- Scenario 3: Average transmission (AT) + Low antimicrobial use (LA) + High vaccine-efficacy 
(100%); 
- Scenario 4: High transmission (HT) + Low antimicrobial use (LA) + High vaccine-efficacy 
(100%); 
- Scenario 5: Average transmission (AT) + Average antimicrobial use (AA) + Medium vaccine-
efficacy (70%); 
- Scenario 6: Average transmission (AT) + Average antimicrobial use (AA) + Low vaccine-
efficacy (50%); 
In addition, the impact of the assumed transmission potential of asymptomatic carriers was 
investigated by simulating scenario 1 and 2 with the two alternative assumptions regarding asymptomatic 
transmission. The first – asymptomatic carriers did not spread C. difficile (1:0); and the second –
symptomatic carriers transmitted as efficiently as symptomatic carriers (1:1). In Supplementary table 3 the 
values used to represent these scenarios are given. Estimation of these values is further explained in the 
model parameterisation section. 
Probabilistic Sensitivity Analysis 
Uncertainty in parameter values other than asymptomatic transmission (see Table 7 for which 
parameters this concerned) was simulated using probabilistic sensitivity analysis, that is running the 
simulations multiple times with parameter values sampled from their distributions (Supplementary table 
4) using Latin hypercube sampling (LHS)[87] as follows. One thousand random samples were drawn 
covering the whole range of possible values for each parameter equally and combined at random to create 
1000 different parameter sets. As the model was stochastic, a different result could be expected for a 
given parameter set. Hence the medians of 100 simulation runs per parameter set were combined to 
obtain the overall median and interquartile range (IQR) of the model output encompassing parameter 
uncertainty.  
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Model parameterisation  
Table 7 summarises the model parameter values. These values were derived from new analysis of 
national and regional healthcare data and peer-reviewed research articles otherwise, discussed in more 
detail below. 
C. difficile transmission parameters (β1 and β2) 
Little is known about the transmission potential of patients infected or colonised with C. difficile. 
Therefore, the transmission potential from symptomatic carriers (β1) and asymptomatic carriers  (β2) was 
fitted to the median CDI acquisition rates in English critical care units in the financial year 2012/13 as 
measured in the Intensive Care National Audit & Research Centre Case Mix Programme (ICNARC) data. 
This data comprises, among others, ‘potential performance indictors’, such as unit acquired CDI, of 202 
NHS adult, general critical care units, defined as ICUs, combined ICU/high dependency units (HDUs) 
and combined general care/coronary care units admitting mixed medical/surgical patients predominantly 
aged older than 16 years[88]. 
The following three steps were applied. Firstly, we sampled 1000 parameter values for β1 from a 
uniform distribution over range 0 to 1 (as negative values were considered biological implausible) using 
LHS and let β2  depend on β1 according to β2 = β1/2. Secondly, we ran the model for each of these 1000 
values for β1 and β2 one hundred times (to minimise stochastic variation) whilst keeping all remaining 
model parameters at their base value (Table 7). Thirdly, we compared the median ICU-onset acquisition 
rates resulting from each set of one hundred model simulations against the median CDI acquisition rates 
in the ICNARC data, i.e. 0.8 [IQR: 0 – 2.1] per 1000 bed days[84], and evaluated which values of β1 (and 
thus β2) minimised the difference between the model output, and the data (Figure 16). This process was 
repeated for the two alternative assumptions for the transmission potential of asymptomatic carriers (i.e. 
1:0 (β2=0) and 1:1 (β2=β1)). Moreover, a similar step-wise process was followed for the scenario of high 
transmission, where β1 and β2 were fitted against the seventy-fifth percentile of the aforementioned CDI 
acquisition rates in the ICU, i.e. 2.1 cases per 1000 patient days (Figure 16). 
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Figure 16: Model output of 1000 values for β1 (and β2 = β1/2; β2 = 0 or β2= β1) 
 
Solid horizontal black line: median CDI acquisition rates in English ICUs (ICNARC data), representative for 
ICUs with average transmission.  Dashed horizontal black line: seventy-fifth percentile of CDI-acquisition rates 
in English ICUs, representative for ICUs with high CDI transmission. Blue dots: Model output for each of the 
values of β1 in the base case, where asymptomatic carriers have half the transmission potential compared to 
symptomatic carriers, i.e. β2 = β1/2 (scenario 2:1). Pink dots: Model output for each of the values of β1 in the 
scenario where asymptomatic carriers have no transmission potential, i.e. β2 = 0 (scenario 1:0). Green dots: Model 
output for each of the values of β1 in the scenario were asymptomatic and symptomatic carriers have equal 
transmission potential, i.e. β2 = β1 (scenario 1:1). Lower black dots: Best fit for β1 (and implicitly for β2) for each 
of the three asymptomatic transmission scenarios when transmission levels are at national average. Upper black 
dots: Best fit for β1 (and implicitly for β2) for each of the three asymptomatic transmission scenarios when 
transmission levels are high compared to the national average. 
 
Daily discharge and death probabilities (dn, di, µn and μi) 
Estimates for ICU-specific daily discharge probabilities and mortality risks for CDI-negative 
patients and asymptomatic carriers (dn and µn respectively) were derived from studies estimating these 
parameters for MRSA negative patients[72, 89], under the assumption that these MRSA negative patients 
did not suffer from CDI. For daily discharge probabilities of CDI positive patients (di) the daily discharge 
probabilities of CDI-negative patients were reduced by 28%, based on the findings of the previously 
presented Cox proportional hazards model estimating excess LoS associated with CDI[76] (see Chapter 
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4). These discharge probabilities were estimated using whole hospital data. A review of the literature 
identified two studies on excess length of stay (LoS) and mortality associated with CDI in the ICU 
specifically using appropriate methods [77, 90]. Using a Cox proportional hazard model, one study found 
reduced daily discharge probabilities for CDI patients as well (HR: 0.82 [95%CI 0.72 – 0.94]). The second 
study used a multistate model and found an excess ICU stay of 6 days (6.3 [2.0 – 10.6]) similar to our 
results. In contrast to our overall hospital estimate, both studies did not find an increased probability of 
death due to CDI in the ICU[77, 90]. Therefore, the daily risk of death in our model for CDI negative 
(μn) and CDI positive (μi) were assumed identical (Supplementary table 5) 
Antimicrobial prescribing in the hospital setting (αicu, αgm and picu) 
In the model, patients could be either admitted directly to the ICU from a community-setting (i.e. 
LTCF or community), or as a result of an internal-hospital transfer, from a GM ward. Therefore, the 
prescribing prevalence for GM (αgm) needed to be obtained, in addition to the daily risk of being 
prescribed antimicrobials in the ICU (picu). To obtain the national prevalence of ward-prescribing in 
England, a mixed-effects logistic regression model, with a normally distributed random-intercept (to 
account for clustering on a Trust level) and ward specialty included as an explanatory variable, was fitted 
to individual patient-level antimicrobial consumption data from a nation-wide point prevalence survey on 
health-care associated infections and antimicrobial use[73]. For this survey, data was collected from 99 
NHS acute Trusts in England on the number of patients on antimicrobials on the one single day the 
survey was conducted[73].  
For the analysis, antimicrobial usage data was restricted to CDI-associated antimicrobial classes 
only, i.e. broad-spectrum penicillins, third-generation cephalosporins, clindamycin, and quinolones. The 
mean probability of being on CDI-associated (or ‘high-risk’) antimicrobials for each ward specialty on a 
random single day (αw) was calculated using the logistic function, given by the inverse-logit: 
α𝑤 =  1/(1 + 𝑒𝑥𝑝(−𝑥𝑤)), 𝑤 =  𝐺𝑀, 𝐼𝐶𝑈 (Equation 1) 
where xw corresponds to the estimated regression coefficients for each ward specialty 
(Supplementary table 6). The within-hospital variance (σw2) of these estimates was used as a proxy for the 
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second-order uncertainty around αw.  In the earlier mentioned probabilistic sensitivity analysis, 1000 
samples were randomly drawn from a normal distribution with mean = xw and standard deviation = √σw2 
using LHS. As these estimates were fitted with a log-link, these 1000 randomly drawn samples were then 
transformed to the identity scale using equation 1. Considering xw was fitted to hospital antimicrobial 
consumption data of one single day, αw represents overall ward prescribing prevalence. This estimated 
prevalence for the GM ward was used to represent the risk of being on CDI-associated antimicrobials 
when admitted from a GM ward (αgm) to the ICU in our model. However, as our model explicitly 
simulated CDI-transmission dynamics in the ICU, and in daily time steps, αicu needed to be converted to 
a daily risk of being prescribed CDI-associated antimicrobials. Assuming each patient in the point 
prevalence data was receiving one CDI-associated antimicrobial only, and the average length of ICU stay 
(Licu) was six days[76], we used the following: 
       𝛼𝑖𝑐𝑢 = 1 − (1 − 𝑝𝑖𝑐𝑢)
𝐿𝑖𝑐𝑢        (Equation 2) 
Where 1 - pw is the risk of avoiding a CDI-associated antimicrobial prescription in the ICU per day. 
Equation 2 can be rearranged to calculate daily risks of starting on CDI-associated antimicrobials for each 
patient: 
             𝑝𝑖𝑐𝑢 = 1 − (1 − 𝛼𝑖𝑐𝑢)
1/𝐿𝑖𝑐𝑢      (Equation 3) 
Finally, for the scenario analysis, an alternative scenario of low hospital prescribing of CDI-
associated antimicrobials was represented by the twenty-fifth percentile of these estimates’ confidence 
intervals, calculated when including both the within (√σw2) and between-Trust variation (√σ2trust)( 
Supplementary table 6).  
Antimicrobial prescribing in the community and LTCF (αltcf and αcom) 
The fraction of LTCF residents and patients admitted from the community that received CDI-
associated antimicrobials prior to ICU admission (αltcf and αcom) were parameterised by European Centre 
of Disease Control (ECDC) point prevalence antimicrobial consumption data from the United Kingdom 
(UK), collected through The European Surveillance of Antimicrobial Consumption Network in 2010 and 
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2011[23, 24] and the Healthcare Associated infections in LTCF (HALT) point prevalence studies of 2010 
and 2013[25, 26]. These data report the Defined Daily Doses (DDD) of antimicrobials per 1000 
individuals using the Anatomical Therapeutic Chemical (ATC) Classification System 
(http://www.whocc.no). DDD represent the assumed average maintenance dose per day for a drug used, 
for its main indication in adults. The ACT classification system is developed by the World Health 
Organisation and divides drugs according to their therapeutic, pharmacological and chemical properties 
using five different levels, where level 1 corresponds to the main group and level 5 to the chemical 
substance. The ECDC point prevalence survey results are reported at ATC level 4. The DDD per 100 
population of the ATC level 4 groups J01D (other beta-lactam antibacterials); J01C (Beta-lactam 
antibacterials, penicillins); J01F (Macrolides, lincosamides and streptogramins); and J01M (Quinolone 
antibacterials) were combined to obtain an estimate of the proportion of patients receiving CDI-
associated antimicrobials in the community and LTCF (Supplementary table 7).  
Importation rates of colonised and infected patients (ai_ltcf, ac_ltcf, as_ltcf, ai_com, ac_com, as_com) 
The fraction of individuals admitted from the community/LTCF that were infected (ai_com/ai_ltcf), 
colonised (ac_com/ac_ltcf) or susceptible (as_com/as_ltcf) on admission were parameterised using ICU-screening 
data collected over 18 months from a 30-bed ICU ward in a large London teaching hospital[91]. The 
particular provenance status (i.e. community home or LTCF) of the patients was not collected as part of 
this study. As an alternative, it was assumed that 4% of the total admissions to the ICU were LTCF 
residents, as was shown by sentinel data collected from seven acute Trusts through The National One 
Week Prevalence Audit of MRSA[75]. For the patients that screened positive for colonisation and/or had 
symptomatic infection, provenance status was obtained by retrieval of the patients’ postcodes of 
residence, which were subsequently matched with LTCF postcodes (using Care Quality Commission data 
further explained later)[92]. 
Using this procedure, 53 of the admissions originated from LTCFs, and 30 of these were 
screened for C. difficile. On admission, infection prevalence among patients admitted from their own 
home (ai_com) was 0.3% (95%CI: 0.1 – 0.8) and colonisation prevalence (ac_com) 2.8% (1.8 – 4.3), whereas 
this was 0% (0 – 11.4) and 0% (0 – 11.4) respectively for patients from LTCFs (Supplementary table 8). 
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As shown in Chapter 1, a recent systematic review of the literature showed a significantly higher weighted 
mean prevalence of asymptomatic carriage in LTCFs of 14.8% (95% CI 7.6 – 24.0), though did find high 
levels of heterogeneity among individual care homes.  
For this reason, we constructed prior distributions for asymptomatic and symptomatic C. difficile 
importation rates from the LTCF, and updated them using the screening data. As a conservative estimate, 
it was assumed that importation rates of colonised (ac_ltcf) and infected (ai_ltcf) individuals from the LTCF 
could be 0-3 times higher than importations from the general community. Two beta distributions with 
shape parameters informed by the above screening data (Supplementary table 4) were used to represent 
community importation rates of infected and colonised cases respectively, whereas a triangular 
distribution (mode 1.5, min=0, max=3) represented the differences in importation rates between 
community and LTCF settings. Using LHS, 10,000 samples were randomly drawn from the beta and 
triangular distributions, and multiplied to obtain a prior distribution for ac_ltcf and ai_ltcf. The probability 
distributions of these priors were updated using the probability distribution of the data (i.e. LTCF 
importation rates according to the above screening data), represented by a binomial distribution (k=0 and 
n=30), in order to obtain posterior distributions for the desired importation rates (Supplementary table 
4).  
Patient movement parameters (adirect_icu, aelect_icu_ltcf, aelect_icu_com, rltcf, rcom and τ)  
Hospital Episode Statistics (HES) contains individual patient-level data for all admissions (i.e. 
spells) to NHS acute Trusts in England. A fraction of this data is publicly available through 
(http://www.hscic.gov.uk/). However, to inform parameters describing: the fraction of individuals that 
was admitted directly into the ICU (adirect_icu); the fraction of ICU admissions that concerned 
LTCF/community patients that were originally admitted electively to the hospital (aelect_icu_ltcf,/aelect_icu_com); 
the readmission rates of LTCF residents and patients admitted from their own home (rltcf,/rcom) and mean 
time elapsed between ICU readmissions (τ), more detailed data was required. For this reason, a HES 
extract involving all admissions with at least one episode in the ICU (i.e. treatment specialty defined as 
‘critical care’) from the financial year April 2012/13 to April 2013/14 was requested. 
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In HES, a hospital spell (i.e. hospital stay) contains multiple episodes, where a patient starts a 
new episode when treated by a consultant from a different treatment specialty. The proportion of patients 
that had their first episode defined as a critical care treatment specialty, informed the fraction of direct 
admissions into the ICU (adirect_icu), which was used to calculate the risk of antimicrobial exposure outside 
the ICU as explained earlier.  
The HES ‘admission method’ and ‘admission source’ data fields informed the fraction of ICU 
admissions that concerned LTCF/community patients that were originally admitted electively to the 
hospital.  That is, aelect_icu_ltcf was the proportion of spells with an ‘Elective’ admissions method and the 
admission source coded as one of the following:  
- 54) NHS run nursing home, residential care home or group home; 
- 65) Local authority Part 3 residential accommodation: where care is provided (from 1996-97); 
- 85) Non-NHS (other than Local Authority) run residential care home (from 1996-97); 
- 86) Non-NHS (other than Local Authority) run nursing home (from 1996-97) 
- 88) non-NHS (other than Local Authority) run hospice.  
aelect_icu_com concerned all elective spells with admission source coded as: 
- 19) The usual place of residence, including no fixed abode.  
Readmission rates (rltcf,/rcom) and readmission time (τ) were defined by the fraction of patients 
that had a readmission to the ICU within three months (considering the colonisation time of C. difficile is 
rarely found longer than three months[19, 71]), and the mean number of days between these 
readmissions. 
Number of vaccines required for strategy 1 (Patients with a history of CDI in the ICU) 
 The number of vaccine doses required for strategy 1 (vaccinating patients that experienced an 
episode of CDI in the ICU, 𝑣𝐶𝐷𝐼_𝑇𝑟𝑢𝑠𝑡), was calculated through a counting process incorporated in the 
model. Over the five year simulation time, for each patient, at the time of ICU-discharge, the model 
checked whether the patient had experienced an episode of CDI (which could have concerned either an 
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importation or an ICU-acquired infection) and if so, and the patient had not been vaccinated within the 
previous two years, added an additional vaccine dose to the cumulative total.  
Number of vaccines required for strategy 2 (Patients admitted from a LTCF) 
To calculate the number of vaccine doses required for strategy 2 (vaccinating residents of 
LTCFs), two publicly available data sources were used, held by the Care Quality Commission (CQC) and 
Health & Social Care Information Centre (HSCIC) respectively. The former comprises logistical data on 
English care homes, such as care home type, postcode and bed numbers[92]. HSCIC is the provider of 
England’s Hospital Episode Statistics (HES). Adult Critical Care data forms part of HES and provides 
details on the number of NHS acute Trusts with reported ICU records[79]. Hence, these datasets 
provided insight into 1) the total number of LTCFs in England, using the care home criteria for elderly 
residents as defined by the CQC (Nltcf); 2) the total number of acute Trusts with reported ICU admissions 
(NTrust); and 3) the mean LTCF bed size (Bltcf, see Table 7 for parameter values). 
Assuming all LTCFs and acute Trusts are homogenously scattered across the country, the 
number of residents requiring vaccination per acute Trust (RTrust) was then defined by: 
𝑅𝑇𝑟𝑢𝑠𝑡 =  
𝑁𝑙𝑡𝑐𝑓
𝑁𝑇𝑟𝑢𝑠𝑡
𝐵𝑙𝑡𝑐𝑓             (Equation 4) 
Our simulation period (t) comprised five years, and it was assumed a booster vaccine was needed 
every two years (ε). Provided that none of the LTCF was admitting new residents, the number of 
residents multiplied by the simulation period divided by the timing a booster vaccine was required gave 
the average number of vaccines required per acute Trust over the full simulation period. 
𝑣𝑙𝑡𝑐𝑓_𝑇𝑟𝑢𝑠𝑡 =  𝑅𝑡𝑟𝑢𝑠𝑡
𝑡
𝜀
                  (Equation 5) 
The model captured the transmission dynamics in the ICU, not elsewhere in hospital. As a result, 
using 𝑣𝑙𝑡𝑐𝑓_𝑇𝑟𝑢𝑠𝑡 as a measure for calculating the number vaccines required to prevent one healthcare-
onset CDI case would underestimate the vaccine efficiency of this strategy. For this reason, we decided to 
adjust 𝑣𝑙𝑡𝑐𝑓_𝑇𝑟𝑢𝑠𝑡 for the proportion of admissions that included an ICU stay (aicu). The total number of 
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ICU admissions per Trust in the financial year 2013/14[79] were divided and weighted by the total 
number of HES admissions[78] to obtain the weighted mean proportion of yearly admissions that 
comprised an ICU admission (aicu). The average number of vaccines required per ICU over the full 
simulation period was then given by:    
𝑣𝑙𝑡𝑐𝑓_𝐼𝐶𝑈 =  𝑎𝑖𝑐𝑢𝑣𝑙𝑡𝑐𝑓_𝑇𝑟𝑢𝑠𝑡                (Equation 6) 
Number of vaccines required for strategy 3 (Patients admitted for elective surgery) 
For strategy 3 (vaccinating elective patients), only a small fraction of ICU admissions is 
planned[79]. However, elective hospital patients could experience an ICU episode during their hospital 
stay. Therefore, regardless of whether a vaccine would target ICU or high-risk hospital ward populations; 
this strategy will involve vaccination of all elective hospital patients. 
To calculate the number of vaccine doses required for this strategy (𝑣𝑒𝑙𝑒𝑐𝑡_𝑇𝑟𝑢𝑠𝑡 ), publicly 
available HES data was used. HES Admitted Patient Care data from 2013/14[78] provided detail on the 
total number of yearly admissions, and the yearly number of elective admissions per acute Trust. The 
mean of the latter multiplied by the simulation period represented the per acute Trust vaccine doses 
required for this strategy. For similar reasons as explained in the previous section, this number was scaled 
to the ICU setting using aicu. 
 𝑣𝑒𝑙𝑒𝑐𝑡_𝐼𝐶𝑈 =  𝑎𝑖𝑐𝑢𝑣𝑒𝑙𝑒𝑐𝑡_𝑇𝑟𝑢𝑠𝑡               (Equation 7) 
Number of vaccines required for strategy 4 (all combined) 
For strategy 4, as the three target groups were not mutual exclusive, 𝑣𝑙𝑡𝑐𝑓_𝐼𝐶𝑈,  𝑣𝑙𝑡𝑐𝑓_𝑇𝑟𝑢𝑠𝑡 and 
𝑣𝑒𝑙𝑒𝑐𝑡_𝐼𝐶𝑈 were combined and deducted by the fraction of admissions that concerned LTCF patients 
(altcf). Here, 𝑣𝐶𝐷𝐼_𝑇𝑟𝑢𝑠𝑡 was calculated as before, but with the model run under the assumption that all 
LTCF and elective patients were vaccinated, thus protected from developing CDI in the ICU. 
 
Results 
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Simulation Results: Base Case Scenario 
The vaccine impact (for four strategies) was first modelled using our base case scenario, where 
asymptomatic carriers are half as infectious as symptomatic carriers, the ward was assumed to have 
average transmission parameters, and antimicrobial prescribing was at the English national average, 
estimated as described in the methods section. 
No vaccination 
In the base case scenario, without vaccination (strategy 0), the median number of new 
symptomatic and asymptomatic C. difficile acquisitions in the ICU was 13.9 [IQR: 13.1–14.9] per 1000 
admissions (Figure 17). 7.7 [6.8–8.6] became symptomatic, of which symptom-onset in the ICU occurred 
in 3.3 [2.9–3.7] cases per 1000 admissions (Figure 18).   
Figure 17: Symptomatic and asymptomatic ICU- acquired C. difficile per 1000 admissions shown for all four 
vaccination strategies  
 
Model outcomes at baseline for strategy 0 (no vaccination); strategy 1 (CDI history); strategy 2 (LTCF residents); 
strategy 3 (elective patients) and strategy 4 (all combined). The middle line in the box represents the median of 
1000 model parameter sets, and upper and lower areas of the box indicate the seventy-fifth and twenty-fifth 
percentiles. Left set of boxes: Total ICU acquisitions (colonised and infected) per 1000 admissions for all strategies; 
middle set of boxes: Total ICU acquisitions that result in asymptomatic carriage (i.e. no symptom onset in- or 
outside the ICU) per 1000 admissions for all strategies; right set of boxes: Total ICU acquisitions that result in 
symptomatic infection (symptom onset in- or outside the ICU) per 1000 admissions for all strategies.  
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Figure 18: Absolute number of imported and ICU-acquired CDI cases in the ICU per 1000 admissions for all four 
vaccination strategies   
 
Model outcomes at baseline for strategy 0 (no vaccination); strategy 1 (CDI history); strategy 2 (LTCF residents); 
strategy 3 (elective patients) and strategy 4 (all combined). The middle line in the box represents the median of 
1000 model parameter sets, and upper and lower areas of the box indicate the seventy-fifth and twenty-fifth 
percentiles. Left set of boxes: ICU acquisitions that result in ICU-onset of symptoms per 1000 admissions for all 
strategies; middle set of boxes: ICU importations with ICU-onset of symptoms per 1000 admissions for all 
strategies; right set of boxes: ICU acquisitions that result in asymptomatic carriage (no symptom-onset in the ICU) 
oer 1000 admissions for all strategies. 
 
In addition, 7.5 infections per 1000 admissions were imported from outside the ICU. A low 
fraction (6.7%) of these were readmissions of patients who developed CDI in their current stay, following 
acquisition of C. difficile colonisation or infection during a previous ICU admission (Supplementary table 
9).  
Vaccine programme effectiveness  
Vaccinating all target populations (strategy 4) resulted in a 43% [IQR: 42 – 44] reduction in ICU-
onset cases over five years, equal to 4.7 [4.3 – 5.1] ICU-acquired and imported CDI cases per 1000 
admissions when compared to strategy 0 (Table 8). Of the strategies restricting vaccination to one target 
group (strategies 1, 2 and 3), vaccinating all patients awaiting elective surgery (strategy 3) yielded the 
largest net reduction (35% [34–36] over a five-year period) in ICU-onset cases. Strategy 1 (vaccinating 
patients after recovery from a CDI episode in the ICU) saw a 1% [0 – 3] reduction over five years. 
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Vaccinating LTCF patients (strategy 2) saw a 9% [7 – 11] reduction in ICU-acquired and imported CDI 
over five years. For all four strategies, the majority of ICU-onset cases prevented were importations. This 
was particularly true for strategy 1 (80%) and 2 (76%) (Table 8). 
Table 8: Number of ICU-onset cases prevented per 1000 admissions and doses required to avert 1 case of ICU-onset 
CDI for all scenarios 
 Transmission Symptomatic: Asymptomatic (2:1) 
Scenario  ICU-onset CDI 
cases 
prevented/1000 
admissions 
(Effectiveness) 
Proportion of the 
ICU-onset cases 
prevented that 
were ICU-acquired 
Doses required to 
avert one ICU-
onset CDI case 
(scaled to ICU) 
(Efficiency) 
Scenario 1 (AT + AA + VE = 
100%) 
   
 1) History of CDI in ICU 0.1 [0 – 0.3] 0.20 83 [33 – NA] 
 2) LTCF residents 1.0 [0.8 – 1.2] 0.24 14 [11 – 17] 
 3) Elective patients 3.8 [3.5 – 4.2] 0.36 146 [133 – 162] 
 4) All combined 4.7 [4.3 – 5.1] 0.34 124 [113 – 137] 
Scenario 2 (HT + AA + VE = 
100%) 
   
 1) History of CDI in ICU 0.5 [0.2 – 0.8] 0.34 43 [27 – 115] 
 2) LTCF residents 1.6 [1.3 – 2.0] 0.50 8 [7 – 10] 
 3) Elective patients 7.9 [7.1 – 8.8] 0.64 72 [65 – 80] 
 4) All combined 9.4 [8.4 – 10.4] 0.61 63 [57 – 70] 
Scenario 3 (AT + LA + VE = 
100%) 
   
 1) History of CDI in ICU - - - 
 2) LTCF residents 0.8 [0.6 – 1.0] 0.19 17 [14 – 23] 
 3) Elective patients 2.8 [2.6 – 3.0] 0.29 199 [183 – 219] 
 4) All combined 3.5 [3.2 – 3.7] 0.26 168 [156 – 181] 
Scenario 4 (HT + LA + VE = 
100%) 
   
 1) History of CDI in ICU - - - 
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 2) LTCF residents 1.1 [0.9 – 1.4] 0.40 12 [10 – 16] 
 3) Elective patients 5.0 [4.5 – 5.5] 0.56 112 [103 – 125] 
 4) All combined 5.9 [5.4 – 6.5] 0.54 99 [91 – 108] 
Scenario 5 (AT + AA + VE = 
70%) 
   
 1) History of CDI in ICU - - - 
 2) LTCF residents 0.8 [0.6 – 1.0] 0.24 17 [14 – 23] 
 3) Elective patients 2.8 [2.5 – 3.0] 0.37 204 [187 – 225] 
 4) All combined 3.4 [3.1 – 3.8] 0.34 171 [152 – 189] 
Scenario 6 (AT + AA + VE = 
50%) 
   
 1) History of CDI in ICU - - - 
 2) LTCF residents 0.6 [0.4 – 0.7] 0.23 23 [17 – 34] 
 3) Elective patients 2.0 [1.8 – 2.3] 0.36 283 [251 – 313] 
 4) All combined 2.6 [2.3 – 2.9] 0.33 228 [207 – 259] 
 
We assumed that vaccination did not provide direct protection against C. difficile colonisation. 
Nonetheless, introduction of vaccination saw a decreased ward-based risk of patients acquiring both 
symptomatic and asymptomatic C. difficile. This can be seen by a reduction in the median total number of 
ICU-acquisitions of 3% [0 – 5], 13% [11 – 16] and 16% [14 – 18] for strategies 2, 3 and 4. Due to this 
population-effect of the vaccine, the reduction in the number of ICU-acquisitions that became 
symptomatic (either in the ICU or post-discharge) was higher than the increase in the number of ICU-
acquisitions that resulted in colonisation for these three strategies (Figure 17).  In the ICU, this meant 
that, post-vaccination, a reduction was observed in both ICU-acquired CDI, as well as colonisations 
(Figure 18), as, when no vaccination was introduced, a large proportion (42%) of patients that remained 
asymptomatic in the ICU, developed symptoms post-discharge.  
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Vaccine programme efficiency  
 
Among the four strategies investigated, strategy 2 was the most efficient, i.e. required the lowest 
number of doses to avert one case of ICU-onset CDI in the base case scenario (Table 8). This was 
followed by strategy 1, but as this strategy included model simulations where no reduction was observed 
(considering the low number of readmissions of previously positive patients that experience subsequent 
onset, Supplementary table 9), this was also the most uncertain strategy. Strategy 3 required over ten times 
more doses than strategy 2, and hence was the least efficient. Finally, vaccinating all target groups 
required over eight times more doses than strategy 2 to prevent one case (Table 8). 
Simulation Results: Scenario analysis 
Vaccine impact (for four strategies) was modelled in six alternative scenarios, as shown in Table 
8. In the following sections, vaccine performance in these scenarios in terms of effectiveness and 
efficiency is discussed. 
Scenarios of high transmission 
Among all six scenarios investigated, the CDI vaccination programmes proved most effective 
and efficient when transmission was high and antimicrobial usage was at the national average (scenario 2, 
see Table 8). Under these assumptions, without vaccination, the median number of new symptomatic and 
asymptomatic C. difficile acquisitions in the ICU was four times higher than in the base case scenario, i.e. 
55.9 [IQR: 52.0 – 59.7] per 1000 admissions, of which 12.6 [11.2 – 14.0] had ICU-onset (Supplementary 
table 10).  
As a result of the higher incidence in the ICU, the probability of previously colonised or infected 
patients being readmitted to the ICU increased (Supplementary table 10), resulting in five times more 
cases being prevented for strategy 1 compared to the base case (Table 8). Two times more ICU-onset 
cases were prevented through vaccination for strategies 3 and 4 (Table 8) as these strategies became more 
effective in preventing onward transmission (Figure 19). Strategy 2 became just 50% more effective. 
Hence, fewer doses of vaccine were required to prevent one CDI case in the ICU for strategies 1, 3 and 4 
in particular, than were needed under base case assumptions. Nonetheless, in scenario 2, as well as among 
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all other scenarios investigated, vaccination of LTCF residents remained the most efficient strategy (Table 
8).  
Figure 19: Absolute number of imported and acquired cases prevented for strategies 1, 2, 3 and 4 
 
A: Model output in Scenario 1 (Base case); B: Model output in Scenario 2 (HT + AA + 100% VE); 
C: Model output in scenario 3 (AT + LA + 100% VE); D: Model output in scenario 4 (HT + LA + 100% VE) 
 
The relative effectiveness of all strategies was only slightly higher compared to the base case, with 
a 45%, 38%, 8% and 2% reduction in ICU-onset CDI for strategy 4, 3, 2 and 1 respectively. 
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Scenarios of low antimicrobial consumption 
In scenario 3, antimicrobial prescribing in the ICU (αicu) and GM (αgm) were reduced with 32% 
and 36% respectively. Consequently, without vaccination, the median number of new symptomatic and 
asymptomatic C. difficile acquisitions in the ICU was 25% lower than in the base case scenario, i.e. 8.3 
[IQR: 6.7 – 9.6] per 1000 admissions, of which 2.0 [1.5 – 2.5] had ICU-onset (Supplementary table 11). 
With such lowered levels of high-risk antimicrobial prescribing, vaccination reduced ICU-onset 
CDI incidence for strategies 2, 3 and 4 (Table 8), with close to similar relative reductions compared to the 
base case (9%, 34% and 42% respectively, i.e. a one percentage decrease for strategy 3 and 4). However, 
considering the lower incidence of ICU–acquired CDI incidence, strategies 3 and 4 required more doses 
in particular to avert one case (Table 8), as they prevented less onward-transmission (Figure 19). The 
impact of antimicrobial usage on these strategies efficiency was even further pronounced when 
transmission was high (scenario 4 compared to scenario 2, (Figure 19)).  
Scenarios of low vaccine efficacy 
With vaccine efficacy reduced to 50% (scenario 6), reductions in ICU-onset CDI were still 
observed. To illustrate, 24% of ICU-onset CDI cases were prevented in strategy 4, compared to 42% at 
the base case of 100% vaccine efficacy. However, with 64%, 94% and 84% more vaccine doses required 
for strategies 2, 3 and 4 respectively, the vaccine strategies’ efficiency was significantly reduced (Table 8).  
Simulation Results: impact of asymptomatic carriers 
We simulated three scenarios for asymptomatic transmission, where the transmission from an 
asymptomatic case (relative to that from a symptomatic case) was varied, namely, 1) half as transmissible 
(the base case scenario), 2) no asymptomatic transmission, and 3) equally transmissible. This section 
discusses how the transmission potential of asymptomatic carriers interacts with the population-level 
effect of the vaccine.  
Under all three scenarios for asymptomatic transmission, vaccination decreased the ward-based 
risk of C. difficile acquisition (symptomatic and asymptomatic) (Figure 20). Intuitively, post-vaccination, 
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reduction in ward-based acquisition was mostly seen when asymptomatic carriers were not transmitting 
(up to 51% [49 – 53] for strategy 4) as, under this assumption, by reducing the number of CDI cases in 
the ICU the transmission source was more successfully contained.  
Figure 20: Total number of ICU-acquired cases (symptomatic and asymptomatic) per 1000 admissions shown for all 
four vaccination strategies, and all three assumptions for asymptomatic transmission  
 
The middle line in the box represents the median of 1000 model parameter sets, and upper and lower areas of the 
box indicate the seventy-fifth and twenty-fifth percentiles. 1:0: no asymptomatic transmission; 2:1: asymptomatic 
carriers are half as transmissible compared to symptomatic carriers; 1:1: asymptomatic and symptomatic carriers are 
equally transmissible. 
However, when transmission of asymptomatic and symptomatic carriers was equal, this so-called 
indirect- or population-effect of vaccination was marginal, with a reduction of less than 4% for all 
strategies (compared to 16% in the base case, Figure 20).  
As a result, under the equal asymptomatic transmission assumption, vaccination resulted in a 
slight increase of asymptomatic carriers (as the vaccine did not provide direct protection against 
colonisation) in the ICU for the most effective strategies 3 (6% [3 – 9]) and 4 (7% [4 – 9]), whereas under 
the base case and no asymptomatic transmission assumption, a decrease was observed (Figure 21A). 
Nonetheless, in terms of the CDI-onset cases prevented in the ICU, the efficiency was only less than 10% 
lower for all strategies (as shown in Supplementary table 12) under the equal transmission assumption 
compared to the base case asymptomatic transmission assumption.  
In the scenario with no asymptomatic transmission, the marked decrease in ICU-acquisitions 
mentioned earlier resulted in a reduction in asymptomatic carriers in- and also outside the ICU. The latter 
was not observed under the base case asymptomatic transmission scenario (Figure 21B).  
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Figure 21: Change in symptomatic and asymptomatic ICU-acquired C. difficile per 1000 admissions shown for all four 
vaccination strategies, and all three assumptions for asymptomatic transmission; A) In the ICU; B) In- and outside the 
ICU   
A 
 
B 
 
Black points: median absolute reduction in symptomatic cases (x-axis) and increase in symptomatic cases (y-axis) of 
the 1000 parameter sets. Transparent ellipses plot the 95% coverage intervals. 1:0: no asymptomatic transmission; 
2:1: asymptomatic carriers are half as transmissible compared to symptomatic carriers; 1:1: asymptomatic carriers are 
equally transmissible.
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Consequently, the least effective strategies (strategy 1 and 2) required fewer vaccines doses 
compared to base case scenario to prevent one CDI case (30% fewer in the case of strategy 1 and 29% 
fewer in the case of strategy 2). This was also true, albeit less pronounced, for strategy 3 and 4, which 
required 14% and 15% fewer doses respectively. As was shown previously, strategies 1 and 2 prevented 
primarily imported cases. This was less true for strategies 3 and 4, which saw a higher proportion of 
acquired ICU-onset CDI prevented than the other two strategies (Table 8). This distinction became less 
apparent when there was no asymptomatic transmission, i.e. strategy 1 and 2 became relatively more 
effective in preventing acquired ICU-onset CDI (as was shown by a higher relative increase in the 
proportion of acquired ICU-onset cases prevented for strategy 1 and 2, Supplementary table 12).  
 
Discussion 
This study presented the first dynamic-transmission model-based evaluation of the projected 
effectiveness of different vaccination strategies on CDI incidence in a high CDI-risk hospital setting. We 
observed that immunising all three patient groups (LTCF residents, elective patients and patients with a 
history of ICU-onset CDI) was the most effective strategy studied. With ~17 CDI cases observed 
annually in our simulated 30-bed ICU (representing current average incidence rates in England[84]), this 
would equal a prevention of ~seven ICU-onset cases per year. Of the three individual target groups, 
vaccinating all patients awaiting elective surgery yielded the largest net reduction in ICU-onset cases.  
A full cost-effectiveness analysis of any putative CDI vaccine was beyond the scope of this study. 
However, we did consider efficiency – measured as the number of vaccination doses needed to prevent 
one case of CDI. We found that vaccinating LTCF residents proved the most efficient in terms of doses 
per case prevented, primarily as asymptomatic colonisation is frequent among the elderly residents of 
LTCF[22], and due to the high rates of antimicrobial prescribing in this group compared to the rest of the 
population[24, 26]. However, it should be noted that the low total number of admissions from LTCF 
resulted in only a small reduction of the overall risk of colonisation in the ICU. Therefore the proportion 
of admissions from the LTCF is an important consideration in the generalisability of our findings. 
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This study is the first to model numerous scenarios to examine the impact of asymptomatic 
transmission on vaccination. We found that the ranking of each of the strategies, from most to least 
effective in prevention of CDI for each of the asymptomatic transmission scenarios did not change, the 
overall impact of vaccination differed markedly. The potential implications of this are further discussed 
below.  
An important finding from this study was the impact of antimicrobial prescribing. In settings 
with ICU-acquired CDI incidence comparable to the English national average[84]; antimicrobial 
stewardship can help prevent onset among asymptomatically imported cases as well as successfully reduce 
onward transmission. With lower levels of high risk antimicrobial prescribing, the efficiency of 
vaccination was greatly reduced and the converse was also true. Therefore, we would suggest that 
vaccination may be most efficient (and perhaps cost-effective) in settings where antimicrobial stewardship 
has not been (or can not be) implemented successfully.  
Comparison of our findings with previous modelling and molecular studies 
Only one previous modelling study by Lee et al, has quantified the impact of CDI vaccination in a 
comparative manner.  They found that a CDI vaccine was most likely to be cost-effective when only 
patients that had experienced a CDI episode[21] were immunised. In our study, vaccinating patients with 
a history of CDI (in the ICU) had close to no effect on CDI incidence in the ICU, and required ~80 
doses to prevent one case. It is likely, however, that our findings differ from those of Lee et al due to the 
differences in the models’ underlying assumptions. Lee and colleagues assumed that recurrent CDI would 
always occur in hospital or result in hospitalisation. In our model, active admission of recurrent cases was 
not incorporated; primarily as such patients are unlikely to be admitted to the ICU. Moreover, in the 
absence of vaccination, less than one case per 1000 admissions of the patients with a recurrent ICU-onset 
CDI was seen, either in the same episode or after re-admissions. This was for two reasons: firstly we 
observed a low number of relapses during a hospital stay, secondly, the risk of ICU readmission when 
colonised was low, as the mean colonisation time, as observed by others [19, 20]) equalled the average 
number of days between ICU-admissions in England as according to HES data (~1 month).  
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In our study, the balance between ICU-importation and ICU-acquisition of CDI drove the 
projected effectiveness of vaccination. Previous statistical and molecular studies have questioned the 
importance of in-hospital transmission from symptomatic patients in the development of CDI in endemic 
settings[5, 44, 45]. Molecular studies have showed high genetic diversity between symptomatic in hospital 
cases, and have found a genetic and epidemiological to another symptomatic source for only a minority of 
hospital-onset cases (i.e. 19 – 25%)[45, 93, 94]. We showed that, when fitting a highly data-driven model 
to English national average ICU acquisition rates (allowing for asymptomatic transmission), and 
using English ICU data-informed colonisation and infection importation rates, the majority (69%) of 
ICU-onset cases were imported from outside the ICU. These importations concerned primarily patients 
that were asymptomatic on admission and developed symptoms following exposure to antimicrobials. A 
recent study also showed that toxigenic C. difficile colonisation on ICU admission was an independent 
risk-factor for developing CDI in the ICU, with the risk of CDI in the ICU mediated by the exposure to 
antimicrobials[95]. This suggests that, the identification and targeting of patients groups at heightened risk 
of colonisation, becomes increasingly important when ward-based CDI-onset is not primarily driven by 
ward-based acquisitions. Vaccinating LTCF residents would be an example of such target populations [58, 
59]. Our findings showed that strategy two was the most efficient strategy, regardless of the level of 
transmission or antimicrobial usage assumed. However, as these patients only formed a fraction of ICU-
admission, our findings imply that such targeted approach should be multifaceted, and informed by 
previous, e.g, [96] and future studies on other risk factors associated with colonisation.  
When acquisition risk through ICU-based transmission was high in our model, e.g. as a 
consequence of high prevalence of BI/NAP1/027[85], the majority of cases were acquired (61%). Not 
surprisingly, under such conditions, the efficiency of the vaccination strategies was increased markedly, in 
particular when vaccinating elective patients, which due to the level of induced herd immunity[97], had 
the greatest population effect. Similarly, Lee et al showed cost-effectiveness of vaccination against first 
occurrence of CDI is highly sensitive to the risk of acquiring CDI[21].  
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Strengths 
 A major strength of our study was that this study has been the first to incorporate data-driven 
patient movements between the hospital, community and LTCF to simulate the dynamics of C. difficile 
transmission. Hence, heterogeneity in risk factors associated with the infection was allowed for, such as 
observed higher levels of antimicrobial usage in LTCF populations, than in community populations. 
Moreover, our individual-based model enabled detailed examination of the complex balance between 
importation and acquisition of CDI and its interaction with vaccine effectiveness. Extensive analysis of 
numerous English national datasets and local level data from individual hospitals was conducted to 
inform key parameters and simulate the English ICU-setting as closely as possible. Great effort was 
invested in obtaining robust parameter estimates, such as for the excess length of stay and ward-based 
antimicrobial prescribing. We carefully propagated parameter uncertainty, e.g. second order uncertainty 
observed in the statistical analysis of antimicrobial usage data was used to inform distributions for the 
probabilistic sensitivity analysis. Also, natural immunity against C. difficile among the critical ill is highly 
uncertain – limited data from a small study including severely ill patients was used as a proxy [74] – which 
was incorporated in our model output. This is particularly important, as the degree of natural immunity in 
the studied population is key in predicting vaccine effectiveness and efficiency (also shown by the 
sensitivity of our model output to the presumed immunity, data not shown). Finally, we investigated a 
high number of different scenarios, hence allowing for enhanced generalisability of our findings. 
Limitations  
This study had several limitations. The calculated number of vaccine doses for strategy 2, 3 and 4 
are approximations, and in particularly for strategy 2, was likely to be an underestimate, as we did not 
account for the high mortality rates among LTCF residents and frequent new admissions to the cohort 
[98]. Secondly, while we considered importations from and infection-onset post ICU discharge, our 
model only evaluated CDI-dynamics in the ICU. Incorporation of discharge and (re)admission dynamics 
elsewhere in the hospital may have improved the effectiveness of some strategies (notably vaccinating 
CDI cases) in preventing healthcare-onset CDI. Also, our model did not incorporate transmission 
dynamics outside the ICU. Hence, onward transmission prevented from cases with symptom-onset or 
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recurrence outside the ICU was not captured, resulting in a potential underestimation of vaccine 
effectiveness in terms of preventing hospital- as well as community-onset CDI. Data to realistically 
inform such a holistic model is currently limited. Therefore, any such model would have been highly 
theoretical and its results uncertain. The United States is among the few that has conducted population-
based surveillance of CDI on a wider national scale[99, 100]. Similarly, a surveillance programme for 
hospital-level antimicrobial prescribing data has only recently been implemented in England[101], and 
while antimicrobial prescribing volume is reported at a general practice level, there is no routine linkage to 
community CDI surveillance or information at a patient level. Such a model would have also allowed for 
the investigation of the potential unintended effect of vaccination. We observed that, when asymptomatic 
carriers contributed to transmission, the number of colonisations outside the ICU increased (though to a 
lesser extend than the decrease in infections). These asymptomatic cases are more likely to remain 
unobserved than symptomatic cases, and when transmission-events from such individuals is present, 
might have unintended consequences for the transmission of C. difficile and CDI incidence outside the 
ICU. When asymptomatic carriers were non-transmissible, this increase in colonisations was not present. 
Therefore, until we are more certain about the role of asymptomatic patients in the transmission of CDI, 
it is difficult to define the true effectiveness of vaccination, as well as any infection prevention control 
strategy.   
Conclusions 
Through careful modelling of the admission and discharge dynamics between healthcare and 
community settings, this study has provided useful insight in how and where respective vaccination 
strategies involving different target groups are most likely to have an impact on CDI incidence rates. 
Vaccinating LTCF residents and elective patients may aid in preventing CDI in high-risk hospital settings 
such as the ICU. However in settings with comparable ICU-acquisition and antimicrobial usage rates to 
England, this would require a high number of vaccine doses, primarily considering the low efficiency of 
vaccination elective patients. This calls for more careful examination of potential target groups at risk for 
colonisation on admission and subsequent healthcare-onset CDI. A future hospital and community cost-
effectiveness analysis, comparing the effectiveness of our selected vaccination programmes to existing 
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strategies such as antimicrobial stewardship could aid in determining whether and how a vaccine could be 
cost-effective. 
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Supplementary material 
 
 
Supplementary table 3: Values used in scenario analysis 
Scenario β1 β2 αicu αgm e 
Scenario 1 (AT+AA+VE=100%) 0.0074 0.0037 0.219 0.081 1 
Scenario 2 (HT+AA+VE=100%) 0.0196 0.0098 0.219 0.081 1 
Scenario 3 (AT+LA+VE=100%) 0.0074 0.0037 0.149 0.052 1 
Scenario 4 (HT+LA+VE=100%) 0.0196 0.0098 0.149 0.052 1 
Scenario 5 (AT+AA+VE=70%) 0.0074 0.0037 0.219 0.081 0.7 
Scenario 6 (AT+AA+VE=50%) 0.0074 0.0037 0.219 0.081 0.5 
Asymptomatic 1:0  
(and AT+AA+VE=100%) 
0.0169 0.0533 
0.219 0.081 1 
Asymptomatic 1:1 
(and AT+AA+VE=100%) 
0.0047 0.0126 
0.219 0.081 1 
 
 
Supplementary table 4: Values used in probabilistic sensitivity analysis 
Parameter Description Distribution LHS 
αicu Fraction of patients on antimicrobials in the ICU on a given day Logitnormal(-1.274; SD 0.08) 
αgm 
Fraction of patients admitted from GM on antimicrobials on 
admission to the ICU Logitnormal(-2.431; SD 0.06) 
αltcf 
Fraction of patients directly admitted from LTCF on antimicrobials on 
admission Beta(0.040; SD 0.006) 
αcom 
Fraction of patients directly admitted from the community on 
antimicrobials on admission Beta(0.012; SD 0.004) 
fltcf = fcom 
Fraction of patients admitted to ICU from the LTCF/ community that 
develop a natural immune response against disease Beta(0.240; SD 0.077) 
ai_ltcf 
Fraction of patients from LTCF that were infected on admission to 
ICU 
Posterior distribution (see 
methods) 
ac_ltcf 
Fraction of patients from LTCF that were colonised on admission to 
ICU 
Posterior distribution (see 
methods) 
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Supplementary table 5: Daily probability of discharge and death in the ICU ward for CDI- and CDI+ patients 
Time 
(days) 
Daily ICU discharge 
probability CDI- 
Daily ICU discharge probability 
CDI+ (↓28%) 
Daily ICU death probability 
CDI-/CDI+ 
0 0.00000 0.00000 0.00000 
1 0.08547 0.06154 0.02610 
2 0.16822 0.12112 0.04064 
3 0.23596 0.16989 0.02714 
4 0.17647 0.12706 0.02583 
5 0.16071 0.11571 0.02491 
6 0.12766 0.09191 0.02668 
7 0.07317 0.05268 0.01765 
8 0.07895 0.05684 0.01885 
9 0.14286 0.10286 0.01893 
10 0.20000 0.14400 0.02631 
11 0.04167 0.03000 0.01367 
12 0.04348 0.03130 0.01637 
13 0.18182 0.13091 0.02334 
14 0.05556 0.04000 0.02143 
15 - - 0.02229 
16 - - 0.01598 
17 - - 0.01847 
18 - - 0.01474 
19 - - 0.01289 
20 - - 0.01387 
21 - - 0.02734 
22 - - 0.01204 
 
 
Supplementary table 6: Model estimates of the mixed-effect logistic regression model 
Ward specialty  xw 
 
√σ2 √σ2trust 𝛼𝑤 =  1/(1 + 𝑒𝑥𝑝(−𝑥𝑤)) 25
th percentile  
(incorporating √σ2trust) 
ICU -1.274 0.08 0.401 0.219 0.149 
General medicine -2.431 0.06 0.403 0.081 0.052 
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Supplementary table 7: Antimicrobial use in the community and LTCF 
 Community LTCF 
 DDD/100 N (per 100 residents) 
 2010  2011  2010   2013  
 
Number of eligible individuals included in 
sample 
59,255,000 63,232,700 7,498 3,954 
  J01C BETA-LACTAM 
ANTIBACTERIALS, PENICILLINS 
0.856 0.872 166 (2.21) 109 (2.76) 
J01D OTHER BETA-LACTAM 
ANTIBACTERIALS 
0.055 0.042 62 (0.83) 29 (0.73) 
J01F MACROLIDES, LINCOSAMIDES 
AND STREPTOGRAMINS 
0.273 0.281 29 (0.39) 27 (0.68) 
J01M QUINOLONE ANTIBACTERIALS 0.046 0.043 24 (0.32) 9 (0. 23) 
Total 1.230 1.238 281 (3.75) 174 (4.40) 
 
Supplementary table 8: Importation rates of infected and colonised individuals 
Status Cases Total 
screened 
Total 
admissions 
Proportion Lower# Upper# 
Carrier ICU 20 744 1332 0.027 0.017 0.041 
Infected ICU 4 744 1332 0.003 0.001 0.008 
Carrier ICU AND LTCF 0 30 53 0 0 0.114 
Infected ICU AND LTCF 0 30 53 0 0 0.114 
Carrier ICU and Community 20 714* 1279* 0.028 0.018 0.043 
Infected ICU and community 4 714* 1279* 0.003 0.001 0.008 
* Under the assumption that four per cent of the total admissions are patients from LTCFs; # 95% confidence 
intervals calculated using the Wilson score method[102]
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Supplementary table 9: Model outcome per 1000 admissions for each of the different vaccination strategies and scenarios under average transmission assumptions 
Average transmission levels + Average antimicrobial use + VE = 100% + Asymptomatic transmission 2:1  (Base case scenario) 
Outcome 
Number of cases per 1000 
admissions 
(Median [IQR]) 
Strategy: 0 
 
Difference 
(Median [IQR]) 
Strategy: 1 
 
Difference 
(Median [IQR]) 
 Strategy: 2 
 
Difference 
(Median [IQR]) 
 Strategy: 3 
 
Difference 
(Median [IQR]) 
 Strategy: 4 
 
Total ICU acquisitions 
infections + colonisations   
13.9 [13.1 – 14.9] 0.1 [-0.2 – 0.4] 0.4 [0.1 – 0.8] 1.9 [1.5 – 2.3] 2.2 [1.9 – 2.8] 
New colonisations 6.2 [5.8 – 6.8] 0 [-0.1 – 0.2] 0.1 [-0.1 – 0.3] 1.2 [0.9 – 1.5] 1.2 [0.9 – 1.4] 
New infections   7.7 [6.8 – 8.6] 0 [-0.1 – 0.2] 0.5 [0.3 – 0.7] 3.1 [2.7 – 3.5] 3.4 [3.0 -3.9] 
   ICU-onset 3.3 [2.9 – 3.7] 0 [-0.1 – 0.1] 0.3 [0.1 – 0.4] 1.4 [1.2 – 1.6] 1.5 [1.3 – 1.8] 
   No ICU-onset 4.4 [3.9 – 4.9] 0 [-0.1 – 0.1] 0.3 [0.2 – 0.4] 1.7 [1.5 – 1.9] 1.9 [1.6 – 2.2] 
Total imported infections 7.5 [7.1 – 8.1]     
Community-acquired 7.0 [6.6 – 7.5] 0 [-0.1 – 0.1] 0.7 [0.5 – 0.8] 2.2 [2.0 – 2.4] 2.8 [2.6 – 3.0] 
Readmission of previously 
colonised/infected case 
0.5 [0.5 – 0.6] 0.1 [0.1 – 0.2] 0.1 [0.0 – 0.1] 0.3 [0.3 – 0.4] 0.4 [0.4 – 0.4] 
Total imported 
colonisations  
20.8 [20.3 – 21.4]     
Community-acquired 18.6 [18.1 – 19.1] 0 [-0.1 – 0.1] 0.6 [0.4 – 0.8] 1.8 [1.6 – 2.0] 2.3 [2.0 – 2.3] 
Readmission of previously 
colonised/infected case 
2.2 [2.1 – 2.3] 0.1 [0.1 – 0.2] 0 [-0.1 – 0.1] 0.1 [-0.1 – 0.1] 0 [0 – 0.1] 
Relapse/recurrence on readmission  0.1 [0.1 – 0.1] 0.1 [0.1 – 0.1] 0 [0 – 0] 0.1 [0.1 – 0.1] 0.1 [0.1 – 0.1] 
Model output in the base case scenario (assuming average transmission levels, asymptomatic carriers have half the transmission potential compared to symptomatic carriers (2:1), 
and average levels of antimicrobial prescribing); Red arrows: increase compared to a strategy 0 (no vaccination); black arrows: decrease compared to strategy 0
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Supplementary table 10: Model outcome per 1000 admissions for each of the different vaccination strategies and scenarios under high transmission assumptions 
High transmission levels + Average antimicrobial use + VE = 100% + Asymptomatic transmission 2:1 (scenario 2) 
Outcome 
Number of cases per 1000 
admissions 
(Median [IQR]) 
Strategy: 0  
 
Difference 
(Median [IQR]) 
Strategy: 1 
 
Difference 
(Median [IQR]) 
 Strategy: 2 
 
Difference 
(Median [IQR]) 
 Strategy: 3 
 
Difference 
(Median [IQR]) 
 Strategy: 4 
 
Total ICU acquisitions 
infections + colonisations   
55.6 [52.0 – 59.7] 0.4 [-0.4 – 1.2] 1.3 [0.6 – 2.1] 7.0 [6.0 – 7.7] 8.3 [7.2 – 9.5] 
New colonisations 25.1 [22.8 – 27.2] 0.1 [-0.5 – 0.2] 0.6 [0.2 – 1.0] 4.9 [4.0 – 6.0] 5.0 [4.1 – 6.1] 
New infections   30.6 [27.0 – 34.2] 0.3 [-0.2 – 0.7] 1.9 [1.4 – 2.4] 12.0 [10.4 – 13.5] 13.3 [11.7 – 15.0] 
   ICU-onset 12.6 [11.2 – 14.0] 0.2 [-0.1 – 0.4] 0.8 [0.6 – 1.1] 5.1 [4.4 – 5.7] 5.7 [5.0 – 6.5] 
   No ICU-onset 18.0 [15.9 – 20.2]  0.1 [-0.1 – 0.4] 1.1 [0.7 – 1.4] 6.8 [6.0 – 7.7] 7.6 [6.7 – 8.6] 
Total imported infections 8.3 [7.6 – 8.8]         
Community-acquired 7.0 [6.5 – 7.4] 0 [-0.1 – 0.1] 0.7 [0.5 – 0.8] 2.2 [2.0 – 2.3] 2.8 [2.6 – 3.0] 
Readmission of     
Previously colonised/ infected case 
1.3 [1.1 – 1.4] 0.1 [0.1 – 0.2] 0.1 [0.1 – 0.2] 0.7 [0.5 – 0.8] 0.9 [0.8 – 1.0] 
Total imported 
colonisations  
23.0 [22.3 – 23.7]         
Community-acquired 18.5 [18.0 – 19.0] 0 [-0.2 – 0.2] 0.6 [0.4 – 0.8] 1.8 [1.6 – 2.0] 2.3 [2.0 – 2.6] 
Readmission of     
Previously colonised/ 
infected case 
4.5 [4.3 – 4.7] 0.3 [0. 2– 0.4] 0 [-0.1 – 0.1] 0.3 [0.2 – 0.4] 0.3 [0.2 – 0.4] 
Relapse/recurrence on readmission  0.3 [0.3 – 0.4] 0.3 [0.3 – 0.4] 0 [0 – 0.1] 0.1 [0.1 – 0.3] 0.3 [0.3 – 0.4] 
Model output in scenario 2; Red arrows: increase compared to a strategy 0 (no vaccination); black arrows: decrease compared to strategy 0. 
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Supplementary table 11: Model outcome per 1000 admissions for each of the different vaccination strategies and scenarios under low antimicrobial use assumptions 
Average transmission + Low antimicrobial use + VE = 100% + Asymptomatic transmission 2:1  (scenario 3) 
Outcome 
Number of cases per 1000 
admissions 
(Median [IQR]) 
Strategy: 0  
 
Difference 
(Median [IQR]) 
 Strategy: 2 
 
Difference 
(Median [IQR]) 
 Strategy: 3 
 
Difference 
(Median [IQR]) 
 Strategy: 4 
 
Total ICU acquisitions 
infections + colonisations   
8.5 [8.1 – 8.8] 0.2 [0 – 0.4] 0.9 [0.7 – 1.1] 1.1 [0.9 – 1.3] 
New colonisations 3.8 [3.5 – 4.1] 0.1 [0 – 0.2] 0.9 [0.7 – 1.0] 0.9 [0.7 – 1.1] 
New infections   4.7 [4.2 – 5.1] 0.3 [0.2 – 0.4] 1.8 [1.6 – 2.0] 2.0 [1.8 – 2.2] 
   ICU-onset 2.0 [1.8 – 2.2] 0.1 [0.1 – 0.2] 0.8 [0.7 – 0.9] 0.9 [0.8 – 1.0] 
   No ICU-onset 2.6 [2.4 – 2.9] 0.2 [0.1 – 0.2] 1.0 [0.8 – 1.1] 1.1 [1.0 – 1.2] 
Total imported infections 6.3 [5.9 – 6.6]       
Community-acquired 5.9 [5.5 – 6.2] 0.6 [0.4 – 0.7] 1.8 [1.7 – 2.0] 2.3 [2.2 – 2.5] 
Readmission of     
Previously colonised/ infected case 
0.4 [0.3 – 0.4] 0 [0 – 0.1] 0.1 [0.1 – 0.3] 0.3 [ 0.1 – 0.3] 
Total imported 
colonisations  
21.4 [21.0 – 21.9]        
Community-acquired 19.5 [19.1 – 19.9] 0.5 [0.3 – 0.7] 1.5 [1.3 – 1.7] 1.9 [1.7 – 2.1] 
Readmission of     
previously colonised/infected case 
1.9 [1.9 – 2.0] 0 [0 – 0.1] 0 [-0.1 – 0.1] 0 [0 – 0.1] 
Relapse/recurrence on readmission  0 [ 0 – 0] 0 [0 – 0] 0 [0 – 0] 0 [0 – 0] 
Model output in scenario 3; Red arrows: increase compared to a strategy 0 (no vaccination); black arrows: decrease compared to strategy 0.
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Supplementary table 12: Scenario analysis for asymptomatic transmission 
  Average transmission High transmission 
 
ICU-onset CDI 
cases 
prevented/1000 
admissions 
Proportion of the 
ICU-onset cases 
prevented that were 
acquired 
Doses required to 
avert one ICU-onset 
CDI case (scaled to 
ICU) 
ICU-onset CDI 
cases 
prevented/1000 
admissions 
Proportion of the 
ICU-onset cases 
prevented that were 
acquired 
Doses required to 
avert one ICU-onset 
CDI case (scaled to 
ICU) 
Symptomatic: 
Asymptomatic (2:1)  
          
Scenario 1 (AA + VE = 
100%) 
          
 1) History of CDI in ICU 0.1 [0 – 0.3] 0.20 83 [33 – NA] 0.5 [0.2 – 0.8] 0.34 43 [27 – 115] 
 2) LTCF residents 1.0 [0.8 – 1.2] 0.24 14 [11 – 17] 1.6 [1.3 – 2.0] 0.50 8 [7 – 10] 
 3) Elective patients 3.9 [3.5 – 4.2] 0.36 146 [133 – 162] 7.9 [7.1 – 8.8] 0.64 72 [65 – 80] 
 4) All combined 4.7 [4.3 – 5.1] 0.34 124 [113 – 137] 9.4 [8.4 – 10.4] 0.61 63 [57 – 70] 
 Symptomatic: 
Asymptomatic (1:0) 
          
Scenario 1 (AA + VE = 
100%) 
          
 1) History of CDI in ICU 0.2 [0 – 0.4] 0.37 58 [15 – NA] - - - 
 2) LTCF residents 1.3 [1.0 – 1.6] 0.38 10 [8 – 13] 2.5 [2.0 – 3.1] 0.64 5 [4 – 7] 
 3) Elective patients 4.5 [4.0 – 5.2] 0.45 125 [110 – 141] 10.7 [9.2 – 12.6] 0.72 53 [45 – 62] 
 4) All combined 5.5 [4.8 – 6.2] 0.42 105 [93 – 121] 12.6 [10.6 - 14.7] 0.70 47 [40 – 45] 
Symptomatic: 
Asymptomatic (1:1) 
      
Scenario 1 (AA + VE = 
100%) 
          
 1) History of CDI in ICU 0.1 [0 – 0.3] 0.04 89 [37 – NA] - - - 
 2) LTCF residents 0.9 [0.7 – 1.1] 0.18 15 [12 – 19] 1.4 [1.1 – 1.8] 0.45 9 [8 – 12] 
 3) Elective patients 3.6 [3.3 – 3.9] 0.31 157 [146 – 172] 7.1 [6.4 – 7.7] 0.61 80 [73 – 88] 
 4) All combined 4.4 [4.0 – 4.8] 0.28 132 [123 – 144] 8.5 [7.7 – 9.3] 0.58 70 [64 – 77] 
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Supplementary table 13: Model outcome per 1000 admissions for each of the different vaccination strategies and scenarios for asymptomatic transmission 
 
Average transmission + Average Antimicrobial use + 100% VE +  
asymptomatic 1:0 
Average transmission + Average Antimicrobial use + 100% VE + 
asymptomatic 1:1 
Outcome 
Number of 
cases  
(Median 
[IQR]) 
Strategy: 0 
Difference 
(Median 
[IQR]) 
 Strategy: 1 
Difference 
(Median 
[IQR]) 
 Strategy: 2 
Difference 
(Median 
[IQR]) 
 Strategy: 3 
Difference 
(Median 
[IQR]) 
 Strategy: 4 
Difference 
(Median 
[IQR]) 
Strategy: 1 
Difference 
(Median 
[IQR]) 
Strategy: 2 
Difference 
(Median 
[IQR]) 
Strategy: 3 
Difference 
(Median 
[IQR]) 
Strategy: 4 
Total ICU 
acquisitions 
infections + 
colonisations   
13.9 [13.1 – 14.9] 0.3 [0.2 – 0.8] 1.6 [1.1 - 2.1] 6.1 [5.1 - 7.0] 7.3 [6.2 – 8.4] 0.1 [-0.3 – 0.3] 0.1 [-0.2 – 0.4] 0.1 [-0.2 – 0.4] 0.5 [0.3 – 0.9] 
New colonisations 6.2 [5.8 – 6.8] 0.1 [0.1 – 0.3] 0.4 [0.2 – 0.7] 1.3 [1.0 - 1.6] 1.9 [1.6 – 2.2.] 0 [-0.1 – 0.2] 0.3 [0.1 – 0.4]  0.3 [0.1 – 0.4]  2.2 [1.9 – 2.5] 
New infections   7.7 [6.8 – 8.6] 0.2 [0.1 – 0.4] 1.1 [0.8 – 1.5]   4.7 [3.8 – 5.7] 5.3 [4.3 – 6.3] 0 [-0.2 – 0.2] 0.3 [0.2 – 0.5]  0.3 [0.2 – 0.5]  2.8 [2.4 – 3.1] 
   ICU-onset 3.3 [2.9 – 3.7]  0.1 [0.1 – 0.2]  0.5 [0.3 – 0.7] 2.0 [2.3 – 3.3] 2.3 [1.9 – 2.8] 0 [-0.1 – 0.1] 0.2 [0.1 – 0.3]  0.2 [0.1 – 0.3]  1.3 [1.1 – 1.4] 
   No ICU-onset 4.4 [3.9 – 4.9] 0.1 [0 – 0.2] 0.6 [0.4 – 0.8]  2.7 [2.2 – 3.3] 3.0 [2.5 – 3.7] 0 [-0.1 – 0.1] 0.2 [0.1 – 0.3] 0.2 [0.1 – 0.3] 1.5 [1.3 – 1.7] 
Total imported 
infections 
7.5 [7.1 – 8.1]                
Community-
acquired 
7.0 [6.6 – 7.5] 0 [0 – 0.1] 0.7 [0.5 – 0.8]  2.0 [2.0 – 2.4] 2.8 [2.6 – 3.0] 0 [-0.1 – 0.1] 0.7 [0.5 – 0.8]  0.7 [0.5 – 0.8]  2.8 [2.6 – 3.0] 
Readmission of 
previously 
colonised/infected 
case 
0.5 [0.5 – 0.6] 0.1 [0.1 – 0.1] 0.1 [0 – 0.1] 0.3 [0.3 – 0.4] 0.4 [0.4 – 0.5] 0.1 [0.1 – 0.1]  0.1 [0 – 0.1]  0.1 [0 – 0.1]  0.4 [0.4 – 0.4] 
Total imported 
colonisations  
20.8 [20.3 – 
21.4] 
               
Community-
acquired 
18.6 [18.1 – 19.1]  0 [-0.2 – 0.1]  0.6 [0.4 – 0.8]  1.8 [1.6 – 2.0] 2.3 [2.0 – 2.5] 0 [-0.2 – 0.1] 0.6 [0.4 – 0.8]  0.6 [0.4 – 0.8]  2.3 [2.0 – 2.5] 
Readmission of 
previously 
colonised/infected 
case 
2.2 [2.1 – 2.3]  0.1 [0 – 0.4]  0.1 [0 – 0.1] 0.2 [0.2 – 0.3] 0.2 [0.2 – 0.3] 0 [-0.2 – 0.1] 0 [-0.1 – 0.1]  0 [-0.1 – 0.1]  0.1 [0.1 – 0.2] 
Relapse/recurrence 
on readmission  
0.1 [0.1 – 0.1] 0.1 [0.1 – 0.01  0 [0 – 0] 0.1 [0.1 – 0.1] 0.1 [0.1 – 0.1] 0.1 [0.1 – 0.1] 0 [0 – 0]  0 [0 – 0]  0.1 [0.1 – 0.1]  
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CHAPTER 6 
 
DISCUSSION 
 
 
The primary objective of this thesis was to evaluate the effectiveness of C. difficile vaccination 
strategies in preventing hospital-onset CDI.  
This chapter summarises the main findings of the thesis (section 6.1), the implications for the 
prevention and control of C. difficile (section 6.2), strengths and limitations of the work conducted other 
than those described in the preceding chapters (section 6.3), and finishes with areas of future investigation 
(section 6.4). 
6.1 SUMMARY OF THE MAIN FINDINGS 
The systematic review (research paper one)[1] presented in Chapter 2 showed that mathematical 
dynamic-transmission models have become an increasingly popular tool to help understand the patient-to-
patient spread of nosocomial pathogens and predict the impact of prevention and control strategies 
(Chapter 2).  Despite the global nature of the burden of HCAI, modelling studies have been primarily 
limited to high-income settings, with MRSA the main subject of study. Up until 2011, C. difficile had rarely 
been modelled. This was despite many countries, such as the US and the UK, prioritising C. difficile, 
infection control programmes. The model developed here is similar to models of MRSA, where there has 
been a shift from a hospital scenario to one where such pathogens are considered within the whole 
healthcare economy e.g. by including the interactions between the home, hospital and other healthcare 
settings such as LTCFs[1]. Both healthcare delivery and pathogen epidemiology provide an ever-changing 
landscape and it is vital for credibility that such models are revisited regularly and revised based on the 
best data available.  
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Research using, amongst other techniques, whole genome sequencing previously revealed that 
transmission from symptomatic cases only explained a minority of the CDI-acquisitions in an English 
hospital and its catchment area community[2–4]. These observations were supported by analysis of the 
national English CDI surveillance data from a few settings (research paper two[5]). A statistically 
significant correlation between reported CDI incidence in different weeks suggested nosocomial C. difficile 
transmission from symptomatic cases was a source of CDI in English hospitals, although the weak 
correlation suggests that the extent of transmission was less than had previously been thought. In 
addition, this analysis provide evidence, for the first time, for seasonal patterns in reported CDI incidence 
in England, with an observed peak in winter (when more antimicrobials are prescribed)[5]. Hence, by 
making a novel use of routinely collected mandatory data, this thesis has provided clinically relevant 
insights into the epidemiology of CDI. 
A majority of previous studies quantifying the health and economic burden of CDI have done so 
using inappropriate methodology, and even the few studies that have used robust methods have shown a 
wide variation in outcome. Having adjusted for time-dependent bias and competing risks, CDI was shown 
to impact the predicted hospital stay of patients with moderate and severe symptoms (research paper 
three[6]). In addition, comparable mortality rates were seen for severe and moderate CDI patients, 
whereas the excess LoS was more than doubled for the former, albeit with overlapping confidence 
intervals. Hence, this study has provided the first severity specific estimate of the additional LoS and 
excess mortality due to CDI, as well as the first robust estimates of the burden of CDI in an English 
hospital-setting[6].  
Finally, the results of an individual-based “state-of-the-art” dynamic transmission model in an 
English ICU (with epidemiological parameters informed by the findings of the statistical models in 
Chapters 3 and 4, and with data-driven patient movement between the community, LTCF and ICU) 
showed that in settings with in-hospital acquisition rates comparable to the national average, immunising 
three patient groups: LTCF residents, elective patients and patients with a history of CDI in the ICU, 
resulted in a 43% reduction of ICU-onset CDI. Such a strategy would require a relatively high number of 
vaccine doses (i.e. over a 100 doses to prevent one case), suggesting this might be an inefficient use of 
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infection prevention and control resources in English ICUs, however a full cost-effectiveness analysis will 
have to provide more conclusive insight. It was shown that CDI dynamics in the high-risk ward setting 
were driven by importation of colonised patients. A targeted strategy involving patients at high risk of 
colonisation on admission, such as LTCF residents proved more efficient. However, a critical fraction of 
this group would have to be identified in order for vaccination to have a population-effect on CDI-
dynamics. As risk factors associated with colonisation, are likely to be multifaceted (e.g. recent 
hospitalisation, frequent antimicrobial use, previous ICU stay[7, 8]), this might prove difficult to translate 
into a practical and feasible vaccination strategy. Nevertheless, this should be an area of further 
investigation.  
This thesis also found that the effectiveness of vaccination proved highly sensitive to the levels of 
ward-based patient-to-patient transmission and antimicrobial usage, with effectiveness increasing as either 
transmission or antimicrobial use increased. Therefore, it was concluded that vaccination might be most 
efficient (and perhaps cost-effective) in settings where implementation of antimicrobial stewardship prove 
to be a challenge.  
Finally, the work presented here highlighted the critical need for improving our understanding of 
the role of asymptomatic carriers in the transmission-dynamics of C. difficile. Vaccination could 
successfully induce a herd-immunity effect in the ICU, i.e. reduce the ward-based C. difficile acquisition risk 
from asymptomatic and symptomatic patients. Nonetheless, if asymptomatic carriers contribute to the 
transmission-dynamics of C. difficile, and assuming that the vaccine did not provide direct-protection 
against asymptomatic carriage, an increase in colonisations outside the ICU was not prevented.  Hence, 
and due to the unique set-up of the mathematical modelling framework used, this thesis provided the first 
insight into the potential unintended consequences of vaccination. 
 
6.2 IMPLICATIONS FOR HEALTH POLICY AND CLINICAL PRACTICE  
 
Existing CDI prevention and control measures, such as improved hand hygiene, isolation and 
environmental cleaning of hospital rooms occupied by CDI positive cases, have primarily focused on 
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containing the transmission from symptomatic carriers (Chapter 1). Chapter 3 suggested that transmission 
from this group of patients is only likely to explain a fraction of CDI incidence in English hospitals 
(otherwise one would expect to see far more clustering of cases in space and time). As discussed in 
Chapter 1, asymptomatic carriers have been suggested as potential contributors to C. difficile acquisition 
since the early 1990s [9–11]. Increased availability of advanced genetic typing methods have allowed for 
more detailed and reliable investigation, and suggested likewise[12], although more research is needed [13]. 
If asymptomatic carriers are at least in part responsible for C. difficile and CDI acquisition, the number of 
new acquisitions due to each asymptomatic case must be low to match the observations of wide genetic 
variability, as discussed also in Chapter 3[5]. Similarly, using less discriminatory molecular typing (i.e. 
restriction enzyme analysis (REA)[14] and arbitrarily primed PCR[15]), it was shown that in non-epidemic 
settings, C. difficile isolates revealed wide genotypic diversity, with little evidence for direct or indirect 
cross-transmission between symptomatic[15], but also between asymptomatic and symptomatic 
patients[14]. Chapter 5 showed, when simulating CDI transmission-dynamics using a model that was 
fitted to ICU-acquisition rates representative of the English national average, a large fraction of the 
healthcare-onset CDI are likely to be imported from outside the ICU. There are wider questions now 
being asked regarding the possible sources of C. difficile due to its recovery from diverse environmental 
sites such as meat and vegetables consumed by humans[16–19], as well as water and soil[20]. Moreover, 
farm and domestic animals have been documented to carry C. difficile with overlapping ribotypes to 
humans[21–23]. However, evidence on the transmission risk from these alternative sources has been 
inconclusive to date [24]. 
These existing uncertainties on human acquisition sources of C. difficile emphasise the importance 
of efforts other than barrier precautions such as isolation and deep cleaning, i.e. those that focus on 
decreasing patients’ susceptibility to C. difficile (producing CDI or colonisation). CDI vaccination could be 
an example of such strategy (although the current toxoid vaccines under development are not thought to 
prevent colonisation), as well as antimicrobial stewardship. Where adequate surveillance is in place, it is 
evident that in some countries, such as the US, CDI incidence remains high[25, 26]. According to a recent 
population-based surveillance study about half a million people annually continue to suffer from CDI, 
including 29,000 deaths [25]. In the US between 2011 to 2013, the C. difficile strain BI/NAP1/027 
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continued to be reported most commonly[27]. In Chapter 5, it was shown that under these conditions, a 
CDI vaccine could have a considerable population-effect, and the use of a strategy of vaccination of a 
large group of patients, e.g. those due for elective surgery, increased significantly in efficiency compared to 
when assuming lower CDI acquisition rates. However, widespread overuse and inappropriate 
antimicrobial prescribing has been documented in many countries including the US[28, 29]. Although not 
the primary aim of this thesis, Chapter 5 revealed that the reduction of ‘high risk’ antimicrobials could 
help reduce both healthcare onset-CDI in imported colonised patients, as well as help reduce healthcare 
acquisition. In previous studies, hospital-based antimicrobial stewardship programmes are associated with 
reductions in CDI rates of up to 60%[30, 31]. In England, the dramatic reductions observed have been 
largely attributed to the significant decline in cephalosporin and quinolone use (Chapter 1). However, the 
exact impact of this measure is difficult to quantify with certainty considering the parallel timing of a 
bundle of government-led measures (i.e. mandatory-surveillance, increased compliance with isolation and 
hand hygiene, target-setting). Future mathematical modelling could help quantify the relative effectiveness 
of individual- and bundled implementation of existing (and new) interventions, and provide further insight 
in how and where antimicrobial stewardship could be valuable as well as feasible. 
There will be situations where reduction of consumption of antimicrobials associated with CDI 
proves unsuccessful, or impossible. Antimicrobial prophylaxis (including the use of cephalosporins (e.g. 
cefazolin) and fluoroquinolones) is recommended for patients at high risk for surgical site infections when 
undergoing certain invasive procedures such as colectomy, hip replacement and cardiac operations[32, 33], 
and has been associated with an increased risk for CDI[32, 34]. Moreover, patients with chronic illness 
such as renal failure[35, 36] may be vulnerable to primary and recurrent CDI due to their frequent 
exposure to antimicrobials, and hospitalisation, as well as presence of other risk factors associated with the 
infection (e.g. immunosuppression and gastro-acid suppressants).  Further clinical trials are needed to 
assess how the vaccine performs among patients with such chronic co-morbidities. Moreover, for any 
future vaccine strategy design, the time required to mount an adaptive immune response post active 
immunisation requires careful attention. The latest clinical trial data suggest there is a need for three doses 
to provoke an antibody response in patients over 65 years old[37], diminishing the vaccine’s suitability for 
182 
 
strategies requiring a rapid immune response. Future modelling research could help identify whether 
vaccination of these and potential other cohorts of vulnerable patients proves feasible (see section 6.4). 
Despite the significant reduction in cephalosporin and fluoroquinolone use, overall frequency of 
antimicrobial prescribing remained stable in England, with increases in piperacillin/tazobactam, co-
amoxiclav and carbapenem use[38–40]. An emergence of extended spectrum beta-lactamase (ESBL)-
producing Enterobacteriaceae has been noted, with resistances now observed nationally and globally against 
the next-line antimicrobials of choice, the carbapenems[41, 42].   This calls for further efforts including the 
monitoring of local and national prescribing and consumption data to aid reduction in the inappropriate 
and overuse of antimicrobials[28, 29].    
In Chapter 5, through extensive data analysis and model parameterisation, it was shown that CDI-
onset in the ICU is unlikely to be primarily driven by ward-based acquisitions, but instead importations. 
Admission screening might aid in early recognition of cases “imported” into the ICU. Recent modelling 
studies concluded that screening patients on admission for asymptomatic carriage could reduce new 
acquisitions by 40-50% and hospital-onset CDI by 10-25%[43], and might be cost-effective[44].  Both 
studies incorporated strong assumptions on the transmissibility of asymptomatic carriers relative to 
symptomatic patients (i.e. equal). As shown in Chapter 5, the presumed infectiousness of the latter group 
has a considerable impact on predicted intervention effectiveness. This calls for further investigation on 
the relative role of alternative transmission routes, before CDI prevention and control policies are 
expanded to include such measures (see section 6.4).  
 
6.3 STRENGTHS AND LIMITATIONS 
 
 
In the preceding chapters, the strengths and limitations of the different sub-studies have been 
discussed. In the section below, more general strengths and limitations of the thesis are acknowledged 
with regards to its overall scope, the data used and the generalisability of the findings.  
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6.3.1 STRENGTHS 
 
This thesis provided the first detailed account of the existing dynamic modelling studies in the 
field of hospital epidemiology (Chapter 2). This should provide an improved understanding of the quality 
of HCAI transmission models, as well as directions for further modelling work to address existing and 
emerging HCAI, such as multi-drug resistant Gram-negative bacteria. 
 
Secondly, by making use of routinely collected mandatory data, this thesis investigated, for the 
first time, the contribution of in-hospital CDI transmission on a national level (Chapter 3). As has recently 
been shown for E. coli bloodstream infections[45], the approach can be easily implemented in settings 
outside England, as well as for alternative infectious agents. 
 
Thirdly, this thesis provided the first and only robust estimates of the excess LoS due to CDI in a 
European-setting (Chapter 4). Also, this thesis assessed the interaction between CDI disease severity and 
excess LoS and mortality, which had not been previously quantified. As excess bed-days are the main 
drivers of associated costs[46], and affect the transmission-dynamics of the bacterium, the work presented 
here has provided accurate estimates to help inform future (cost-)effectiveness analysis of vaccination, as 
well as other therapies (e.g. faecal transplantation [47]), and new antimicrobial therapies [48] in the 
pipeline.  
 
Finally, Chapter 5 presented the first dynamic-transmission model-based evaluation of the 
projected effectiveness of different vaccination strategies on CDI incidence in a high CDI-risk hospital 
setting. A major strength of the approach employed was the incorporation of data-driven patient 
movements between the hospital, community and LTCF to simulate the dynamics of C. difficile 
transmission. This enabled detailed examination of the complex balance between importation and 
acquisition of CDI and its interaction with intervention effectiveness. Moreover, the extensive analysis of 
numerous data sources to inform (and the explicit inclusion of associated uncertainties) sets an example 
for future modelling work. The model structure can be easily adapted to alternative settings, and extended, 
e.g. to include patient movement patterns in the hospital, provided appropriate data is available.  
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6.3.2 LIMITATIONS 
 
The work presented in this thesis had its focus limited to nosocomial CDI, and within the 
hospital, to the ICU-setting.  Hence, the work presented here might have missed potential uses of 
vaccination outside this setting.  
The model attempted to incorporate C. difficile dynamics between hospital and community settings 
by including readmission dynamics from LTCFs and the general population. However, fixed importation 
rates from community settings were used. Thus, the effectiveness of vaccination policies were probably 
underestimated in the model, as one would expect a lower importation rate from these settings after 
vaccination is adopted. Moreover, the model could not discriminate between the locations of CDI-onset, 
i.e. elsewhere in hospital or in the community. Ideally, the model would have included patient movements 
between the ICU and other hospitals wards, as well as include a dynamic account of the transmission 
outside the ICU (i.e. other hospital wards as well as in the community). This would have allowed for the 
effectiveness of vaccination in the prevention of onward transmission within the hospital as a whole as 
well as community-settings.  
For example, in LTCFs where C. difficile carriage can be high [49], and implementation of 
traditional prevention and control measures such as environmental decontamination and isolation are 
more challenging, vaccination could help reduce community-onset of diarrhoea. The rationale for the 
narrow scope taken was two-fold. First of all, individual-based models are computationally demanding. 
This combined with the high number of model permutations deemed necessary (due to the uncertainty in 
the epidemiology of CDI, patient characteristics, as well as the heterogeneity between ICU-settings) 
resulted in a computationally expensive analysis. Modelling a wider hospital population would have 
increased the computational time significantly, let alone inclusion of community and LTCF dynamics. 
Secondly, extensive data analysis was performed to ensure representation of an ICU in England as closely 
as possible. Limited data is available on C. difficile incidence and transmission in community-settings. 
Therefore, a holistic dynamic hospital-community model would have been highly theoretical and 
potentially damaged the validity of what has been achieved.  
185 
 
Although the model included heterogeneity in risk factors associated with CDI between the 
general community and LTCF populations, no further details differences in term of risk profiles among 
the ICU patients were included. For example, elective patients were assumed to be at equal risk of 
exposure to antimicrobial use as the rest of the ICU population. As mentioned earlier, for certain surgical 
procedures, antimicrobial prophylaxis is a common prescription. Including more heterogeneity in risk 
would allow for further investigation of potential vaccine populations. However, this would be highly data 
demanding.     
Finally, this thesis did not include a cost-effectiveness analysis, therefore could not provide conclusive 
results on whether vaccination would be a cost-effective use of infection prevention and control 
resources. 
 
6.4 AREAS OF FURTHER RESEARCH 
 
An additional extension to the presented model would be enhanced incorporation of heterogeneity in 
patients based on risk factors associated with the infection such as reason for admission (including type of 
elective surgery), age, and co-morbidity. This may aid in optimising the identification of target groups 
most likely to benefit from vaccination. Moreover, an evaluation of the cost-effectiveness of the 
investigated vaccination strategies was beyond the scope of this thesis, but would be an obvious future 
step. As this model did not investigate the full scope of CDI vaccination (such as prevention of 
community onset and transmission), a future cost-effectiveness approach could extend the model 
presented here by including patient movement patterns between hospital wards as well as dynamic-
transmission between healthcare- and community-settings. This would require further understanding of C. 
difficile transmission dynamics in both hospital- and community-settings. Studies involving the screening of 
patients on hospital admission for C. difficile colonisation, combined with whole genome sequencing of 
isolates from asymptomatic and symptomatic cases, could provide more conclusive insight into the 
contribution of asymptomatic carriers in the transmission-dynamics of the bacterium[50]. However, such 
studies are costly (although are becoming more affordable) and may be, at least for now, unfeasible. As 
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shown in Chapter 2, using formal fitting techniques, mathematical models have proven capable of 
estimation of the various sources of acquisition routes of healthcare-associated bacteria, provided the 
colonisation status of all patients on admission is known [51, 52]. Therefore, a suggested future area of 
research could involve the application of these models using on-admission screening data, e.g.[53].   In 
addition, further understanding is needed on the C. difficile dynamics in community settings. Useful data 
could be drawn from household studies, involving the screening of household members of patients found 
positive for symptomatic or asymptomatic C. difficile, as has recently been done to investigate the spread of 
Gram-negative bacteria[54]. These could help inform meta-population models of C. difficile that could 
quantify the patient-to-patient spread in the community. Estimated (transmission) parameters from these 
structurally more parsimonious models (as opposed to the model presented here) could be used to inform 
the aforementioned holistic model.  
Also, an improved general understanding of the health needs of patients in LTCF is required. In 
Europe, antimicrobial use and healthcare-associated infection surveillance in these settings has been 
limited to ad hoc point prevalence surveys [55, 56]. The US has recently implemented a comprehensive 
population-based surveillance for CDI, which incorporates a separate definition for LTCF onset cases 
[25]. To identify the need for prevention and control measures in these settings, national surveillance 
systems should be expanded to surveillance of CDI outside hospital-settings, as has been initiated in the 
US. 
Antimicrobial stewardship can help prevent onset among asymptomatically imported cases as well 
as successfully reduce onward transmission. Similar conclusions have been drawn based on retrospective 
observations (e.g. the decline in C. difficile rates observed in England), and statistical analyses[30, 31]. 
However, infection prevention and control intervention strategies are commonly implemented 
simultaneously, making the quantification of the relative effectiveness of the implemented strategies 
challenging. Future mathematical modelling could help quantify the relative effectiveness of individual- 
and bundled implementation of existing (and new) interventions, and provide further insight into how and 
where antimicrobial stewardship could be valuable as well as feasible. 
187 
 
Finally, further research is needed to understand differences between studies in the effect of CDI 
on patient LoS. In Chapter 4, it was shown that neither difference in age and co-morbidity, nor in the 
severity of the CDI infection explained why in a Canadian study, using robust methods, CDI was found to 
increase patients’ stay[57] but not in an Australian study[58]. This thesis concurs with the Canadian study, 
finding an excess LoS of approximately one week due to CDI.  All three studies concern single hospital-
settings, with relatively small datasets, resulting in more uncertain estimates. A recent study, conducted in 
the US, used retrospective data from 120 acute care facilities and found, similarly to this thesis, that 
severity of CDI had an increased impact on LoS[59]. The data comprised a detailed account of patient 
characteristics (age, sex, ICU stay on admission) and facility characteristics (teaching hospital or not, bed 
size, rural location or not, census region). Interestingly, when fitting a multi-state model to sub strata of 
data (as was done in this thesis), differences in the impact of CDI were observed within the US census 
regions, similarly to the differences described above (i.e. less than one day increase up to ~5 day increase 
in LoS across regions). As accounting for multiple co-variates in a multi-state model remains a 
computationally challenging task to date, these results did not show the interaction between the above 
listed factors. Using similarly rich data to fit e.g. a Cox proportional hazards model as done in this thesis 
could identify whether these patient and/or facility characteristic could explain these regional differences. 
If not, this might hint at other factors, such as hospital practice on e.g. infection prevention and control, 
which should be area of further investigation. 
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APPENDIX A: OVERVIEW OF ALL CDI VACCINE CLINICAL TRIALS 
Vaccine Sponsor 
Start 
date 
End 
date Phase Trial number 
Study 
group Country Intervention Primary endpoint(s) Ref 
ACAM-
CDIFF™ 
Sanofi 
Pasteur 
Jul 
2005 
Mar 
2006 I 
NCT0012780
3 
Adults 
18 to 55 US   
Placebo vs 3 dose values of toxoid 
vaccine respectively (i.e. 2μg, 
10μg, 50μg). Doses provided on 
day 0, 28 and 56 
1) Solicited injection 
site erythema and 
tenderness post-
vaccination; 2) 
Treatment-emergent 
adverse events [87,290] 
  
Nov 
2005 
Feb 
2006 I 
NCT0021446
1 
Adults 
>= 65 US 
Placebo vs 3 dose values of toxoid 
vaccine respectively (i.e. 2μg, 
10μg, 50μg). Doses provided on 
day 0, 28 and 56 
1) Treatment-emergent 
adverse events [87,290] 
  
Mar 
2006 
Jun 
2006 I 
NCT0077295
4 
Adults 
18 to 55 ? 
Placebo vs 2 dose values of toxoid 
vaccine respectively (i.e. 50μg, 
100μg). Doses provided on day 0, 
28 and 56 
1) Treatment-emergent 
adverse events [87,290] 
  
Feb 
2009 
Jun 
2012 II 
NCT0077234
3 
Adults 
18 to 85 US, UK 
Placebo vs low dose with adjuvant 
vs high dose with adjuvant vs high 
dose without adjuvant. Doses 
provided on day 0, 7 and 28 
1) Recurrence of CDI 
~13w post-vaccination 
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Oct 
2010 
Mar 
2013 II 
NCT0123095
7 
Adults 
40 to 75 US 
Placebo vs low dose with adjuvant 
vs low dose without adjuvant vs 
high dose with adjuvant vs high 
dose without adjuvant. Provided 
on day 0, 7 and 30. Moreover, 
high dose with and without 
adjuvant are also provided on day 
0, 30 and 180 in two separate 
groups 
1) Safety profile in each 
study group; 2) 
immune response to 
toxoid A and B 
 
  
Jul 
2013 
Jun 
2014 I/II 
NCT0189683
0 
Adults 
40 to 75 Japan Placebo vs toxoid vaccine 
1) Safety profile in each 
study group; 2) 
immune response to 
toxoid A and B 
 
  
Jul 
2013 
Dec 
2017 III 
NCT0188791
2 
Adults 
>= 50 
Australia, Brazil, 
Canada, Chile, 
Colombia, Finland, 
France, Germany, 
Republic of Korea, 
Mexico, Peru, Puerto 
Rico, Singapore, 
Sweden, Taiwan, UK, 
US Placebo vs toxoid vaccine 
1) Efficacy of vaccine 
in preventing CDI 
onset after at least 1 
injection 
 
IC84 
Valneva 
(was 
Intercell) 
Dec 
2010 
Apr 
2013 I  
NCT0129638
6 
Adults 
>= 65 Austria, Hungary 
2 dose values of IC84 (75μg and 
200μg) with and without alum (4 
groups in total). Provided on day 
0, 7, 28 and 56 
1) Treatment-emergent 
adverse events 
 
VLA84 Valneva 
Dec 
2014 
Oct 
2015 II 
NCT0231647
0 
Adults 
>= 50 Germany, US 
Placebo vs 3 dose values of 
VLA84. Provided on day 0, 7 and 
28 
1) Seroconversion rate 
on Day 56; 2) 1) 
Seroconversion rate for 
IgG against toxin A  
 
195 
 
and B on Day 56   
Adjuvanted 
vaccine Pfizer 
Jan 
2014 
Jul 
2015 I 
NCT0205272
6 
Adults 
50 to 85 US, Canada 
Placebo vs vaccine with adjuvant 
provided at month 0, 1 and 3 vs 
vaccine with adjuvant on day 1, 8 
and 30 
1) Proportion of 
subjects reporting local 
reactions and their 
severity; 2) Proportion 
of subjects reporting 
systemic events and 
their severity 
 
  
Jul 
2014 
Apr 
2016 II 
NCT0211757
0 
Adults 
55 to 85 Us, Canada 
Placebo vs 2 dose values of 
vaccine (low and high). Provided 
on day 1, 8 and 30 
1) Neutralizing 
antibody levels at Day 
37; 2) local reactions 
and their severity; 3) 
Systemic reactions and 
their severity; 4) 
Treatment-emergent 
adverse events  
 
- GSK 
Feb 
2013 
Jul 
2015 - 
NCT0171653
3 
Adults 
>= 18 US, Canada 
CDI recurrence group vs not 
recurrence group. Blood sampling 
done at day 0, 14, at recurrence (if 
applicable) and end of follow up. 
Moreover, stool sampling at day 0, 
14 and at recurrence (if applicable) 
C. difficile immune 
response as measured 
in blood samples at day 
14 
  
